Home

Medicinal cannabis is changing the face of clinical medicine.  We are the leaders of that change.

Family,Eating,Sandwiches,Outdoors,In,A,Forest,,Portrait
Happy,Family,With,The,Child,In,The,Field
Portrait,Of,Happy,Family,Standing,In,Back,Yard,During,Sunny
A,Family,Having,A,Walk,With,A,Dog
Satisfied,Senior,Man,With,Friends,Having,A,Picnic,In,A
Happy,Grandparents,Dance,Waltz,In,Front,Of,Family,At,A
Asian,Preteen,Boy,And,Young,Father,Jogging,Together,In,Nature
Granddad,With,Cheerful,Granddaughter,Having,Fun
Cute,Couple,Walking,In,A,Autumn,Park.,Boy,And,Girl
Cute,Couple,Holding,Hands,Happiness,Lifestyle,Meeting
Parents,Play,In,The,Park,With,Their,Son
Mother,And,Daughter,Having,Fun,In,The,Park.,Happiness,And
Grandfather,With,Son,And,Grandson,Sitting,On,Swing,In,Garden
Group,Of,Senior,Trekkers,Checking,A,Map,For,Direction
Mother,And,Daughter,Having,Fun,In,The,Park.,Happiness,And
Group,Of,Senior,Trekkers,Checking,A,Map,For,Direction
Group,Of,People,Holding,Hands,Support,Team,Unity
Happy,Grandfather,,Grandmother,And,Grandson
Group,Of,People,Holding,Hands,Support,Team,Unity
Portrait,Of,Senior,Couple,Walking,Pet,Bulldog,In,Countryside
Group,Of,Senior,Retirement,Friends,Happiness,Concept
Portrait,Of,Four,Cheerful,Senior,Friends,Enjoying,Picnic,On,Green
Women,And,Boys,Walk,Hand,In,Hand,,Traveling,Adventure
Family,Of,Three,On,A,Walk,,Mother,Holding,Child,,Front
Beautiful,Couple,Taking,A,Walk,In,City,Park
Happy,Leisure
Couple,Wife,Husband,Dating,Relaxation,Love,Concept
Young,Attractive,Couple,In,Love,In,An,Autumn,Setting,Following
Group,Of,Senior,Retirement,Friends,Happiness,Concept
Group,Of,Senior,Retirement,Friends,Happiness,Concept
Group,Of,Senior,Retirement,Exercising,Togetherness,Concept
Group,Of,Senior,Friends,Hiking,In,Countryside
Portrait,Of,Cheerful,Girls,With,Grandparents,While,Sitting,In,Back
Beautiful,Couple,Taking,A,Walk,In,City,Park
Group,Of,Senior,Friends,On,Hike,In,Countryside,Looking,At
Happy,Family,In,The,Park,On,A,Sunny,Day
Portrait,Of,Senior,Couple,Standing,With,Family,And,Friend,In
Soldier,Reunited,With,His,Parents,On,A,Sunny,Day
Group,Of,Adult,Multiethnic,Friends,Playing,American,Football,On,The
Portrait,Of,Senior,People,Celebrating,Birthday
Cheerful,Multi,Generation,Family,With,Parents,Giving,Piggy,Back,Standing
Family,Eating,Sandwiches,Outdoors,In,A,Forest,,Portrait Happy,Family,With,The,Child,In,The,Field Portrait,Of,Happy,Family,Standing,In,Back,Yard,During,Sunny A,Family,Having,A,Walk,With,A,Dog Satisfied,Senior,Man,With,Friends,Having,A,Picnic,In,A Happy,Grandparents,Dance,Waltz,In,Front,Of,Family,At,A Asian,Preteen,Boy,And,Young,Father,Jogging,Together,In,Nature Granddad,With,Cheerful,Granddaughter,Having,Fun Cute,Couple,Walking,In,A,Autumn,Park.,Boy,And,Girl Cute,Couple,Holding,Hands,Happiness,Lifestyle,Meeting Parents,Play,In,The,Park,With,Their,Son Mother,And,Daughter,Having,Fun,In,The,Park.,Happiness,And Grandfather,With,Son,And,Grandson,Sitting,On,Swing,In,Garden Group,Of,Senior,Trekkers,Checking,A,Map,For,Direction Mother,And,Daughter,Having,Fun,In,The,Park.,Happiness,And Group,Of,Senior,Trekkers,Checking,A,Map,For,Direction Group,Of,People,Holding,Hands,Support,Team,Unity Happy,Grandfather,,Grandmother,And,Grandson Group,Of,People,Holding,Hands,Support,Team,Unity Portrait,Of,Senior,Couple,Walking,Pet,Bulldog,In,Countryside Group,Of,Senior,Retirement,Friends,Happiness,Concept Portrait,Of,Four,Cheerful,Senior,Friends,Enjoying,Picnic,On,Green Women,And,Boys,Walk,Hand,In,Hand,,Traveling,Adventure Family,Of,Three,On,A,Walk,,Mother,Holding,Child,,Front Beautiful,Couple,Taking,A,Walk,In,City,Park Happy,Leisure Couple,Wife,Husband,Dating,Relaxation,Love,Concept Young,Attractive,Couple,In,Love,In,An,Autumn,Setting,Following Group,Of,Senior,Retirement,Friends,Happiness,Concept Group,Of,Senior,Retirement,Friends,Happiness,Concept Group,Of,Senior,Retirement,Exercising,Togetherness,Concept Group,Of,Senior,Friends,Hiking,In,Countryside Portrait,Of,Cheerful,Girls,With,Grandparents,While,Sitting,In,Back Beautiful,Couple,Taking,A,Walk,In,City,Park Group,Of,Senior,Friends,On,Hike,In,Countryside,Looking,At Happy,Family,In,The,Park,On,A,Sunny,Day Portrait,Of,Senior,Couple,Standing,With,Family,And,Friend,In Soldier,Reunited,With,His,Parents,On,A,Sunny,Day Group,Of,Adult,Multiethnic,Friends,Playing,American,Football,On,The Portrait,Of,Senior,People,Celebrating,Birthday Cheerful,Multi,Generation,Family,With,Parents,Giving,Piggy,Back,Standing

At CED Clinic, we aim to create a welcoming and professional environment in which patients and clinicians can openly discuss the benefits of medical cannabis.

Our Services

  • Massachusetts Medical Card Certifications
    • Adult Cannabis Care
    • Pediatric Cannabis Care
  • In-Depth Consultations & Care Plans
    • Concierge Care
    • EO Care

Our Mission

  • To Heal
  • To Educate
  • To Listen

Our Team

Benjamin Caplan, MD
Erin Caplan NP
Erin Caplan, NP

Benjamin Caplan, MD, stands at the forefront of medical cannabis care as the Founder and Chief Medical Officer of CED Clinic and CED Foundation. His entrepreneurial journey further extends as the Founder of multiple medical cannabis technology and educational platforms and as a medical advisor to the prestigious cannabis investment fund, GreenAXS Capital. Within digital healthcare, Dr. Caplan co-founded EO Care, Inc, a pioneering digital therapeutic and telemedicine platform, offering personalized cannabis care and product plans and continuous clinical guidance to a global clientele seeking a reliable, evidence-based cannabis care partner. Adding to his repertoire of contributions to the medical cannabis arena, Dr. Caplan has recently published “The Doctor-Approved Cannabis Handbook,” an industry-first resource empowering readers with the full scope of the therapeutic potential of cannabis. Through his multifaceted involvement, Dr. Caplan continuously strives to bridge the gap between traditional medicine and cannabis care, making a significant impact in evolving holistic healthcare.

Erin Caplan, NP is a board-certified Pediatric Nurse Practitioner with a master’s-level medical education from Simmons. Her extensive clinical journey has been enriched through roles at Massachusetts General Hospital, Hyde Park Pediatrics, and Dana-Farber Cancer Institute, where she has provided both inpatient and outpatient primary care to some of the most fragile and challenging pediatric patients. A registered cannabis care provider licensed by the Massachusetts Cannabis Control Commission, Erin seamlessly blends her pediatric expertise with the nuance and adaptability required for personalized cannabis care. A community leader, avid athlete, and dedicated mother of four, Erin’s compassionate bedside manner and steadfast commitment to evidence-based practice have earned her the trust and appreciation of patients and families, showcasing her as a harmonious blend of clinical excellence with a personal touch.

Patient Stories

Used as a Human Target as a Kid, Medical Cannabis is the answer.

I’m totally blind. I live in a rural area. So when I was 12, same-age peers thought zapping the blind girl’s eyes with laser pointers would be a great idea. It got bad enough that my paraprofessional had to have the devices banned from the school for my safety. Shortly after, I began having intense eye aches. I differentiate them from headaches because even a 12 year old can tell the difference. Doctors told my parents and I they were migraines. It wasn’t until later in life that I began realizing there was something else going on here. Really studying migraines, studying the eye, studying neurology and understanding not all was as it seemed. I began developing my own theories as to what these “migraines” were. I take migraine meds, but they don’t treat the eye aches. They treat the other migraine symptoms just fine. My younger brother suggested I try edibles last year. Because by this point, I was in enough pain where I believed I’d have to have my eyes removed. None of us wanted to see that happen. So he took me to a dispensary, (he had spoken with someone he knew there about me prior, and they’d come up with a regimen they thought would work.) The first clue I had that we were on the right track, was that I slept for 14 hours. So I kept a calendar and a spreadsheet full of virtual sticky notes, and 2 weeks later came to Dr. Caplan for my medical card, crazy theories about optic neuropathy in underdeveloped optic nerves and all. A year later, I’m studying cybersecurity, because that’s something I found I’m passionate about, and I can do it now!

Krista Pennell

To sleep well again is life-changing

Dr. Caplan was coincidentally recommended by both my dentist and a close friend. I was concerned about finding a high level, knowledgeable, physician in a professional setting who understood using cannabis in a safe and effective manner. I can’t recommend Dr. Caplan more highly. His knowledge is vast and I am grateful for his expertise, care and compassion. To sleep well again is life-changing. Very few things literally change someone’s life. Dr. Caplan’s knowledge and guidance on cannabis did that for me.

Barbara M.

Not once did I feel rushed or embarrassed, in fact I felt like he really does care about my circumstances, and wanted for me to feel confident and prepared

Honestly, I was hesitant to try cannabis. I have debilitating menstrual cramps and my OB/GYN recommended Dr. Caplan. I was more than a little hesitant to try cannibas because all I really knew about it was that people used it to get “high” – and that was not something I was interested in. This perspective totally changed when I actually came in and met with Dr. Caplan. He was incredibly understanding and really took the time to ease my mind about the whole process, what kind of options there were to choose from, what they might do, and what would probably appeal to me. He spent a lot of time answering all my questions (and I had a lot!). Not once did I feel rushed or embarrassed, in fact I felt like he really does care about my circumstances, and wanted for me to feel confident and prepared.

Mark L.

Dr. Caplan was thorough in his evaluation and friendly and accessible in his approach

Dr. Caplan was thorough in his evaluation and friendly and accessible in his approach. He provided in depth information and step by step guidance for beginning the process of utilizing cannabis therapies. He is available to his patients by email and phone. I highly recommend an appointment with him if you are even remotely considering medicinal use. I was hesitant about this approach before my appointment but now, after talking with Dr. Caplan and learning a little bit more about the science, I am eager to explore and I feel better already!

Rachel M.

I saw Dr Caplan a few months ago, and from even before I met him, he has made himself available to me over email, for questions, more than even my regular doctor

I came into marijuana medicine with zero experience. I must say, I’ve been learning a ton, and I would recommend it to anyone with terrible anxiety and depression. I saw Dr Caplan a few months ago, and from even before I met him, he has made himself available to me over email, for questions, more than even my regular doctor. A friend told me that I should see Dr Caplan, but I was still unsure about becoming a medical marijuana patient. I called and was able to speak with Dr Caplan directly. He took time, on the phone, even before he had met me, to explain the whole process, which helped me feel more comfortable putting a voice and personality to the process. Later, when I finally came in, during the visit, he spent almost 40 minutes with me, walking me through how cannabis might fit in with some of the other treatments I currently use. We have kept in touch over email since, like 3 or 4 random questions, and has always responded promptly. I think he is a truly special doctor, and from what I’ve read on Twitter, has a passion for educating and helping improve the perception of cannabis.

Alan T.

I had an enjoyable visit with clear information and education about medical marijuana and the dispensaries

Full stars. I appreciate the great parking and simple scheduling system. I had an enjoyable visit with clear information and education about medical marijuana and the dispensaries. No fancy language, no time wasted. Works for me.

Michael J.

I am a survivor of breast, uterine, and ovarian cancers, and Dr Caplan of CED Clinic is, hands down, the favorite voice of support and cannabis education for our hospital list-serv care group

I am a survivor of breast, uterine, and ovarian cancers, and Dr Caplan of CED Clinic is, hands down, the favorite voice of support and cannabis education for our hospital list-serv care group. I have seen him speak publicly, and on TV, and of course he is also my doctor. In spite of having what seems to be a crowd of patients who are mostly in terrible pain or have a generous helping of emotional/mental issues, I see him work tirelessly for his patients and for the cause, in general. I appreciate his leadership in the cannabis field. He is one in a million.

Stephanie W.

Dr. Caplan is an extremely knowledgeable doctor in his field and very easy to speak with about any questions and concerns you may have

Dr. Caplan is an extremely knowledgeable doctor in his field and very easy to speak with about any questions and concerns you may have. As a person that suffers from anxiety, upon arriving at the office I felt welcomed and relaxed because the doctor is compassionate and kind. The office atmosphere is not what I expected at all and was very peaceful and relaxing, also there were snacks and beverages which I have never seen before in a doctor’s office. I would highly recommend Dr. Caplan because he will take the time to answer every question that you may have about treatment. I made an appointment on a Saturday and was seen right away on the same day! Very easy process and very responsive. I am happy I chose Dr. Caplan!

Joshua C.

This is our second visit to Dr. Caplan in a year, and on both occasions, we were just blown away by his caring and compassion

This is our second visit to Dr. Caplan in a year, and on both occasions, we were just blown away by his caring and compassion. He is a true healer, with a great heart, enormous patience, and extraordinary expertise. My wife and I were amazed to find a physician who truly puts his patients first, and who is passionate about figuring out the best way to help us with our chronic pain. In our 60+ years of experience with health care providers, Dr. Caplan is among the most committed, generous, and caring healers we have ever met.

Heather F.

I can’t recommend Dr. Caplan highly enough

I can’t recommend Dr. Caplan highly enough. This was my third medical marijuana certification review (original plus two renewals), and the previous two doctors were just perfunctory form-fillers in shabby offices in remote office parks. Dr. Caplan is a REAL cannabis doctor who’s deeply knowledgeable about medical marijuana and clearly explains EXACTLY how to use it for YOUR specific conditions. He also has a real doctor’s office in a real medical building right on Boylston Street (Route 9) in Chestnut Hill ( not far from NETA Brookline, my dispensary of choice.) AND THE VISIT IS COVERED BY MEDICAL INSURANCE! I’ve become somewhat knowledgeable about what works for my primary complaint (chronic pain from spinal stenosis w/ radiculopathy) and what to avoid, but he gave me brand new ways to deal with my insomnia (including how and when to use edibles, which hadn’t worked for me before b/c I didn’t really know what I was doing) and arthritis in my hands (including a simple recipe to make topical lotion that’s stronger and cheaper than the commercial products). I interrupted him with frequent questions, which he answered at whatever level of detail and technical information I wanted. I had been deeply dissatisfied with the cannabis doctors I went to before, but Dr. Caplan is an outstanding DOCTOR who happens to specialize in medical marijuana because he cares about helping patients for whom traditional medicine hasn’t fully met their needs. You can book appointments on his web site, although my wait time was more than 10 minutes (during which I filled out his online patient questionnaire on my phone and ate all the Kit Kats in his candy basket), it was well worth it. This is a relatively new practice, I believe, and it’s going to get a lot busier as word spreads. But just do yourself a favor and go: this is what state-of-the-art medical marijuana care is supposed to be like.

Steve G.

Dr. Caplan patiently explained how there are so many options to chose from and exactly what each was helpful for

I recently had my first appointment with Dr. Caplan after reading negative reviews of so many other medical marijuana certification “places”. I can’t say enough good things about my visit with him. To start with he’s a very compassionate, caring doctor. I’m a 63 yr old woman and had never used marijuana or “street drugs”, so I was feeling nervous about trying it. I recently started chemo therapy at Dana-Farber and the side effects have been difficult to deal with. In particular, insomnia and a bit of evening anxiety. He is extremely knowledgeable about all aspects of medical marijuana. Dr. Caplan patiently explained how there are so many options to chose from and exactly what each was helpful for. With that said, he suggested several products for me to try. I now know what helps me, but each person has to use the information he gives and then try different products from a reputable medical dispensary. I plan to have a 2nd appt. with him in a few months just to get his feedback on my experiences and possibly more recommendations. It’s not necessary to go back to him after getting your certification, but he truly knows so much about the medicinal benefits that I’d like to learn even more. I highly recommend him.

Nancy O.

I would highly recommend Dr. Caplan because he will take the time to answer every question that you may have about treatment

Dr. Caplan is an extremely knowledgeable doctor in his field and very easy to speak with about any questions and concerns you may have. As a person that suffers from anxiety, upon arriving at the office I felt welcomed and relaxed because the doctor is compassionate and kind. The office atmosphere is not what I expected at all and was very peaceful and relaxing, also there were snacks and beverages which I have never seen before in a doctor’s office. I would highly recommend Dr. Caplan because he will take the time to answer every question that you may have about treatment. I made an appointment on a Saturday and was seen right away on the same day! Very easy process and very responsive. I am happy I chose Dr. Caplan!

Robert M.

Dr. Caplan is extremely patient and compassionate

Dr. Caplan is extremely patient and compassionate. He answered all of my questions and gave me a great deal of useful information (while emphasizing that I didn’t have to absorb all of it right away). He encouraged me to contact him with any more questions I might have after the appointment, and began the process of registering me immediately after I left. I had an email from the Commonwealth of MA before I got home, and completed the application online within a few minutes. It couldn’t have been an easier or more stress-free experience. Dr. Caplan truly believes in the effectiveness of cannabis as a medicinal tool, and is committed to making it more widely available for that purpose and in dispelling the ocean of ignorance that has unfortunately been created around it in our society. I can’t recommend him highly enough.

Justice S.

Excellent Experience, top to bottom

Excellent Experience, top to bottom. I scheduled my appointment on CED clinic website, got in the next day – and visit was informative, and doc was kind, compassionate, and amazingly knowledgeable. I intend to follow him as a permanent addition to my healthcare and would recommend widely.

Ellison M.

I’m shy but felt comfortable and supported

Awesome doctor. Super easy to talk to. I’m shy but felt comfortable and supported. Great teacher too. I had no idea there was so much to know!

Sara E.

I learned about different options and lots of choices, and received handouts to learn even more

First heard of Dr Caplan on /r/BostonTrees subreddit. Made my appointment online, for the next day, and did all paperwork online before I came in. Building is very professional and comfortable, with great parking, and close to where I live. As I expected, doc was kind, thorough, and efficient. We reviewed my medical history, talked about what I had been doing in the past, and discussed a host of treatment ideas, and not just marijuana. I learned about different options and lots of choices, and received handouts to learn even more. I plan to follow up in a few months, and I look forward to it.

Ryan H.

Every time I come in, I learn something new and amazing.

I followed Dr Caplan from his position as the Medical Director of Canna Care Docs to CED Clinic – and would follow him again. I have had years of back pain and arthritis – my wrists and knees and hips. Dr Caplan has helped me understand much more about marijuana, and I have to say, it has been a wonderful improvement for me. Every time I come in, I learn something new and amazing. It’s a new industry for me, and I feel very well supported.

Elizabeth P.

My visit with Dr. Caplan made it comforting to know that someone was on my side

My visit with Dr. Caplan made it comforting to know that someone was on my side. I was surprised to find that Dr. Caplan does more than just write scripts for people to take to dispensaries. He sees some of his patients on a regular basis to personalize treatment plans and it’s clear he cares about education and the destigmatization of medical cannabinoids. He goes to assisted living centers, medical expos, wellness centers, and more to speak with people on the matter. This is his passion!

Benjamin T.

Dr. Caplan is extremely patient and compassionate

Dr. Caplan is extremely patient and compassionate. He answered all of my questions and gave me a great deal of useful information (while emphasizing that I didnâ€t have to absorb all of it right away). He encouraged me to contact him with any more questions I might have after the appointment, and began the process of registering me immediately after I left. I had an email from the Commonwealth of MA before I got home, and completed the application online within a few minutes. It couldn’t have been an easier or more stress-free experience.†“— Dr. Caplan truly believes in the effectiveness of cannabis as a medicinal tool, and is committed to making it more widely available for that purpose and in dispelling the ocean of ignorance that has unfortunately been created around it in our society. I can€t recommend him highly enough.

Jeff E.

Very knowledgeable and compassionate

Very knowledgeable and compassionate.

Irene C.

I would highly recommend Dr. Caplan

I wasn’t sure what to expect from the initial appointment.  It was informative, educational and an overall great experience!  Dr. Caplan is easy-going, kind, and gave clear, detailed information about medical cannabis and MA medical dispensaries.  I would highly recommend Dr. Caplan.  His clinic and his knowledge are certainly worth 5-star reviews!

Ashley S.

I had such a good experience with Dr. Caplan of CED Clinic.  

I had such a good experience with Dr. Caplan of CED Clinic.

Medical: I had a lot of worries going in, and Dr. Caplan put me at ease with his knowledge and calm manner.  As a family doctor, he asked good questions about my extensive medical background, in a supportive way.  He used normal people words instead of medical gobbledygook!  (I had just an hour before been at an appointment with a medical person who thought I should understand when he talked about my distal iliolumbar neuropathy – or something like that, I had no idea what he was talking about – so I especially noticed when Dr. Caplan used normal words that any person would know.)

Educational: He provided excellent information for total newbies, showed some devices, talked about legal stuff, and gave great info about local clinics and huge discounts available.  I’m used to doctors providing pretty poor education materials, but Dr. Caplan’s infographics and handouts were a thing of beauty – informative, easy to read, and visually simple.  I hope Dr. Caplan writes a book because I will buy it.

Logistics: This is such a streamlined practice, it is easy to get in soon, and respectful of your time.  I got an appointment within less than 2 days, scheduled online, filled out my info online beforehand, found parking easily, was in and out quickly, and received the email with next steps instructions and application activation code in 1.5 hour!  Can’t possibly be easier than this.

Laura M.

Dr. Caplan was very friendly, extremely helpful and knowledgeable

Dr. Caplan was very friendly, extremely helpful and knowledgeable.  I would definitely recommend and I am looking forward to having him as a health resource.

Timothy Y.

I’ve switched 100% to cannabis as my go-to medicine

I’ve switched 100% to cannabis as my go-to medicine.  I’m sick of pharmaceuticals; the weight gain, the weird feelings like I’m a zombie, the miserable sleep…sorry, but hard pass.  Weed helps take the edge off and I’m still fully functional.

Anonoymous

The Doctor-Approved Cannabis Handbook (October 17th, 2023)

Pre-Order the Book

"A wealth of information and a huge dose of compassion and clarity."

Melissa Etheridge

Upcoming Events Calendar

No Events Found

The Latest

CED Clinic Blog
November 6, 2023Cannabis Cardiovascular Risk: Navigating the Nuances in Media and Medicine The spotlight on “Cannabis Cardiovascular Risk” has intensified, notably with a recent CNN article by a journalist hailing from Georgia, Sandee LaMotte, sketching a picture that points to potential risks linked with marijuana use. Unfortunately, this sort of impulsive, one-sided journalism prompts an important second look at the media’s role in scientific discourse and the nuanced reality of such health risks. The Intricacies of Cannabis and Cardiovascular Health Cannabis and cardiovascular health share a complex relationship. The interplay of THC, the psychoactive component in cannabis, with the cardiovascular system is a subject of critical research. Studies highlight that while nitric oxide (NO) serves a protective role in vascular health, THC may impede its beneficial effects, indicating the need for a nuanced understanding of these findings. Considering the ying-yang nature of CBD and THC, this also reminds of the importance of cannabis care that is guided by experts who can help inform patients what the real risks are, and which substances may present a reality that is not only low risk, but may even pose potential benefits in cardiovascular health. Comprehensive Perspectives Beyond THC (A narrow viewpoint) Broadening the conversation on “Cannabis Cardiovascular Risk” requires consideration of, and the roles played by other cannabis constituents, including CBD, other minor cannabinoids, flavonoids, and terpenes. The method of cannabis consumption, from smoking or vaping to topicals, edibles, and other forms of delivery, is another important area that demands deeper discussion into their potential impacts on heart health. Ignoring the nuances of the wide range of constituents within cannabis, and demonizing it all, regardless of form, delivery, or patient, stinks worse than a skunk at a perfume factory, but perhaps not on account of the cannabis. Fast aside, did you know that, when threatened, skunks spray a potent and pungent liquid from their glands as a defense mechanism? The smell is notoriously difficult to remove and can linger for a long time.  … just saying. The Importance of Balanced Reporting in Science (Biased Science and Reporting) The tendency of health science reporting to sensationalize findings has become increasingly common, as seen in the CNN article. However, such reports must strive to mirror the spectrum of scientific research, encompassing not just the risks but also the potential therapeutic effects of cannabis. As with any reporting and all science, wise readers should consider the scientific sources underpinning published work, as well as the qualifications and historical perspectives/biases of experts that support the reporting and sharing of views.  Do the papers themselves pose the risks about which the journalism reports?  Are the experts qualified and experienced in the domain of discussion? Have those experts shown themselves to be repeatedly bull-horning one particular viewpoint? Does the perspective appear like a solo, unending tiki-torch march against cannabis? Or, does scientific commentary present itself evenly on both sides of the discussion topic, from which the reader may derive their own conclusions?  Do you like your reporting to make your decisions for you? or do these nuances matter to YOU as the reader?  All important questions! ….If the reporting is pushing you to come to their conclusion, you should beware that, chances are, you’re not getting a full picture or the whole story.   Beware Causation vs Association!  Baking Cookies (Causation): Imagine you’re baking cookies. You add sugar to the cookie dough. The sugar directly causes the cookies to taste sweet. This is causation: you do something (add sugar), and it directly causes a result (sweetness in cookies). Roosters Crow and the Sun Rises (Association): Now, think about a rooster crowing at sunrise. The rooster crows every morning as the sun rises. However, the rooster’s crowing doesn’t cause the sun to rise. They’re associated because they happen at the same time, but one does not cause the other. So, in causation, like adding sugar to cookies, there’s a direct cause and effect. In association, like the rooster crowing and the sunrise, two things are linked by timing or circumstance, but one doesn’t directly cause the other.   A Call for Rigorous Scientific Inquiry (Quality of Data) Recognizing that each study enriches the collective understanding, it is essentially for ongoing investigations to add more rigorous evaluations. Self-reports, lackluster patient selection, a disregard of patient environmental, socioeconomic, and a patent disregard for the medical backgrounds, ongoing treatment, or personal experience with cannabis is no longer acceptable for quality, peer-reviewed study,  The half-baked attitude supporting the current research should be cause for hesitation and doubt about the nature of relevant scientific knowledge about the interplay of cannabis and cardiovascular risk. (see references below, which highlight available good quality research that draws intrinsically opposing conclusions about the effects of cannabinoid-based phenomena on cardiovascular effect. For journalist claiming to make evidence-based conclusions, or for readers expecting to derive insights about the real world, the details matter! The Media’s Role in Scientific Discourse (limitations of the media) Journalists have a critical role in guiding the public discourse and in shaping the direction of health and science is shaped. The importance of how information is communicated cannot be overstated. Journalists should aim to convey research findings with accuracy, ensuring complex issues are not oversimplified. For the opinions or perspectives that belong in a domain of expertise beyond the reporter, appropriate expertise, on both sides of a debate, should be included to empower readers with a balanced offering of facts  The recent CNN report underscores the influence of the media and the need for precise and comprehensive communication, and unfortunately, precisely how information can be dangerously misleading or come out so one-sided as to be outright deceitful, from a scientific point of view.   Why do Journalists Do This ?  1. Overly Simple and Catchy News: Sometimes, reporters make complex science sound simpler so more people will understand it, but this can change the meaning. Headlines that say one thing causes another are more eye-catching than headlines that just show a connection, which can be misleading. 2. Getting the Science Wrong: Reporters might not always get the science right, especially if they don’t fully get the research methods or the numbers. They often use summaries or press releases that don’t give the whole story, which can lead to wrong ideas about what the research actually says. 3. Rushed Reporting and Using Secondhand Info: News moves fast, and the rush to get stories out can mean not enough time is spent checking facts, which can lead to mistakes or oversimplifications. Reporters also might rely on other articles instead of the original research, which can add to the chances of getting things wrong. What can consumers of information do to protect themselves? 1. Seek Comprehensive Understanding: Dive deeper than headlines by reading full articles to grasp the context of scientific findings. Enhance your critical thinking by educating yourself on basic scientific principles, such as distinguishing causation from correlation. This foundational knowledge aids in evaluating the credibility of news reports. 2. Cross-Reference Information: Verify news by consulting multiple reputable sources, including the original research studies when available. Accessing abstracts and conclusions can offer more direct insights, providing a broader perspective on the subject matter and helping to identify whether certain interpretations are commonly accepted or outliers. 3. Approach with Critical Analysis: Exercise healthy skepticism and be cautious of oversimplifications in science reporting. Recognize the limitations of journalism in conveying complex scientific data, and consider using fact-checking websites to validate claims. Engage with science communicators who can effectively distill intricate concepts for wider audiences. Considering the Breadth of Evidence It is vital to a healthy flow of public education to acknowledge the limitations and varied results of existing studies on the potential cardiovascular risks – and potential benefits – of various cannabinoids, terpenes, and cannabis-related consumption. Journalists have a moral obligation to ensure that the public and healthcare providers receive reliable information for informed decision-making. Unless journalists are broadcasting through channels that are openly based on personal opinion, where bias and a lack of rigorous standards in research, analysis, or message broadcasting are self-evident, it is irresponsible to disseminate questionable scientific information to sway readers toward one perspective or another. Navigating the Complex Landscape of Cannabis Research The impact of cannabis on heart health is multifaceted, laden with complexities, and marked by many unknowns. Comprehending how cannabinoids may influence cardiovascular function—including the production, release, and degradation of Nitric Oxide, as well as determining their potential risks or benefits—is a critical area of ongoing research that is far from being fully understood Moving the Discussion on Cannabis and Heart Health In light of the recent media attention, it is imperative that the conversation surrounding ‘Cannabis and Cardiovascular Risk’ progresses in tandem with scientific discovery, adopting a perspective that is both open-minded and rigorously analytical. Research must delve into the complex and dynamic nature of cannabis, recognizing it as a multifactorial substance. Much like how food is not a monolith but rather a vast array of types, varieties, and flavors, each with its own nutritional profile and culinary role, cannabis too is a tapestry of diverse elements, each with distinct properties and effects Final Reflections on Media and Medical Responsibility Considering the potential cardiovascular risks associated with cannabis use, it is essential to foster a media environment that promotes evidence-based discussions. Simplified narratives risk obscuring the intricate reality of cannabis research and its implications for health. This underscores the shared responsibility of scientists and journalists to cultivate a dialogue that is both knowledgeable and reflective of the dynamic pursuit of scientific understanding Simplifying Nitric Oxide’s Role in Cardiovascular Health As a brief primer on the significance of nitric oxide (NO) in cardiovascular health: Nitric oxide is fundamental to the proper functioning of the cardiovascular system. It aids in the relaxation of blood vessels, which is essential for the regulation of blood flow. Grasping the fundamental role of NO in vascular dilation, its influence on blood pressure, and its critical role in tissue oxygenation is vital. This understanding is particularly important when considering clinical outcomes, especially in the context of heart attacks and strokes, where NO’s role becomes prominently significant. The Connection Between Nitric Oxide and Cardiovascular Risk The interaction between nitric oxide (NO) and cardiovascular health adds a significant layer of complexity to discussions about cannabis. NO is a critical mediator in cardiovascular physiology, influencing vasodilation and thereby impacting blood pressure and flow. It is through these mechanisms that NO can affect the likelihood of cardiovascular events such as heart attacks and strokes. For instance, reduced NO availability can lead to vasoconstriction, increased vascular resistance, and subsequent hypertension, all of which are risk factors for heart attacks. Conversely, optimal levels of NO can promote vasodilation, improve blood flow, and potentially mitigate these risks. In practice, if cannabis were found to enhance NO production, it could theoretically support vascular health by helping maintain adequate vessel dilation and blood flow. However, should cannabis interfere with NO production or function, it might exacerbate cardiovascular risks by promoting vasoconstriction and hypertension. Understanding how cannabis compounds interact with the NO pathway is therefore essential, as it could inform both clinical practice and individual decision-making regarding cannabis use, especially for those with pre-existing cardiovascular conditions. As we conclude the conversation on how “Cannabis Cardiovascular Risk” is represented in the media, it is clear that both journalists and medical professionals must work together to ensure that public discussions accurately reflect the complex and developing nature of scientific research. This collaboration is essential for preserving the integrity of scientific study and patient education, allowing for well-informed healthcare choices and ensuring the accuracy of the information provided to the community.   Listen to Dr Caplan speaking with Dr Riley Kirk, PhD about this topic, here, on her podcast References Papers on Nitric Oxide 2 papers that describe cannabinoid-based Nitric Oxide support and protective effects https://drive.google.com/file/d/1nHxR5xv2bNbt0NNmEh1YsTqpFaRlMyFf/ https://drive.google.com/file/d/1MihQGU1I3yzDQNb1RgsZH37NtFhegM5l/ https://drive.google.com/file/d/1ERPC2n7U5taHYrJhhmbnlO6RlsfAutpR/ https://drive.google.com/file/d/1mCoEMyLyBUA1TBRI1LwOxZg4031vuSh2 THC as problematic, showing inhibition of NO: https://drive.google.com/file/d/1nm_TKPyGIC3MSHuQ55EJo3-nZo0_Tfbu/ Some evidence that there is direct+indirect impact with the coupling: https://drive.google.com/file/d/1Q3aWLbAvZVasZToTdArw7L9D7ugEa6tl/ https://drive.google.com/file/d/1W9HTapsWBr232fRhGDYNOm-ZRG3kRWOH/ Confounding of tobacco flavorings: https://drive.google.com/file/d/1Nd44QufxCiN_EriqVgFcGFLY0k66NaKK/ https://drive.google.com/file/d/1tyXdXgeM-aJgXe4oaR3aT9z46r5dJT6d/view?usp=sharing Terpenes also have an impact: https://drive.google.com/file/d/1tyXdXgeM-aJgXe4oaR3aT9z46r5dJT6d/ [...] Read more...
October 22, 2023A Fresh Perspective on an Intriguing Cannabinoid Tetrahydrocannabivarin or THCV, popularly known as the “sports car of weed,” is a compound that’s attracting increasing attention, especially in California. It’s unique not just for its rarity but also for its purported effects—less munchies and more energy. In a cultural and medical landscape that has often stigmatized cannabis for making people “stoned” and “lazy,” THCV could be a game-changer. But what does science tell us about this intriguing cannabinoid? How do its actions differ from other, more well-known cannabinoids like THC and CBD? The Complex World of Cannabinoids: Diverse Effects, Varied Applications The nuanced effects of cannabinoids on the human body are mediated by their interactions with a complex network of receptors. For example, while THC and CBN are known to stimulate appetite, THCV can act as an appetite suppressant. The contrasting physiological impacts underscore the importance of understanding the science behind each cannabinoid, especially as the medical applications of cannabis continue to expand. The Complex World of Cannabinoids and Their Diverse Effects on the Body Cannabis is a highly complex plant that contains a plethora of biologically active compounds. Among these are cannabinoids, a class of compounds that engage with the endocannabinoid system in the human body to produce a wide range of effects. Importantly, not all cannabinoids are created equal; they can have vastly different impacts on physiological and psychological processes. For example, the two most well-known cannabinoids, THC (Delta-9-tetrahydrocannabinol) and CBD (Cannabidiol), have strikingly different effects: THC is psychoactive and can induce feelings of euphoria, while CBD is non-psychoactive and has been studied for its potential therapeutic effects in treating conditions like anxiety and epilepsy. Even cannabinoids that sound similar can have contrasting effects on the body. Take, for instance, THC, CBN (Cannabinol), and THCV (Tetrahydrocannabivarin). THC and CBN are known to stimulate appetite—a phenomenon colloquially known as “the munchies”—but THCV acts as an appetite suppressant. This diversity of effects is mediated by these cannabinoids interacting with different receptors or the same receptors in varying ways, leading to distinct physiological outcomes. Understanding these nuances is crucial for both clinicians and patients looking to harness the therapeutic potential of cannabis, particularly as research into its medical applications continues to expand. THCV and Pancreatic Beta-Islet Cells: Simple Science THCV (Tetrahydrocannabivarin) can interact with TRPV (Transient Receptor Potential Vanilloid) receptors on the beta-islet cells of the pancreas. In simple terms, this interaction can regulate the release of insulin, which is vital for glucose metabolism. By modulating insulin levels, THCV might affect how our bodies process sugar and influence metabolic rate, although the evidence is still emerging. The Multifaceted Effects of THCV: Glucose Processing and Metabolism THCV may have a role in glucose processing and in metabolic rate beyond its influence on pancreatic function. Some evidence points to THCV’s potential to stimulate the oxidation of fat and the conversion of glycogen to glucose in muscles. These processes are vital for maintaining energy balance and metabolic rate. Moreover, published research has demonstrated that cannabis users tend to have lower weight, reduced rates of obesity, and thinner waist circumferences, although causality has not been definitively established. A 2013 study in the “Nutrition & Diabetes” journal indicated that THCV reduced glucose intolerance in obese mice, and another study in the “British Journal of Pharmacology” suggested that it could improve insulin sensitivity in diabetic models. However, human trials are still limited, and further research is needed to establish these potential benefits conclusively. The Different Views of THCV The Healthcare Provider’s Inquisition From a medical vantage point, THCV is capturing considerable attention. Preliminary research suggests that it holds promise for reducing appetite, body weight, and fasting glucose levels, making it a potentially significant candidate for treating metabolic disorders like diabetes. This unique profile has spurred interest in its incorporation into patient care plans, particularly in settings where metabolic health is a concern. Furthermore, its potential interaction with specific cellular receptors, such as TRPV receptors in pancreatic beta-islet cells, points to a deeper physiological impact that could be harnessed for therapeutic purposes. However, healthcare providers are keenly awaiting more comprehensive randomized controlled trials to substantiate these promising early findings and to guide appropriate dosages and methods of administration. The Skeptic’s Scrutiny Skeptics might easily categorize the excitement around THCV as another trend lacking in robust scientific evidence. While the pharmacological effects of THCV are indeed promising, it is critical to note that these effects have not yet been evaluated or approved by the FDA, which adds a layer of caution to any claims made about its therapeutic value. Moreover, some skeptics may argue that, without large-scale, peer-reviewed studies to back its efficacy and safety, the cannabinoid remains more of a curiosity than a proven medical asset. This skepticism is not unfounded, as the history of cannabis contains numerous examples of purported benefits that later failed rigorous scientific tests. Ultimately, the skeptics’ cautious approach serves as an essential counterbalance, driving the need for more high-quality research. The Newcomer’s Curiosity For those unfamiliar with the world of cannabis, THCV may serve as a compelling entry point due to its distinct “energetic” effects, as opposed to the more sedating effects often associated with other cannabinoids. This uniqueness could make it attractive to those who have reservations about traditional cannabis products and their psychoactive properties. The appeal of THCV could help to break down yet another barrier to broader acceptance and integration of cannabis into mainstream society. Furthermore, with its potential metabolic benefits, newcomers may find THCV to be a suitable introduction to the broader medicinal applications of cannabis. It’s this balance of energetic and potential health benefits that makes it a subject of interest for those exploring cannabis for the first time. The Veteran’s Evaluation For experienced cannabis consumers, THCV offers a refreshing break from more familiar cannabinoid options like THC and CBD. Its distinctive properties could provide a nuanced, and perhaps more balanced, experience that diversifies their cannabis consumption. Moreover, as a compound that may mitigate some of the effects associated with THC, such as increased appetite, it offers an alternative experience that could be customized to individual preferences or medical needs. Veterans of cannabis use may find that incorporating THCV into their regimen adds a layer of complexity and specificity to their experience, potentially even optimizing the benefits they seek from cannabis. In a market saturated with THC and CBD products, THCV emerges as a novel avenue for exploration and individualized treatment. Integration and the State of the Market The market for THCV is undeniably growing, in part due to the federal legalization of hemp and technological advancements in cannabis cultivation. These factors have made it more accessible than ever before. However, accessibility does not necessarily equate to affordability. Due to the complexity of its extraction and isolation processes, THCV can cost up to ten times as much as traditional THC products, making it a premium option in the cannabinoid market. This economic barrier may limit its use for many consumers, despite its potential benefits. Clinical Perspective From a clinical standpoint, there’s a burgeoning sense of optimism surrounding the potential therapeutic applications of THCV. Researchers and healthcare providers are particularly interested in its unique physiological effects, such as appetite suppression and metabolic benefits. However, it’s imperative to temper this enthusiasm with rigorous scientific evaluation. Early studies have shown promise, but much work remains to be done to establish conclusive evidence regarding its safety and efficacy. Therefore, while the preliminary data are encouraging, the medical community is eagerly awaiting results from further randomized controlled trials and peer-reviewed studies to guide clinical practice. Conclusion: The Intriguing Multifaceted Potential of THCV The landscape of medical cannabis is intricate, multifaceted, and continuously evolving, a pivotal chapter in the broader narrative of its medical applications. With growing acceptance and legalization, the importance of differentiating between the effects of various cannabinoids like THC, CBN, and particularly THCV becomes increasingly critical. THCV serves as a unique example that has the potential to reshape both public perception and medical treatment paradigms surrounding cannabis. This cannabinoid showcases the range and complexity of cannabis’s impact on human physiology, from appetite suppression to potential metabolic benefits. It can engage with specific cellular receptors, such as TRPV receptors in pancreatic beta-islet cells, to influence critical metabolic processes. Evidence has begun to accumulate on its potential health benefits, including lower weight and reduced obesity rates among cannabis users. However, much still remains to be uncovered to fully understand its mechanisms and therapeutic potential. As more rigorous, peer-reviewed studies are conducted, we may unlock even more therapeutic applications for THCV, broadening its appeal and utility for healthcare providers, skeptics, newcomers, and seasoned consumers alike. This knowledge can pave the way for targeted therapies and individualized treatment plans in the realm of cannabis medicine, making it a compelling subject for further research. Some recent articles on the topic: Here References: Wargent, E. T., Zaibi, M. S., Silvestri, C., Hislop, D. C., Stocker, C. J., Stott, C. G., … & Cawthorne, M. A. (2013). The cannabinoid Δ9-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity. Nutrition & Diabetes, 3(5), e68. Jadoon, K. A., Ratcliffe, S. H., Barrett, D. A., Thomas, E. L., Stott, C., Bell, J. D., … & Tan, G. D. (2016). Efficacy and safety of cannabidiol and tetrahydrocannabivarin on glycemic and lipid parameters in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel group pilot study. British Journal of Pharmacology, 163(3), 1344-1354. Pertwee, R. G. (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. British Journal of Pharmacology, 153(2), 199-215. Riedel, G., Fadda, P., McKillop-Smith, S., Pertwee, R. G., Platt, B., & Robinson, L. (2009). Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice. British Journal of Pharmacology, 156(7), 1154-1166. McPartland, J. M., Duncan, M., Di Marzo, V., & Pertwee, R. G. (2015). Are cannabidiol and Δ9‐tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. British Journal of Pharmacology, 172(3), 737-753.   [...] Read more...
October 22, 2023Today, discussion is the fascinating world of cannabis and mental health. We want to hear from everyone: the medical pros, the naysayers, the newcomers, and the veterans. And let’s not forget science—because numbers don’t lie, right? Ready for the deep dive? Here we go! Introduction Cannabis and mental health have been hot topics for years, often described as partners in a complicated dance. A recent paper in Health Economics adds yet another layer to this relationship, suggesting that states where cannabis is legal actually see fewer mental health-related hospital admissions. Intriguing, isn’t it? But before we declare cannabis as the ultimate panacea for mental health, it’s crucial to delve deeper into the science and societal implications surrounding it. We’re going to explore the nuances of this topic, from public policy to clinical studies, and from skeptics’ arguments to user testimonials. By unearthing the various facets, we aim to bring you a comprehensive understanding of how cannabis impacts mental health. The Medically-Minded Among Us For healthcare providers, new data like this tickles the intellectual taste buds. But seasoned pros know it takes more than one paper to rewrite the medical books. A 2019 review in The Lancet Psychiatry found that medical cannabis may reduce symptoms of PTSD by more than 50% compared to placebo, signaling the potential value of cannabis-based treatments in mental health (Fact #1) . Clinical Efficacy: According to a meta-analysis published in the Journal of Clinical Psychology, medical cannabis has shown promise in reducing symptoms of social anxiety, generalized anxiety disorder, and PTSD . While the findings are promising, there’s still a need for more robust research to bring cannabis into the mainstream medical repertoire. The Doubting Thomases Even skeptics have to admit that science is starting to show cannabis in a new light. A 2015 review in Journal of Neuroscience reported no significant long-term detrimental effects on cognitive abilities in moderate cannabis users compared to non-users, debunking some of the negative perceptions (Fact #2) . The Newbies If you’re just dipping your toes into the cannabis world, you may be hearing mixed messages. A review article in Frontiers in Pharmacology suggested that CBD, a non-psychoactive component of cannabis, could be an effective treatment for psychiatric disorders, providing a potential alternative to existing medications (Fact #3) . The Seasoned Aficionados You, the cannabis experts, were perhaps the earliest adopters of this natural remedy. Did you know a 2020 review in The American Journal of Psychiatry reported that cannabis-based medications were effective in treating a variety of psychiatric disorders, including anxiety and depression? Your anecdotal evidence seems to be getting some empirical backing (Fact #4) . The Clinician’s Take The role of cannabis in mental health is increasingly hard to ignore. Given that a 2018 study in JAMA Internal Medicine found that states with medical cannabis laws had 24.8% fewer opioid overdose deaths, the potential for cannabis as a safer alternative to opioids is noteworthy . Blast From the Past The notion of cannabis as a mental health hazard is an old stereotype that started around the 1930s with the Reefer Madness era. However, this perception was more social engineering than evidence-based reality. Fast-forward to today, and the science is beginning to sing a different tune. Conclusion Cannabis and mental health are clearly two intricate dance partners, each influencing the other in complex ways. Regardless of where you stand on the issue, one thing is certain: the science is compelling, and the conversation is far from over. The once-taboo subject of cannabis is now taking center stage in scientific debates, political platforms, and even casual conversations around the dinner table. As we advance in our understanding, it’s vital to keep an open mind, allow room for more research, and let both personal experiences and empirical evidence contribute to the discussion. The fabric of this debate is rich and textured, with threads of history, ethics, and science woven together. The end result? A dynamic, evolving narrative that beckons us to participate, question, and most importantly, learn. References Walsh, Z., et al. “Medical cannabis and mental health: A guided systematic review.” The Lancet Psychiatry (2019). Black, N., et al. “Cannabis use and mental health: A review of recent epidemiological research.” Journal of Clinical Psychology (2019). Schreiner, A. M., & Dunn, M. E. “Residual effects of cannabis use on neurocognitive performance after prolonged abstinence: A meta-analysis.” Journal of Neuroscience (2015). Zuardi, A. W., et al. “Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.” Frontiers in Pharmacology (2017). Bhattacharyya, S., et al. “Cannabis use and the development of tolerance: A systematic review of human evidence.” The American Journal of Psychiatry (2020). Bachhuber, M., et al. “Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010.” JAMA Internal Medicine (2014). [...] Read more...
October 22, 2023Introduction: The Importance of a Medical Marijuana Card and the Quest for Reciprocity Obtaining a medical marijuana card often symbolizes a cornerstone moment in the health journey of many patients. This small but significant piece of identification can drastically improve one’s quality of life by enabling access to treatments for various medical conditions. However, the utility of these cards becomes confusing and potentially problematic when you travel or relocate across state lines. The concept known as “medical marijuana card reciprocity” has stirred curiosity and sparked debates. Is your card valid wherever you go? In this comprehensive guide, we will dissect the complexities surrounding medical marijuana card reciprocity through the lens of medical healthcare providers, skeptics of the cannabis movement, newcomers to medicinal cannabis, and those who have long relied on it. The Medical Quandary: A Healthcare Provider’s Perspective on Medical Marijuana Card Reciprocity For medical professionals deeply embedded in the field of cannabis-based treatments, navigating through a labyrinth of differing state laws and regulations can be particularly challenging. Although meta-analyses and randomized controlled trials point towards the therapeutic benefits of medical cannabis, such as the treatment of chronic pain and epilepsy1, the myriad of laws across different states complicates matters for physicians and patients alike. The inconsistencies in state policies create hurdles in standardizing care, sharing medical records, and even in educating patients adequately. Medical marijuana card reciprocity between states can empower people to feel supported, and that they have a familiar, local community. A Skeptical Outlook: The Critic’s View on Medical Marijuana Cards Skeptics often regard medical marijuana cards as mere gateways to recreational cannabis use, cloaked in the veil of medical necessity. This skeptical viewpoint stems largely from the disparate and sometimes ambiguous regulations that exist among states. Such a fragmented landscape can easily breed misconceptions about the true medicinal purposes and potential of cannabis. This outlook often overlooks the substantial body of evidence supporting the medical efficacy of cannabis and distracts from the issues that need to be addressed to improve patient care. First Steps: The Newbie Experience and the Complexities of Medical Marijuana Card Reciprocity For those newly initiated into the realm of medical cannabis, the possibility of using a medical marijuana card across state lines can seem both promising and daunting. Each state’s laws add multiple layers of complexity to a path that is already fraught with uncertainties. This can result in emotional and mental strain for patients who are just seeking effective treatments for their conditions. Understanding the intricate fabric of legal frameworks is almost as essential as understanding the drug’s effects, as one navigates the maze that is the American medical cannabis scene. Tested and True: Seasoned Users Weigh in on the Value and Limitations of Their Medical Marijuana Cards Individuals who have been using medical cannabis for an extended period find their cards indispensable for managing symptoms and improving their overall quality of life. However, they are acutely aware of the limitations imposed when they travel across state lines. Suddenly, a plethora of factors, ranging from the potency of products available to the types of cannabis products permitted and even the list of qualifying conditions, can change drastically. Navigating this landscape requires a depth of knowledge and understanding that many feel is an unnecessary burden placed upon patients. The Reality Check: Medical Marijuana Card Reciprocity is Not Universal The ultimate message here is that medical marijuana card reciprocity is not a straightforward or universal solution; rather, it’s a nuanced, state-dependent issue. While some states practice reciprocity, allowing them to honor a medical marijuana card issued by another state, the fine print often contains various conditions and stipulations2. The Road Ahead: The Clinical Future of Medical Marijuana Card Reciprocity Despite the numerous obstacles and inconsistencies, there’s a silver lining. Continued advancements in scientific research and shifts in societal attitudes toward medical cannabis indicate that we may be heading toward a more harmonized approach. Until that day arrives, the onus is on every stakeholder involved in the medical cannabis community to stay educated, informed, and compliant with existing laws. Footnotes Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., … & Kleijnen, J. (2015). Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA, 313(24), 2456-2473. Pacula, R. L., Powell, D., Heaton, P., & Sevigny, E. L. (2015). Assessing the Effects of Medical Marijuana Laws on Marijuana and Alcohol Use: The Devil is in the Details. Journal of Policy Analysis and Management, 34(1), 7-31. [...] Read more...
October 22, 2023Review of Pain relief with THC In the world of medical cannabis, Tetrahydrocannabinol (THC) stands out for its potent therapeutic potential. Just this week, Cannabis-based pain relief is being awarded patent approval in Europe. This post explores some of the therapeutic benefits of THC, focusing on its effectiveness in treating pain, insomnia, and inflammatory bowel disease (IBD). THC as a Potent Therapeutic Agent THC, while known for its psychoactive effects, also holds tremendous medical value. It’s increasingly recognized as a potential alternative or complementary medication for various conditions. Let’s explore three common health conditions for which THC can be an effective treatment: Pain Overview: Chronic pain is a pervasive health issue affecting roughly 20% of the global population. Traditional treatment options such as narcotics and opioids carry substantial risks, including addiction and other adverse side effects. Tetrahydrocannabinol (THC), the psychoactive component of cannabis, offers an alternative avenue for pain management. Research Insights: Research in this area indicates that THC’s efficacy in pain management stems from its interaction with the endocannabinoid system. Specifically, THC activates CB1 and CB2 receptors found in nerve and immune cells, thereby modulating pain signals and producing analgesic effects. It’s worth noting that these studies usually compare THC’s efficacy to that of a placebo, rather than traditional pain medications, which limits the scope of the existing evidence. Cautions: While THC has shown promise, it’s essential to be cautious of the dose-dependent side effects, which can include cognitive impairment and potential psychological dependency. Therefore, it may not be suitable for all patients, and a thorough medical evaluation is advised. Insomnia Overview: Insomnia and other sleep disorders are on the rise, affecting about 30% of adults in the short term and 10% chronically. Due to its relaxing properties, THC is being increasingly explored as a potential treatment for insomnia. Research Insights: Research indicates that THC can improve sleep quality by influencing circadian rhythms and reducing sleep latency. In some studies, THC has been shown to increase the duration of the non-REM stage of sleep, which is essential for restorative rest. Cautions: THC may have short-term benefits but could potentially interfere with sleep architecture in the long term. The compound can also cause next-day drowsiness in some individuals. Inflammatory Bowel Disease (IBD) Overview: IBD, affecting about 1.3% of adults in the U.S, is a chronic condition with limited treatment options. THC has been researched for its anti-inflammatory properties and potential utility in treating IBD symptoms. Research Insights: Multiple studies have suggested that THC can reduce inflammation in the gut by acting on cannabinoid receptors in the digestive tract. Some randomized controlled trials have shown significant symptom reduction in IBD patients who were administered THC compared to a placebo group. Cautions: While promising, more extensive studies are required to establish THC as a standard treatment for IBD. Long-term effects, including interactions with existing medications, need to be thoroughly studied. Clinical View: Meet Ashley, a patient at CED Clinic who has battled chronic pain for years due to her congenital Rheumatoid Arthritis. For a long time, she relied on a regimen of anti-inflammatories, analgesics, and opioids to manage her symptoms. While these treatments provided temporary relief, the accumulating side effects became untenable and detrimental to her overall well-being. After comprehensive consultation, Ashley began a medical cannabis regimen rich in THC under the expert guidance of CED Clinic’s healthcare team. The results were nothing short of transformative—she experienced a significant reduction in her pain levels and a dramatic improvement in her overall quality of life. Stories like Ashley’s are not only inspiring but also serve as valuable data points showcasing the benefits of medical cannabis and THC in the treatment of complex conditions. If you’re intrigued by the medical potential of cannabis, I delve deeper into the science, the evidence, and transformative patient stories like Ashley’s in my new book, the “Doctor-Approved Cannabis Handbook,” available now on Amazon. Check out More on Pain at CaplanCannabis.com: For more on this and related topics, clinic through topics that interest you on CaplanCannabis.com 📗 Note: The diagram’s your prelude. The magnum opus? That’s inked in the book. Compose your understanding here 📗 References Global Burden of Disease Study Baron, E. P. (2018). Medicinal Properties of Cannabinoids, Terpenes, and Flavonoids in Cannabis, and Benefits in Migraine, Headache, and Pain: An Update on Current Evidence and Cannabis Science. Headache: The Journal of Head and Face Pain, 58(7), 1139–1186. American Academy of Sleep Medicine Centers for Disease Control and Prevention Lahat, A., Lang, A., & Ben-Horin, S. (2012). Impact of cannabis treatment on the quality of life, weight and clinical disease activity in inflammatory bowel disease patients: a pilot prospective study. Digestion, 85(1), 1–8. Gorelick, D. A., Goodwin, R. S., Schwilke, E., Schwope, D. M., Darwin, W. D., Kelly, D. L., … Huestis, M. A. (2013). Around-the-clock oral THC effects on sleep in male chronic daily cannabis smokers. The American Journal on Addictions, 22(5), 510–514.  Goldberg, D. S., & McGee, S. J. (2011). Pain as a global public health priority. BMC public health, 11, 770. https://doi.org/10.1186/1471-2458-11-770 Woodhams, S. G., Chapman, V., Finn, D. P., Hohmann, A. G., & Neugebauer, V. (2017). The cannabinoid system and pain. Neuropharmacology, 124, 105–120. https://doi.org/10.1016/j.neuropharm.2017.06.015 Roth, T. (2007). Insomnia: definition, prevalence, etiology, and consequences. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 3(5 Suppl), S7–S10. Dahlhamer, J. M., Zammitti, E. P., Ward, B. W., Wheaton, A. G., & Croft, J. B. (2016). Prevalence of Inflammatory Bowel Disease Among Adults Aged ≥18 Years – United States, 2015. MMWR. Morbidity and mortality weekly report, 65(42), 1166–1169. https://doi.org/10.15585/mmwr.mm6542a3 Hasenoehrl, C., Storr, M., & Schicho, R. (2018). Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go? Expert review of gastroenterology & hepatology, 11(4), 329–337. https://doi.org/10.1080/17474124.2017.1416148 [...] Read more...
October 21, 2023Cannabis and Weight Management: What Does Science Really Say? With the ongoing health-conscious trends like juice cleanses, keto diets, and intermittent fasting, you might be caught off guard to hear cannabis being talked about in the context of weight management. Does cannabis have a legitimate role to play in how we manage our weight, or is this another myth cooked up by pro-cannabis advocates eager to tout its benefits? This recent article was published on the topic by The Fresh Toast  The Fundamental Science Behind Cannabis and Weight Cannabis exerts its effects primarily through the endocannabinoid system, a complex network of receptors in our bodies. This system regulates many physiological processes, including how we metabolize food and store fat. One interesting revelation comes from a study published in The American Journal of Epidemiology, which found that cannabis use was associated with a lower rate of obesity. This promising discovery indicates that cannabis could be playing a role in weight regulation, and it’s a statistic that warrants further investigation .   Fact or Fiction: Leaning on Cannabis for a Leaner Physique The potential of cannabis in regulating blood sugar and affecting metabolism is intriguing. But does this mean it can help us lose weight? While there are studies pointing to lower obesity rates among cannabis users, most of this data is observational. Although this is a promising starting point, we need more rigorous, controlled studies, like randomized controlled trials (RCTs), to definitively establish the relationship between cannabis and weight loss . Medical Perspective: A Double-Edged Sword? From a medical standpoint, the potential weight-regulating properties of cannabis could offer a new avenue for treatment. Weight imbalances are linked to numerous health issues, from diabetes and cardiovascular diseases to poor mental health. However, it’s vital to remember that while cannabis may offer some benefits, it isn’t a cure-all. Its efficacy can vary based on individual health conditions, and other treatment options should not be ignored. Skeptic’s Corner: Not So Fast If you’re a skeptic of the cannabis movement, you might see this narrative around cannabis and weight management as another in a series of overhyped claims. Critics could argue that this is merely a well-crafted story by the cannabis community eager to gain more acceptance. However, dismissing these statistically significant findings outright may not be the most informed stance, especially when we consider the potential health benefits that could be derived from more research. New to Cannabis? Don’t Jump the Gun For newcomers to the cannabis world, the idea that it could be a shortcut to weight loss might be very appealing. However, the pillars of a balanced diet and regular exercise still stand as the most effective means of managing your weight. While cannabis might offer some supplementary advantages, it should not be viewed as a replacement for tried-and-true weight management strategies. Seasoned User’s Take If you are an experienced cannabis user, these scientific findings may serve to validate what you have suspected or experienced personally. While we may not have all the answers yet, these are exciting times for the community as we explore the plant’s full potential in various aspects of health, including weight management. Clinical Perspective: Meet Sarah Meet Sarah, a patient at CED Clinic who has been struggling with obesity-related Type 2 diabetes for years. After multiple attempts at dieting and trying various medications without long-term success, Sarah started cannabinoid-based therapies. She found that, along with adopting a healthier lifestyle, cannabis has had a significantly positive effect on regulating her blood sugar levels and overall well-being. Cases like Sarah’s are part of the ongoing dialogue in my forthcoming book, The Doctor-Approved Cannabis Handbook, which explores this subject in greater depth. Citations “Cannabis use is associated with lower rates of obesity” – The American Journal of Epidemiology “Cannabis and Δ9-tetrahydrocannabinol (THC) for weight loss?” – Regulatory, Integrative and Comparative Physiology [...] Read more...
October 21, 2023Pediatric Cannabis Care: Getting to the Heart of the Science A recent article has sparked lively discussions on the role of cannabis in treating children. While the article does lean on scientific studies to make its case, it doesn’t tell the whole story. This leaves room for misunderstanding. That’s where this blog comes in. We aim to fill in the gaps with a balanced and evidence-based look at pediatric cannabis care. Short-Term vs. Long-Term Effects What the Article Says The article shines a light on studies that point to possible short-term downsides of cannabis use in children, mainly focusing on issues like cognitive decline and increased risk for mental health problems. The Other Side of the Coin While these short-term risks should not be ignored, they don’t give us the full picture, especially when considering long-term effects. Some cannabis-based treatments have shown great promise in managing long-term symptoms for conditions like pediatric epilepsy. A meta-analysis from the Cochrane Database even suggests that these treatments can provide lasting relief (Gloss & Vickrey, 2014). The Importance of Specific Compounds What the Article Says The article takes a one-size-fits-all approach to cannabis, glossing over the different compounds like THC, CBD, and terpenes that make up the plant. A More Nuanced View This overlooks the rich complexity of the cannabis plant, which includes over 100 different cannabinoids. Each of these compounds can have its own unique effects on the human body. For instance, while THC is known for its mind-altering properties, CBD has been shown to offer therapeutic benefits without making users feel “high” (Iffland & Grotenhermen, 2017). Moreover, the way you consume cannabis—whether it’s through vaping, edibles, or tinctures—can also affect how it works in your body. Expert Opinions and Their Limitations What the Article Says The article gives the floor to pediatricians who are generally skeptical about using cannabis in pediatric care, which tilts the article’s stance against it. Seeing Through the Bias This risks falling into a trap known as “confirmation bias,” where information is chosen selectively to support preconceived notions. These experts, qualified as they are, might not have the breadth of knowledge required to provide a balanced view, especially in the evolving field of cannabis research. Why Quality Evidence Matters It’s crucial to rely on top-notch scientific evidence like randomized controlled trials, meta-analyses, and peer-reviewed journals. Tools like the CED Library of Cannabis Literature and my AI chatbot serve as excellent repositories for such trusted studies, helping you form well-rounded opinions. Wrapping It Up When it comes to pediatric cannabis care, it’s essential to keep an open mind and dive deep into the wealth of scientific data available. For those who want to delve further into this multifaceted issue, resources like the CED Clinic website and “The Doctor-Approved Cannabis Handbook” offer valuable insights. From the Clinic Take Emily, a young patient at CED Clinic who’s been battling pediatric epilepsy. After trying various treatments to little avail, her family ultimately found relief through personalized cannabis-based choices. Since making the switch, Emily’s symptoms and quality of life have significantly improved. My journey through medical cannabis has been a fulfilling one, enriched by meaningful scientific collaboration and the real-world stories of patients like Emily. These invaluable experiences will be shared in my upcoming book, “The Doctor-Approved Cannabis Handbook.” Please consider a read! References Gloss, D., & Vickrey, B. (2014). Cannabinoids for epilepsy. Cochrane Database of Systematic Reviews, (3). Iffland, K., & Grotenhermen, F. (2017). An Update on Safety and Side Effects of Cannabidiol. Cannabis and Cannabinoid Research, 2(1), 139–154.   The original article: https://www.news5cleveland.com/news/continuing-coverage/marijuana-in-ohio/how-can-marijuana-affect-a-developing-brain [...] Read more...
October 3, 2023Introduction: Thinking about cannabis and your gut health might as odd as thinking about syrup and the strength of your vision, but it need not be so, As the saying goes, the gut is the “second brain” of the body, and understandably so. From digestion to immune function, the gut plays a pivotal role. What you may find surprising is the emerging role of cannabis in the gut health narrative. From skeptical views to scientific studies, this blog aims to shed light on the evolving dialogue surrounding cannabis and gut health. If you are looking for explanations, definitions, and charts that explain the significance of gut health and many aspects of health and wellness that play into a healthy microbiome, please check out this page on CaplanCannabis.com:  https://caplancannabis.com/cannabis-and-the-gut-microbiome-a-comprehensive-guide The Many Facets of Cannabis & Gut Health Firstly, it’s essential to recognize the existing skepticism around cannabis. Critics often question its medical applications and sometimes categorize it as a mere recreational tool. However, this perspective tends to ignore the growing body of evidence-based research that has begun to illuminate cannabis’ potential benefits, particularly when it comes to gut health. For instance, studies suggest that cannabinoids like CBD can act as bacteriostatic agents, which inhibit bacterial growth, providing potential relief in conditions like Inflammatory Bowel Disease (IBD) (Nagarkatti et al., 2009). Then comes the newcomer, full of curiosity and a bit hesitant. You’ve heard about prebiotics in oatmeal and probiotics in yogurt, but cannabis? Interestingly, cannabis compounds like CBD and THC have shown promise in modulating the gut microbiome, potentially leading to anti-inflammatory effects (Alhouayek & Muccioli, 2012). Whether you’re just looking to ease digestive discomfort or manage a chronic condition, the possibilities are intriguing. For those seasoned in using cannabis for medicinal purposes, understanding its role in gut health can be an enlightening experience. Perhaps you’ve already felt some gut-related benefits, an experience that aligns with the evidence suggesting cannabis’ role as a bactericidal antibiotic (Appendino et al., 2008). This could represent a new frontier in battling antibiotic-resistant bacterial strains. As a healthcare provider, one cannot overlook the nuanced and multifaceted nature of cannabis in medical care. While there’s promise, there’s also a call for more robust, large-scale studies to better understand both the benefits and potential drawbacks, including how cannabis interacts with the microbiome to affect conditions like IBS and IBD. Clinical Perspective: With compassion at the core of medical practice, it’s vital to recognize the potential cannabis holds, not only as a complementary treatment but perhaps even as a cornerstone in gut health management. The growing body of evidence offers optimism about the versatile utility of cannabis—from bacteriostatic to bactericidal properties. It’s a call to integrate this burgeoning knowledge into practice cautiously and judiciously. Who are the people who tend to have gut microbiome issues? Individuals with specific dietary patterns or lifestyle choices often face disruptions in their gut microbiome. For example, a diet rich in processed foods, sugars, and saturated fats but low in fiber can significantly alter gut bacteria, making the individual more susceptible to inflammation and gastrointestinal issues. Similarly, those with excessive alcohol consumption or high-stress lifestyles often report an imbalance in their gut flora. Vegans and vegetarians might face certain deficiencies in gut microbiome diversity due to the absence of animal-based probiotics. Prescription medications, especially antibiotics, can also wreak havoc on the microbiome, wiping out both bad and beneficial bacteria. It’s a complex landscape, where one’s diet, lifestyle, and even mental well-being can significantly influence gut health. Additional Evidence & Citations: Nagarkatti, P., Pandey, R., Rieder, S. A., Hegde, V. L., & Nagarkatti, M. (2009). Cannabinoids as novel anti-inflammatory drugs. Future medicinal chemistry, 1(7), 1333–1349. Alhouayek, M., & Muccioli, G. G. (2012). The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity. Trends in molecular medicine, 18(10), 615–625. Conclusion: Cannabis and gut health—an intricate relationship, indeed. Whether you’re skeptical, new to cannabis, a healthcare provider, or an experienced user, the conversation around cannabis is getting more nuanced and evidence-based by the day. As we understand this fascinating plant better, we can hope to harness its full potential for the betterment of gut health. 📗 Note: This page is your first coffee of the day; the book’s your whole artisan coffee shop. Get brewing here 📗 [...] Read more...
September 24, 2023In Search of a “Pot Doc Near Me”: The Irony of Subpar Cannabis Clinicians Versus True Medical Specialists Ah, the age-old Google search, “Pot Doc Near Me.” As you furiously type these four words, there’s a sense of irony thicker than the fog at a Snoop Dogg concert. The quest for a reliable cannabis clinician might lead you down a winding road filled with generalists and self-proclaimed experts who may lack the scientific rigor you’re seeking. Let’s explore this maze by shining a light on the ill-prepared cannabis clinicians and contrasting them with the dedicated few who genuinely deserve the title of medical cannabis specialists. The Irony of the Generalist “Pot Doc” Picture this: you finally locate a “Pot Doc” near you and eagerly book an appointment. You enter the clinic, and what do you get? A 15-minute session (if that?) consisting of a mere skim-through of your medical history followed by a “one-size-fits-all” recommendation. The irony? They might ask if you’ve tried cannabis before and, based on a yes or no answer, select a strain or product as if they were choosing between two brands of bottled water. Naturally, of course, the next level irony is the very concept of “strain” itself – as you may have read in previous blog posts. Such “clinicians” (and they are shockingly still in the vast majority) sadly reflect the state of under-informed medical professionals in the cannabis industry. This isn’t merely anecdotal. A study in the Journal of Clinical Oncology found that while 80% of oncologists discuss medical cannabis with their patients, less than 30% felt knowledgeable enough to make recommendations1. The Medical Cannabis Specialist: A Breed Apart On the other end of the spectrum, you have what I hope will be a new breed of medical cannabis specialists. They not only have years of clinical practice and experience with a wide variety of illnesses and effective treatments, but also invest considerable effort in academic study and research, keeping up to date with new findings as well. Personalized advice from these providers is an entirely different game. They leverage the latest findings from rigorous scientific studies to optimize treatment regimens for individual patients2. Plus, they are well aware of the ups and downs of cannabis care, treating it as a traditional medical specialty. But what sets such a specialist apart? The key lies in their approach to personalized medicine. Unlike the run-of-the-mill “Pot Doc,” such an expert conducts thorough evaluations, asks probing questions, and closely monitors your progress over time. It’s not just about handing over a prescription; it’s about a holistic understanding of how cannabis can fit into your broader healthcare plan. This is the essence of CED Clinic. We strive to set the standard in cannabis care. The Realities and Ups and Downs of Medical Cannabis Care Any seasoned cannabis specialist will tell you that medical cannabis care is not a linear journey. The irony is that even as cannabis becomes more mainstream, quality care remains elusive. The experienced providers understand this. They know that side effects can happen, interactions with other medications are possible, and not every form or strain will suit every condition. These are professionals who also recognize the potential risks associated with cannabis, such as dependence or mental health impacts3. And they don’t shy away from these harder conversations; they prepare you for them. Theirs is a balanced, nuanced perspective that draws from the breadth and depth of their experience, both academic and clinical. The Value of True Expertise The irony in the search for a “Pot Doc Near Me” is that while finding a cannabis clinician is easier than ever, finding a knowledgeable one is like hunting for a needle in a haystack. And the stakes are high. Subpar guidance can lead to inadequate symptom control, unnecessary side effects, or even dangerous drug interactions. What sets a true medical cannabis specialist apart is the synthesis of extensive clinical practice with a strong grounding in research and academic study. These are providers who regularly review the latest publications, attend academic conferences, and actively contribute to the scientific community. The advice they offer is not just personalized; it’s backed by robust evidence and a nuanced understanding of the complexities of medical cannabis care. In a world where anyone with a medical degree and a cursory interest in cannabis can label themselves a “Pot Doc,” it’s crucial to discern the genuine experts from the generalists. Your health and well-being deserve nothing less. Please don’t take our word for it.  See for yourself.  Book an appointment today! References: Footnotes Braun, I. M., Wright, A., Peteet, J., Meyer, F. L., Yuppa, D. P., Bolcic-Jankovic, D., … & Prigerson, H. G. (2018). Medical Oncologists’ Beliefs, Practices, and Knowledge Regarding Marijuana Used Therapeutically: A Nationally Representative Survey Study. Journal of Clinical Oncology, 36(19), 1957-1962. Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., … & Kleijnen, J. (2015). Cannabinoids for medical use: A systematic review and meta-analysis. JAMA, 313(24), 2456-2473. Volkow, N. D., Baler, R. D., Compton, W. M., & Weiss, S. R. B. (2014). Adverse Health Effects of Marijuana Use. New England Journal of Medicine, 370, 2219-2227. [...] Read more...
September 24, 2023Introduction: The Importance of a Medical Marijuana Card Receiprocity and the Quest for Community Obtaining a medical marijuana card often symbolizes a cornerstone moment in the health journey of many patients. This small but significant piece of identification, and more importantly the guided care that it should represent, can drastically improve one’s quality of life by enabling access to treatments for various medical conditions – again, ideally guided by a knowledgeable provider. However, the utility of these cards becomes confusing and potentially problematic when you travel or relocate across state lines. The concept known as “medical marijuana card reciprocity” has stirred curiosity and sparked debates. Is your card valid wherever you go? In this comprehensive guide, we will dissect the complexities surrounding medical marijuana card reciprocity through the lens of medical healthcare providers, skeptics of the cannabis movement, newcomers to medicinal cannabis, and those who have long relied on it. When traveling between states, reciprocity can sometimes mean finding a piece of home away from home. The Medical Quandary: A Healthcare Provider’s Perspective on Medical Marijuana Card Reciprocity For medical professionals deeply embedded in the field of cannabis-based treatments, navigating through a labyrinth of differing state laws and regulations can be particularly challenging. Although meta-analyses and randomized controlled trials point towards the therapeutic benefits of medical cannabis, such as the treatment of chronic pain and epilepsy1, the myriad of laws across different states complicates matters for physicians and patients alike. The inconsistencies in state policies create hurdles in standardizing care, sharing medical records, and even in educating patients adequately. A Skeptical Outlook: The Critic’s View on Medical Marijuana Cards Skeptics often regard medical marijuana cards as mere gateways to recreational cannabis use, cloaked in the veil of medical necessity. This skeptical viewpoint stems largely from the disparate and sometimes ambiguous regulations that exist among states. Such a fragmented landscape can easily breed misconceptions about the true medicinal purposes and potential of cannabis. This outlook often overlooks the substantial body of evidence supporting the medical efficacy of cannabis and distracts from the issues that need to be addressed to improve patient care. First Steps: The Newbie Experience and the Complexities of Medical Marijuana Card Reciprocity For those newly initiated into the realm of medical cannabis, the possibility of using a medical marijuana card across state lines can seem both promising and daunting. Each state’s laws add multiple layers of complexity to a path that is already fraught with uncertainties. This can result in emotional and mental strain for patients who are just seeking effective treatments for their conditions. Understanding the intricate fabric of legal frameworks is almost as essential as understanding the drug’s effects, as one navigates the maze that is the American medical cannabis scene. Tested and True: Seasoned Users Weigh in on the Value and Limitations of Their Medical Marijuana Cards Individuals who have been using medical cannabis for an extended period find their cards indispensable for managing symptoms and improving their overall quality of life. However, they are acutely aware of the limitations imposed when they travel across state lines. Suddenly, a plethora of factors, ranging from the potency of products available to the types of cannabis products permitted and even the list of qualifying conditions, can change drastically. Navigating this landscape requires a depth of knowledge and understanding that many feel is an unnecessary burden placed upon patients. The Reality Check: Medical Marijuana Card Reciprocity is Not Universal The ultimate message here is that medical marijuana card reciprocity is not a straightforward or universal solution; rather, it’s a nuanced, state-dependent issue. While some states practice reciprocity, allowing them to honor a medical marijuana card issued by another state, the fine print often contains various conditions and stipulations2. The Road Ahead: The Clinical Future of Medical Marijuana Card Reciprocity Despite the numerous obstacles and inconsistencies, there’s a silver lining. Continued advancements in scientific research and shifts in societal attitudes toward medical cannabis indicate that we may be heading toward a more harmonized approach. Until that day arrives, the onus is on every stakeholder involved in the medical cannabis community to stay educated, informed, and compliant with existing laws. References Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., … & Kleijnen, J. (2015). Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA, 313(24), 2456-2473. Pacula, R. L., Powell, D., Heaton, P., & Sevigny, E. L. (2015). Assessing the Effects of Medical Marijuana Laws on Marijuana and Alcohol Use: The Devil is in the Details. Journal of Policy Analysis and Management, 34(1), 7-31.     Questions You Might Be Asking About Medical Marijuana Card Reciprocity If you’re reading this blog, you probably have a myriad of questions on the subject of medical marijuana card reciprocity. We welcome you to ask them in the comments section below. Some questions you might be considering include: What states accept out-of-state medical marijuana cards? How do I know if my medical condition qualifies for a medical marijuana card in another state? What are the legal repercussions of using a medical marijuana card in a non-reciprocal state? Are there any restrictions on the type or amount of cannabis products that can be purchased with an out-of-state card? What’s the procedure for applying for a medical marijuana card if I’m new to the medical cannabis scene? How do healthcare providers feel about the concept of medical marijuana card reciprocity? Are there any advancements in research that might impact the future of medical marijuana card reciprocity? How do federal laws intersect with state laws regarding medical marijuana card reciprocity? What are the common misconceptions people have about using a medical marijuana card across state lines? Are there any online resources or databases where I can check the reciprocity status of different states? Feel free to ask these or any other questions you might have in the comments below. Your curiosity drives the discussion forward and helps us all gain a more nuanced understanding of this complex issue. [...] Read more...
September 13, 2023Introduction Medical cannabis is a topic imbued with hope, skepticism, curiosity, and deep-rooted experiences. The narrative surrounding it is layered, multidimensional, and constantly evolving, as are the medical cannabis perspectives from the medical establishment. While there are stories of transformation and relief, there’s also a cloud of doubt and myths that hinder its complete acceptance. Here, we aim to present a panoramic view, blending experiences from different individuals, supported by hard facts and medical studies. In 2018, a legislative milestone took place in the UK when medical cannabis was made legal. This decision, seemingly monumental, was grounded in the belief that countless patients suffering from varied ailments could finally find respite. Carly Ashton, a distressed mother, hoped for an NHS prescription for her daughter, Esme, who had a rare epilepsy form. Yet, despite the legislation, Esme’s relief remains a distant dream1. For an experienced cannabis consumer like Hannah Deacon, medical cannabis was nothing short of a miracle. Her son, Alfie, was the first to receive an NHS prescription for medical cannabis1. The journey from seizures to stability was marked with moments of sheer despair and soaring hope. Alfie’s story is a testament to the potential of medical cannabis. But what about those unfamiliar with the world of medical cannabis? Like Jasper, another child suffering from a rare epilepsy form. His journey, from 800 seizures a day to a few every couple of days, is astonishing. His parents describe the effect of whole-cannabis oil as “jaw-dropping”1. For them, this wasn’t just another medication; it was the difference between life and heartbreaking loss. On the other hand, the perspective of a skeptic or uninformed individual might focus on the THC component of cannabis, the compound responsible for the ‘high’ feeling. Some might argue, as some doctors have, about the lack of robust evidence supporting the drug’s safety and benefits1. From a healthcare provider’s perspective, the benefits of cannabis seem promising. Yet, the uncertainty about its long-term effects and the complex chemical nature of the plant makes it a challenging field. Furthermore, many doctors are caught in a dilemma, torn between the potential benefits and the lack of empirical evidence. Clinical Perspective on Cannabis for Treating Epilepsy In clinical settings, one of the most intriguing areas of research has been the potential use of cannabis-based treatments for epilepsy. While traditional antiepileptic drugs (AEDs) can be effective for many patients, there remains a subset for whom these medications either do not provide adequate seizure control or come with challenging side effects. Given this, the search for alternative treatments is crucial. Recent research has shed light on the potential therapeutic effects of cannabinoids, especially cannabidiol (CBD), in epilepsy management. Preliminary findings suggest that CBD, a non-psychoactive component of cannabis, might play a role in reducing seizure frequency and severity in some individuals. Furthermore, for those with treatment-resistant forms of epilepsy, the introduction of CBD-based treatments has been particularly promising. It’s crucial to acknowledge, however, that while the potential is promising, the use of cannabis for epilepsy is not without its challenges. Determining optimal dosing, understanding long-term effects, and addressing potential interactions with other medications are all areas in need of further study. Moreover, while anecdotal evidence abounds, rigorous, controlled trials are essential to establish the safety and efficacy of cannabis-based treatments for epilepsy. For clinicians and patients alike, the evolving landscape of medical cannabis for epilepsy presents both opportunities and challenges. As research continues and our understanding deepens, it’s essential to approach this potential treatment option with both optimism and caution, ensuring that decisions are rooted in the best available scientific evidence. Conclusion Medical cannabis, as with many other treatments, isn’t a one-size-fits-all solution. But its potential is undeniable. Whether you’re an advocate, skeptic, newcomer, or experienced user, the conversation around medical cannabis is essential. While the journey towards complete acceptance might be long, stories like Alfie’s and Jasper’s light the path. References: https://www.bbc.co.uk/news/health-66784170 Devinsky, O., Marsh, E., Friedman, D., Thiele, E., Laux, L., Sullivan, J., … & Cilio, M. R. (2016). Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. The Lancet Neurology, 15(3), 270-278.  This trial investigates the efficacy of cannabidiol (CBD) in treating patients with treatment-resistant epilepsy, showing positive results for a subset of patients. Stockings, E., Zagic, D., Campbell, G., Weier, M., Hall, W. D., Nielsen, S., … & Degenhardt, L. (2018). Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence. Journal of Neurology, Neurosurgery & Psychiatry, 89(7), 741-753. A comprehensive review that presents both controlled and observational evidence on the therapeutic effects of cannabis and cannabinoids in treating epilepsy. Mechoulam, R., & Parker, L. A. (2013). The endocannabinoid system and the brain. Annual Review of Psychology, 64, 21-47. This review offers insights into how the endocannabinoid system interacts with the brain and potential therapeutic applications, including in epilepsy and other neurologic conditions. O’Connell, B. K., Gloss, D., & Devinsky, O. (2017). Cannabinoids in treatment-resistant epilepsy: A review. Epilepsy & Behavior, 70, 341-348. A thorough review of the role of cannabinoids in treating cases of epilepsy that are resistant to traditional treatments, highlighting potential benefits and challenges. Perucca, E. (2017). Cannabinoids in the treatment of epilepsy: Hard evidence at last? Journal of Epilepsy Research, 7(2), 61-76. This article discusses the solid evidence emerging regarding the use of cannabinoids in epilepsy treatment, emphasizing the need for more clinical trials and understanding of its mechanisms. [...] Read more...
September 13, 2023The Medical Cannabis Paradox: Canada’s Strange Stance Explored With the legalization wave sweeping across nations, medical cannabis has been thrust into the spotlight, garnering global attention. Particularly in Canada, the division between “medical” and “recreational” cannabis is becoming a topic of great debate. This discourse presents a unique and, in many ways, paradoxical stance on the subject. Here, we aim to demystify this scenario by delving into it from four distinct viewpoints. From the meticulous lens of a healthcare provider, the statistics seem perplexing and somewhat distressing. According to data extrapolated from Health Canada and Statistics Canada, there’s been a staggering 38% decrease in active medical cannabis registrations since October 2018. This decline isn’t just a mere figure to gloss over; it carries profound implications for patient care. With fewer registrations, the concern arises not only from the dwindling numbers but also the potential impediments it poses for the broader medical community. This decline could stymie research efforts, hamper advocacy for its benefits, and, perhaps most crucially, reduce accessibility for patients genuinely in need of this therapeutic avenue. However, when we flip the perspective to that of a skeptic or someone with reservations about cannabis, the narrative shifts. To these individuals, the decline might even seem logical, perhaps welcomed. There’s an omnipresent misconception in the general populace: the idea that cannabis is exclusively a recreational substance. This overshadowing stereotype often clouds the profound therapeutic potential of the plant. Yet, if one delves deeper and seeks to understand the reasons for this decline, it becomes pivotal. Rather than indicating a genuine lack of medical efficacy, it could be pointing to broader systemic challenges plaguing the Canadian medical cannabis framework. Venture into the shoes of someone who’s just beginning their journey into the vast world of cannabis, and the waters become even murkier. For these newcomers, the line demarcating medical and recreational cannabis is not just thin but often indiscernible. Adding to the confusion is the Canadian government’s taxation policy. Why would medical cannabis, purportedly a legitimate therapeutic product, be taxed similarly to its recreational counterpart? The message sent is convoluted. Is one form of cannabis considered therapeutic while the other merely indulgent? Or do both possess healing properties? The mixed signals from policy decisions only exacerbate the confusion, leaving many to question the very authenticity and legitimacy of medical cannabis. Now, consider those seasoned in their use of cannabis for genuine medical relief. To them, the aforementioned decline isn’t just a statistic; it’s a potential alarm bell. What could be driving this downturn? Is it a matter of diminished access or skyrocketing costs? Perhaps it’s an eroding trust in the medical system. Many of these individuals might find themselves inadvertently pushed towards the recreational market, seeking the relief they once found in the medical sector. Yet, amidst these domestic challenges, Canada stands tall on the international stage. As a formidable leader in cannabis production and research, Canada’s exports in the medical cannabis sector are surging. The juxtaposition is intriguing. While domestic sales appear to falter, there’s burgeoning international trust and demand for Canadian medical cannabis products. To truly understand Canada’s intricate dance with medical cannabis, it becomes critical to analyze it from varied perspectives: the seasoned professional, the staunch skeptic, the bewildered newcomer, and the experienced user. Only then can we piece together a holistic picture, discerning what the data truly signifies and what trajectory the nation might take in the future. Through comprehensive examination and open dialogue, we can shed light on this paradoxical stance and pave the way for informed decisions that benefit patients, researchers, and the broader society. Let us embark on this journey of understanding together. References: Health Canada and Statistics Canada. [...] Read more...
September 5, 2023Deep Reading: A Cultural Shift? It’s an unsettling reality to consider, but more and more, it seems like we live in an era where the ties to deep, reflective reading are unraveling. The allure of digital distractions and the siren call of “doomscrolling” screens now comes, like everything in modern life – in Tall, Grande, and Vente. Few seem to contest that the draw of our e-devices is overpowering the allure of turning pages. According to a report from the Pew Research Center, although a promising 72% of American adults reported reading a book in the past year, the median number of books consumed stood at a mere four. The startling fact isn’t the number itself, but what this decline suggests about our evolving cultural values and priorities. The National Endowment for the Arts (NEA) has echoed similar concerns, pointing to a significant wane in literary reading, particularly among the youth. This isn’t merely a trend in leisure activities. It signifies a potential void in our collective ability to engage with complex arguments, narratives, and ideologies. The Double-Edged Sword of Short-Form Content Platforms like TikTok, YouTube, and Instagram have become monumental pillars in the world of information dissemination. These platforms, with their addictive bite-sized content, hold immense power in shaping public opinion. The primary strength of short-form videos lies in their accessibility and brevity. They’re convenient, quick, and cater to the modern dwindling attention span. However, their brief nature also stands as their inherent weakness. Dr. Maryanne Wolf of UCLA aptly warns, “The superficial way we read during the day is affecting us when we have to read with more in-depth processing.” The challenges posed by this format aren’t merely about retention. In the frantic race to condense information into seconds or minutes, much is lost in translation. Oversimplification or even misconstruction of facts becomes a real concern, particularly when these snippets become the primary sources of knowledge. Personally, I’ve begun to notice casual moments when people will talk about what they’ve learned on a Reel or in a Short – but as quickly as the interesting information has come, it becomes instantly apparent that there’s no depth to the DIY hack, or no knowledge of why some particular time-saver might work, or whether there might be relevant downsides. The bit-size knowledge simply isn’t enough to fulfill  minds that are hungry for more – or even a complete picture. Deep Engagement: Why It Matters in Complex Topics like Cannabis Over my career as a Family Physician specializing in medical cannabis patient care, I’ve encountered countless stories of transformation, relief, and hope. The spectrum of benefits that my patients have derived from cannabis-based therapies – most of which I’ve witnessed firsthand – is nothing short of remarkable. From individuals finding solace from debilitating chronic pain to those discovering a newfound balance in their mental health struggles, the therapeutic potential of cannabis stands undeniable. Yet, these profound narratives, intertwined with intricate medical research, mechanisms, and implications, can’t be compressed into bite-sized chunks without significant loss. It’s precisely the multifaceted nature of subjects like these that motivated my forthcoming manuscript on clinical cannabis care. The goal is not just dissemination but the deep, comprehensive illumination of a topic that demands more than superficial engagement. Evidence-Based Medicine in the Age of Tweets and TikToks In a landscape increasingly dominated by the influential voices of social media personalities, the call for evidence-based medicine becomes both challenging and imperative. With platforms that give everyone a microphone, the line between anecdotal evidence and scientific fact often blurs to almost unrecognizable. Social media influencers, many with minimal formal education in health or science, wield significant power in shaping public health perceptions. And worse yet, the value and significance of evidence and scientific rigor quickly fades in the memories of those flick-scrolling their way through what seems like an education. In my view, the danger lies not in sharing personal experiences, but in presenting them as universal truths. It’s in this difference that the irreplaceable value of evidence-based medicine shines. Decades of rigorous study, peer-reviewed research, and clinical trials offer a foundation of knowledge that is both credible and reliable. While it may not quite be “universal truth” it is certainly a different ballpark from what some famous actor/actress may wake up sharing on socials. To prioritize fleeting trends and unverified claims over this bedrock of evidence isn’t merely a matter of preference; it’s a question of public health, safety, and well-being. Add an element of time and human forgetfulness, and it could be reasonable to worry about the health of future generations. Final Thoughts While the digital age offers access to information like we’ve never seen before, there are critical challenges we still face to discern quality from quantity. Deep reading and comprehensive engagement, although seemingly antiquated in a world that overflows with snippets, remain crucial in fostering understanding, empathy, and critical thinking. As we stride further into this digital era, we must champion a balanced culture where both immediacy and depth are valued, ensuring that the allure of convenience doesn’t overshadow the quest for truth.   Citations: Pew Research Center. (2019). Who doesn’t read books in America? National Endowment for the Arts. (2007). To Read or Not To Read: A Question of National Consequence. Wolf, M. (2018). Reader, Come Home: The Reading Brain in a Digital World.   tl;dr: This blog considers the declining trend in deep reading, the rise and implications of short-form content across various media in contrast with longer form materials, and the value of evidence-based medicine in a digital landscape that is influenced by social media personalities. I try to champion the necessity of a well-rounded approach to information consumption, valuing both depth and brevity. And, hopefully anyone reading this will be that much more tempted to consider reading my own long-form book, The Doctor-Approved Cannabis Handbook [...] Read more...
August 30, 2023 Introduction Marijuana Positivity Rates in workplace drug tests have soared to a 25-year high, sparking a diverse range of views and approaches to cannabis use by employees. Let’s delve into four distinct perspectives: the medical viewpoint, the skeptical stance, the newcomer’s curiosity, and the experienced user’s wisdom. The Medical Perspective Recent studies indicate a general decline in opioid and barbiturate positivity rates in the same tests. This suggests a potentially momentous shift towards cannabinoid-based treatments, which often offer a more manageable side-effect profile than traditional pharmaceutical options The Skeptical Viewpoint about Rising Marijuana Positivity Rates For those skeptical about marijuana’s therapeutic potential, it’s important to note that a positive test doesn’t necessarily equate to on-the-job impairment. Drug screens can detect usage from as far back as a month. Employers have to navigate the labyrinthine mix of federal and state laws, which adds a layer of complexity to employee testing and subsequent actions. The Newcomer’s Curiosity Newcomers might be intrigued by the National Basketball Association’s new stance: removing marijuana from its prohibited-substance list starting the 2023-24 NBA season. For those unfamiliar with medicinal cannabis, this highlights the shift in social attitudes and may prompt further inquiry into the growing body of published cannabis research. The Experienced User’s Wisdom For veterans in the medicinal cannabis community, the increased rates of marijuana positivity are less of a ‘new phenomenon’ and more of a ‘return to normal’. Cannabis has been a part of human history, and the tide seems to be turning back towards natural, cannabinoid solutions over pharmaceutical ones. Clinical Perspective: Meet Sarah, a patient at CED Clinic struggling with chronic pain. For years, she relied on opioids, until the side effects became unbearable. With cannabinoid therapy, Sarah experienced symptomatic relief and improved quality of life. It’s a privilege to contribute to this field, alongside scientific collaborators and my patients. My forthcoming book, The Doctor-Approved Cannabis Handbook, aims to address these very issues.  Read Sarah’s story on page 249 of the book! Order here: https://a.co/d/3T6jYaQ  Summary: The Changing Landscape of Cannabis Use in the Workplace The dramatic rise in marijuana positivity rates in workplace drug tests to a 25-year high encapsulates a broader shift in attitudes and approaches to cannabis. This change is affecting everyone—from the medical community to employers, from cannabis newcomers to experienced users. From Opioids to Cannabinoids From a medical standpoint, this spike could indicate a cultural and medical shift away from traditional opioids and barbiturates towards cannabinoids. Multiple studies have shown that cannabinoids often present fewer side effects than these more traditional substances. Redefining Impairment Skeptics must grapple with the fact that marijuana positivity does not necessarily correlate with immediate impairment. Legal complexities at the federal and state levels add to the challenge of interpreting these tests. As cannabis legalization spreads, laws may need to adapt to better assess on-the-job impairment rather than historical use. Cultural Acceptance The NBA’s new policies on cannabis reflect changing social norms, influencing newcomers to cannabis and hinting at a broader societal acceptance. This may lead to greater interest and engagement in the scientific community’s growing body of cannabis research. A Return to Roots For experienced users, this trend is more of a return to normalcy than a radical change. The increasing preference for natural cannabinoid solutions is seen as a positive development that aligns with historical use and understanding of the plant. Bridging Gaps in Clinical Practice From a clinical perspective, the stories of patients like Sarah highlight the promising therapeutic potential of cannabis. Through published research, clinical experience, and educational resources like The Doctor-Approved Cannabis Handbook, healthcare providers and patients alike can make more informed decisions about cannabinoid therapies. In summary, the surge in workplace marijuana positivity rates is not an isolated phenomenon. Rather, it reflects evolving perspectives on cannabis, influenced by medical research, cultural shifts, and individual experiences. This change has implications for legal frameworks, workplace policies, and healthcare practices. References 1: “Decline in opioid and barbiturate positivity rates in workplace drug tests,” Journal of Occupational Medicine and Toxicology, 2021. 2: Moeller, K. E., Lee, K. C., & Kissack, J. C. (2008). Urine drug screening: Practical guide for clinicians. Mayo Clinic Proceedings. 3: Caplan, B. The Doctor-Approved Cannabis Handbook, 2023. 4: Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., … & Kleijnen, J. (2015). Cannabinoids for medical use: A systematic review and meta-analysis. JAMA. 5: “Marijuana Legalization and Workplace Safety: A Short Review of the Literature,” Journal of Occupational and Environmental Medicine, 2018. 6: “NBA Changes in Cannabis Policy and Public Perception,” Sports Medicine Journal, 2023. 7: Russo, E. B. (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology. To find these articles: https://cedclinic.com/resources/cannabis-literature-library/   _______________________________________________________________________________________   Top 10 Takeaways from the Surge in Workplace Marijuana Positivity Rates Introduction: Marijuana positivity rates in workplace drug tests have hit a 25-year high, making headlines and leading to broader conversations about cannabis use among employees. Based on a news article by Anne Marie Chaker, published on May 18, 2023, we’re examining the top 10 things you need to know about this growing trend. 1. Record-Breaking Positivity Rates More than 6 million general workforce tests screened for marijuana in 2022 showed that 4.3% came back positive, which is the highest rate since 1997. 2. Post-Accident Rates Soar The percentage of employees testing positive for marijuana following an on-the-job accident rose sharply to 7.3% in 2022. 3. Opioid and Barbiturate Rates Decline Contrastingly, positivity rates for certain classes of opioids and barbiturates declined last year. 4. Rising Amphetamine Positivity Besides marijuana, tests for amphetamines also showed an increase in positivity, rising from 1.3% in 2021 to 1.5% in 2022. 5. State Vs. Federal Law Complications The growing number of U.S. states legalizing marijuana use adds complexity to workplace drug testing policies, as federal laws may still require testing. 6. Shift in Employer Screening Policies Companies like ManpowerGroup are starting to screen less often for marijuana, partly due to the challenges of hiring enough front-line workers. 7. NBA’s Progressive Stance The NBA is removing marijuana from its prohibited substance list for the 2023-24 season, signaling a shift in social attitudes towards marijuana use. 8. Amazon’s Inclusive Approach Amazon has stopped screening many job applicants for marijuana, citing that the tests disproportionately impact people of color. 9. Employee Impairment Challenges Because some drug screens can detect marijuana use that goes back days or even weeks, a positive test does not necessarily indicate on-the-job impairment1. 10. The Impact on Various Industries The rise in marijuana positivity rates isn’t restricted to one sector; it spans multiple industries including food services, retail, and accommodation. Summary The surge in workplace marijuana positivity rates reflects broader societal shifts in attitude towards cannabis, but it also introduces complexities for employers navigating drug testing policies. While some companies are reevaluating their approach to marijuana screening, debates around safety and legal liabilities continue. Overall, the rise poses challenges and opportunities in workforce management, health, and social policy. Citations Note Points 1-8 are extracted from the news article “American Workers Testing Positive for Marijuana Reaches 25-Year Record” by Anne Marie Chaker, published on May 18, 2023. Points 9-10 are supplemented with information from peer-reviewed literature. Footnotes National Safety Council: “Drug Testing Isn’t a Single Solution” – Katie Mueller, Senior Program Manager [...] Read more...
August 21, 2023Discover the potential of cannabinoids in pain management. Explore medical insights, opposition viewpoints, and real experiences. Learn how cannabinoids could reshape the future of pain treatment. Introduction: The opioid crisis has become a public health emergency in the United States, with over 130 people dying every day from opioid-related drug overdoses. As the medical community grapples with this crisis, a new frontier in pain management is emerging: cannabinoids. Recent research suggests that medicinal cannabis may offer a promising alternative to opioids for pain relief. This blog post will explore the medical perspective on cannabinoids, address common misconceptions, and consider the viewpoints of both new and experienced users of medicinal cannabis. The Medical Perspective on Cannabinoids From a medical standpoint, cannabinoids present an exciting opportunity to address the opioid epidemic. Studies have shown that medicinal cannabis can significantly reduce opioid consumption, with some patients finding cannabis alone more effective than a combination of cannabis and opioids. However, the integration of cannabinoids into medical practice requires careful consideration of dosing, legal regulations, and patient education. Continued research and development of prescribing guidelines are essential to ensure safe and effective treatment. The opioid crisis has led to a search for alternatives, and cannabinoids present a promising solution. Research supports the use of medicinal cannabis to reduce opioid consumption and provide effective pain relief. The medical community is urged to consider this option, recognizing the need for proper guidelines and continued research. Misconceptions and Opposition to Medical Cannabis Despite the promising evidence, some individuals remain opposed to medicinal cannabis. Common misconceptions include fears about its psychoactive effects, potential for abuse, and lack of regulation. Clear, evidence-based communication is vital to dispel these myths and provide accurate information about the therapeutic benefits of medicinal cannabis. Addressing legal and ethical concerns also requires collaboration between lawmakers, healthcare providers, and the community. Some individuals remain skeptical of medicinal cannabis, often due to misunderstandings about its effects and potential for abuse. Education and transparent communication about the scientific evidence supporting cannabis as a treatment option are essential to address these concerns. The Experience of New and Seasoned Cannabis Users For those new to medicinal cannabis, initial apprehensions may include concerns about side effects, social stigma, and legal issues. Comprehensive education and support can help alleviate these concerns. On the other hand, individuals experienced with medicinal cannabis often report significant benefits, including reduced opioid consumption and improved quality of life. Their insights and advocacy can foster acceptance and understanding within the broader community. Policy and Regulatory Considerations The legal status of medicinal cannabis varies across states, creating a complex regulatory environment. Developing consistent, evidence-based regulations is crucial to ensure safe and equitable access to this treatment option. Engaging with various stakeholders, including healthcare providers, researchers, policymakers, and patients, is essential to create a regulatory framework that supports responsible use.   The exploration of cannabinoids as an alternative to opioids for pain management is a multifaceted issue that requires a nuanced approach. By considering various perspectives and engaging in open dialogue, we can work towards a future where pain management is more effective, compassionate, and personalized. The potential of cannabinoids in reshaping pain treatment is promising, but realizing its full potential requires collaboration, education, research, and empathy.     This blog post delves into the medical viewpoint, opposition to medical cannabis, and the experiences of both new and seasoned medicinal cannabis users, but check out The Doctor-Approved Cannabis Handbook for this and more: https://amzn.to/3QFToba          [...] Read more...
August 7, 2023The Impact of Alcohol and Cocaine Misuse on Cognitive Flexibility: Multiple Perspectives The Medical Perspective From a clinical standpoint, the intricacies of how alcohol and cocaine misuse affects cognitive flexibility is a matter of profound interest. The brain is a complex organ, with multiple pathways and neural connections that control not only our physical actions but also our thoughts, decisions, and emotions. The recent study provides a compelling look at the neural pathways, such as the impact on striatal cholinergic interneurons and the activity of direct-pathway medium spiny neurons, which are altered by these substances. Medical professionals are particularly interested in these findings as they can guide the development of therapeutics to treat substance use disorders. Furthermore, understanding the decline in cognitive flexibility can assist clinicians in devising therapeutic interventions, which might include cognitive-behavioral strategies, medications, or even neurofeedback sessions, to boost or restore this vital cognitive function. The Skeptical Perspective Some individuals remain wary of the current science, often comparing the misuse of substances like alcohol and cocaine to medical cannabis. This skepticism usually stems from preconceived notions, past experiences, or misinformation. They might argue that drawing conclusions from a rodent study might not translate effectively to humans, making such studies less definitive. In comparing it to medical cannabis, these individuals often point out the lack of long-term studies or the possible risks of misuse and addiction, even if used for medical purposes. While their concerns cannot be entirely dismissed, it’s essential to differentiate between misuse and medical application, and to stay updated with evolving scientific research. Newbie’s Perspective For someone new to cannabis or the broader discourse on substance misuse, the intricate details of how alcohol and cocaine affect the brain might be overwhelming. They might wonder: “How does this relate to cannabis? Is it equally harmful, or does it offer medicinal benefits?” These individuals often seek rudimentary understanding. They might find the concept of cognitive flexibility intriguing, especially if they can relate it to their daily life experiences. Perhaps they’ve noticed changes in their behavior or thought patterns after consuming alcohol or know someone battling cocaine addiction. Being new to the subject, they’re open to learning but might be vulnerable to misconceptions or biases, making it crucial to present them with clear, accurate, and digestible information. Experienced Cannabis User’s Perspective For those who consume cannabis for medical purposes, such a study on alcohol and cocaine might provide a dual reaction. On the one hand, they might be curious about how different substances can influence the brain in varied ways. On the other, they might feel defensive, anticipating that detractors could lump medical cannabis into the same category as alcohol and cocaine. These individuals have firsthand experience of the therapeutic benefits of cannabis. They know that when used judiciously and under medical supervision, cannabis can provide relief from pain, anxiety, and various other ailments. When juxtaposing their experience against the backdrop of the study on alcohol and cocaine, they might assert the importance of distinguishing between “use” and “misuse”. For them, the underlying theme remains: everything in moderation, and under the right guidance. Conclusion:   the subject of substance misuse, brain health, and cognitive flexibility is multi-faceted. By looking at it from various perspectives, we can appreciate the nuances and complexities of this vital topic. Every viewpoint offers a piece of the larger puzzle, emphasizing the importance of open dialogue and continuous research. [...] Read more...
August 1, 2023In a surprising turn of events, more than a third of people aged 65 or older have tried marijuana, a figure that’s tripled since 2009. This trend is explored in depth in a recent article from The Washington Post, which also delves into the question of whether these older cannabis users are more likely to be NPR listeners. The article provides a wealth of information on the topic, including data from the National Survey on Drug Use and Health, and insights from researchers and experts in the field. It also highlights the potential influence of legalization on the increased use of cannabis among older adults. What are your thoughts on this trend? Are you surprised to see the older generation embracing cannabis? And do you know any NPR-listening, cannabis-loving seniors? Read the full article here: https://wapo.st/3Kc4QXO [...] Read more...
July 31, 2023Introduction The name Shawn Collins may not have been a household name a decade ago, but in recent years, it has become synonymous with the burgeoning Massachusetts cannabis industry. As the Executive Director of the Cannabis Control Commission, Collins has played an instrumental role in the development and regulation of the industry, drawing both praise and criticism from various quarters. In this blog, we delve deeper into the impact of Shawn Collins’ work, examining it from the perspectives of medical professionals, typical customers, and those indifferent or new to cannabis. Section 1: A Medical Perspective From a medical standpoint, cannabis is not just about recreational enjoyment; it has significant health implications. Many health professionals have praised Collins’ efforts to regulate the industry, which have made it possible for patients to have access to safe, tested, and reliable cannabis products for therapeutic use. Under Collins’ leadership, the Commission has ensured the strict regulation of product quality, offering a degree of certainty that was previously lacking. For conditions such as chronic pain, epilepsy, and multiple sclerosis, cannabis has shown considerable promise. Thus, having a well-regulated supply chain has been crucial in patient care. However, not all feedback from the medical community has been positive. Some health professionals argue that the commission’s focus on commercial and recreational use might overshadow the importance of medical cannabis, pushing patients’ needs to the backburner. Section 2: The Customer’s Lens For the average customer, the rise of the cannabis industry under Collins’ watch has been a welcome change. The most obvious benefit has been the availability of a wider range of products. Consumers now have access to a variety of cannabis strains and related products, from edibles and tinctures to topicals and concentrates. Furthermore, rigorous quality checks mean that customers can trust the products they buy. Another important aspect from the customer’s perspective is the economic impact. The cannabis industry has generated significant revenue and created numerous jobs. Many customers appreciate that their purchases are contributing to local economic growth and job creation. Section 3: The View from the Sidelines Not everyone is a fan or user of cannabis, and for these people, the growing prominence of the industry can be a source of indifference or even resentment. Some fear that easy access to cannabis might lead to increased misuse, particularly among younger users. However, many recognize that regulation is preferable to prohibition. Having clear laws and regulations in place is seen as a way to control misuse while allowing adults who wish to use cannabis responsibly to do so. In this context, Collins’ work is acknowledged as necessary, even by those who might not personally support cannabis use. Conclusion Shawn Collins’ impact on the Massachusetts cannabis industry is undeniably substantial. His efforts have helped create a well-regulated, economically vibrant sector that caters to both medical patients and recreational consumers. While some criticism and challenges are inevitable, the industry’s growth is a testament to Collins’ dedication and the comprehensive framework the Commission has put in place. It remains to be seen how the industry will evolve in the coming years, but for now, Massachusetts seems to be on the right track. [...] Read more...
July 25, 2023The recent fluctuations in the market have sent ripples across industries, and one sector that has especially caught our attention is the cannabis industry. The intriguing part? Unlike the majority of stocks that are riding the upward wave, cannabis stocks are demonstrating a distinct trend, diving when others are soaring. This unexpected behavior, as perplexing as it is, offers us an opportunity to delve deeper into the complex world of the cannabis industry and its stock market performance. Why Cannabis Stocks Are Falling When discussing stock market trends, it’s important to understand that these trends are reflections of a multitude of factors, both tangible and intangible. In the case of cannabis stocks, these factors are as diverse as the products the industry produces. Firstly, let’s discuss the elephants in the room – regulatory barriers. Cannabis, despite its increasing acceptance, still finds itself tangled in a web of legal constraints. The varying laws from state to state and the federal illegality of cannabis in the US pose serious challenges for the industry. These uncertainties can make investors uneasy and lead to volatility in cannabis stocks. Secondly, the cannabis industry is still in its infancy, with companies still exploring the best ways to operate profitably. Many cannabis companies are focusing heavily on scaling their operations, often prioritizing growth over profitability. This can result in inflated valuations that are not backed by strong financials, making the stocks more susceptible to market downturns. Tilray: A Case Study Take Tilray, for example, a cannabis company that also has stakes in pharmaceutical distribution and alcohol businesses. Despite its diversified portfolio, Tilray has not been immune to the current downturn in cannabis stocks. Its stock has seen a significant dip in 2023, a worrying indication ahead of their Q4 report. This illustrates that the industry’s challenges can impact even the biggest players, regardless of their diversification strategies. Looking Ahead: What Could Potentially Turn Things Around? Despite the current downturn, there are reasons to remain optimistic about the future of cannabis stocks. One such reason is the potential for regulatory reform. As societal attitudes towards cannabis continue to evolve, there’s hope for a more progressive legislative framework that could alleviate some of the current regulatory pressures. Moreover, as the industry matures, we can expect to see companies beginning to focus more on profitability rather than just growth. This shift could lead to more robust financials, thereby making cannabis stocks more attractive to investors. Ultimately, the future of cannabis stocks remains uncertain. Investors and stakeholders must stay informed, adaptable, and open to new perspectives. With a thorough understanding of the industry’s fundamentals and a close eye on market trends, it’s possible to navigate through this uncertain terrain and make informed investment decisions. [...] Read more...
July 19, 2023I’m absolutely thrilled to share with you the upcoming launch of my very own “Doctor-Approved Cannabis Handbook”. This has been a labour of love, the fruit of years of intense research, and a quest to bring forth the multifaceted benefits of this incredible plant – cannabis. Yes, you heard that right. My mission is not just to shed light on the often misunderstood world of cannabis, but to challenge our prevailing perceptions, and spark an informed conversation about its potential. Click to check out the amazing endorsements and to order: https://www.amazon.com/Doctor-Approved-Cannabis-Handbook-Wellness-Marijuana-ebook/dp/B0BSKRN1M7 Can you believe that over the last decade, cannabis has undergone such a remarkable transformation? It’s moved from being a largely taboo topic to becoming a potential game-changing therapeutic tool within our medical community. This transition is undoubtedly encouraging, yet it has been clouded by widespread misinformation and a whole lot of uncertainty. To address this, I’ve written an all-inclusive guide that seeks to demystify the medical applications of cannabis. My handbook is designed to empower you, whether you’re a healthcare professional, a patient, a caregiver, or just someone curious about the subject. In Part 1 of the book, I take you through a guided tour around the cannabis plant, explaining its intricacies, and discussing the various products you can buy off the market. But that’s not all. I even delve into how you can DIY cannabis edibles and topicals, opening up an exciting world of homemade therapeutic treatments. As we move into Part 2 of the book, we dive deeper into the clinical uses of cannabis. Every single claim made is backed by an indexed, evidence-based, peer-reviewed reference. Together, we explore the potential of cannabis in addressing a range of conditions: mental health issues, sleep disturbances, headaches, neurodegenerative diseases, seizures, and even end-of-life care. But the journey doesn’t end there. My book also unravels how cannabis can be a potent ally in managing physical pain, skin conditions, gastrointestinal issues, enhancing sexual health, and even mitigating symptoms associated with cancer treatments. You see, the “Doctor-Approved Cannabis Handbook” is not just another medical guide on the shelf. It’s a testament to the REAL opportunity that holistic, patient-centered healthcare presents. In a world that’s largely dominated by pharmaceutical models, I’m hoping (and trying my best!) to bring alternative approaches to the forefront. Can you imagine what it would mean if a cannabis-positive book made it to a best-seller list? It would not only command attention but also bring much-needed respect to an industry that has often been run over. More importantly, it could bring hope to millions of people who have suffered unnecessarily because of a lack of access to this information! As we embark on this path, we do recognize the challenges we face. Societal prejudices, regulatory complexities, and even the frustrating “algorithm” which often auto-cancels cannabis. But with informed knowledge and a shared understanding, we can overcome these hurdles together. After all, every paradigm shift begins with a single, daring step. So join me in this journey to redefine wellness. Pre-order your copy of the “Doctor-Approved Cannabis Handbook” today, and together, let’s command attention, respect, and inspire a change that could potentially save lives for the better. [...] Read more...
July 13, 2023The use of cannabis for self-medication is a growing trend, particularly among neurodivergent individuals. A recent poll found that 1.8 million people in the UK are using cannabis to manage symptoms and improve their quality of life, a 29% increase from 2019. This trend highlights the unique intersection of physical and psychological phenomena that cannabis research is uncovering. The Medical Perspective From a medical standpoint, the use of cannabis for self-medication among neurodivergent individuals is a complex issue. On one hand, cannabis has been shown to help improve attention, emotion regulation, concentration, and executive functioning, while also reducing anxiety and sleep problems. These are common symptoms among neurodiverse individuals, making cannabis an attractive option for self-medication. However, the medical community also recognizes the potential risks associated with self-medication, particularly when it comes to unregulated substances. Without proper regulation and oversight, individuals may be at risk of consuming cannabis with high levels of THC, which could induce paranoia, anxiety, or psychosis. The Viewpoint of Someone Against Medical Cannabis Those against the use of medical cannabis often cite the potential for abuse and the lack of comprehensive research as reasons for their opposition. They argue that while cannabis may provide temporary relief for some symptoms, it does not address the underlying causes of these symptoms. Additionally, they express concern about the potential for dependency and the long-term effects of cannabis use. The Perspective of Someone New to Cannabis For someone new to cannabis, the idea of using it for self-medication can be both intriguing and intimidating. The stigma associated with cannabis use can be a significant barrier, as can the legal implications. However, the potential benefits of cannabis for managing symptoms of neurodivergence can also be very appealing. The Perspective of Someone Experienced with Cannabis Consumption for Medical Purposes Those who have experience with using cannabis for medical purposes often have a more nuanced perspective. They understand the potential benefits of cannabis, but also recognize the importance of using it responsibly and under the guidance of a healthcare professional. They may also have firsthand experience with the challenges of obtaining cannabis for medical use, particularly in regions where it is not yet legal. In conclusion, the rise of self-medication with cannabis among neurodivergent individuals is a complex issue with many different perspectives. As our understanding of both neurodivergence and the potential therapeutic uses of cannabis continues to evolve, it is crucial to continue the conversation and explore all angles of this important topic. [...] Read more...
July 11, 2023In the dynamic world of cannabis, THC-O-acetate has recently emerged as the new player on the field, largely due to bold claims of it providing a ‘psychedelic’ experience. But what does the science actually say? A new study led by UB has delved into these claims and found that the effects of THC-O-acetate are more aligned with inducing relaxation, euphoria, and pain relief rather than a psychedelic experience. This contradicts the current narrative floating around the cannabis community. Moreover, the study raises an important point of concern. The cannabis market, as it currently stands, is largely unregulated. This can result in product contamination, potentially causing unexpected and undesirable effects. Hence, it emphasizes the importance of being cautious in this seemingly Wild West market. As consumers, it’s crucial to be vigilant and rely more on scientific evidence rather than simply accepting manufacturer claims. In the rapidly expanding world of cannabinoids, safety should always be paramount. Dive deeper into the study here: https://bit.ly/46KsuEv [...] Read more...
March 14, 2023Whether you have tried other forms of treatment and failed to find relief, or you just prefer a holistic alternative, you may be wondering if medical cannabis is right for you. As a whole, over the last several decades we have learned so much about the benefits of cannabis and how this plant can help you find relief. However, we’re learning each day that the plant is complex in how it works with our bodies. No matter your symptoms or type of relief you’re seeking, it’s important to learn how to know if medical cannabis is right for you. History of Medical Cannabis Patients have touted the benefits of medical cannabis for not only years, and decades, but also through the centuries. Evidence suggests that cannabis was used extensively in what is now Romania, more than 5,000 years ago. And before that, archeological evidence has found cannabis in human culture as far back as 12,000 years ago.  In the U.S., cannabis was widely utilized as a patent medicine during the 19th and early 20th centuries, described in the United States Pharmacopoeia for the first time in 1850. In the grand scheme of things, cannabis prohibition only existed for a handful of recent years, as opposed to centuries of acceptance. Over the last several decades, many states, including Massachusetts have recognized the need and legalized cannabis in some capacity. Massachusetts now allows both recreational and medical cannabis use, but there are still a number of benefits to obtaining a medical marijuana card in Massachusetts. How Does Cannabis Work? Every creature with vertebrae has an endocannabinoid system. A series of receptors exists throughout the body and serves the purpose of restoring and maintaining balance (homeostasis), as well as other multiple forms of neurological communication. Cannabinoids (cannabis molecules) interact with these receptors in different ways depending on their molecular structure. Some major cannabinoids include THC and CBD. Others you may have heard of include CBN, CBG, CBC many more (over 100 more, actually). There are a plethora of cannabis strains to choose from. Just like there are countless varieties and hybrids of roses, the same can be said for cannabis strains. Like any other plant, they can be cultivated to have specific properties like a higher ratio of CBD, or other plant compounds like terpenes, fatty acids, and proteins. Different combinations of cannabinoids and plant compounds may affect the body in slightly different ways. For example, the terpene linalool is also found in lavender and is known to have a calming effect, so strains with more linalool may be encouraged for those who are anxious or stressed. What Are The Benefits of Medical Cannabis? There are countless benefits of consuming medical cannabis, though it is important to note that your experience may not be exactly the same as someone else’s. In general, some of the primary ways medical cannabis can help you find relief is through:        • pain relief,        • decreased stress, anxiety, or worry        • better sleep habits and sleep patterns        • along with other more specific benefits depending on your specific need Qualified Conditions For a Massachusetts Medical Card In answering the question, “how do you know if medical cannabis is right for you,” it’s important to note how the condition you are seeking treatment for is certainly relevant. In order to obtain a medical cannabis certification, the state requires that you have a qualifying condition. Patients 18 and older with a Massachusetts medical cannabis card can buy larger quantities of cannabis than those who purchase recreational cannabis. Some of these qualifying conditions in a medical cannabis evaluation include:        • Amyotrophic Lateral Sclerosis (ALS)        • Cancer        • Crohn’s disease        • Glaucoma        • HIV/AIDS        • Hepatitis C        • Multiple Sclerosis        • Parkinson’s disease These conditions are governed by the Massachusetts Cannabis Control Commission for medical marijuana doctors and patients and are continually updated as additional conditions are evaluated. The diagnosis of any of these qualifying conditions must be verified by a medical doctor, and the patient must go through an application process. If your exact condition is not listed above, do not let that be a deterrent. Dr Caplan has the ability to determine what conditions may benefit from medical cannabis and has the authority to issue cards for any condition where it is medically appropriate. How Do You Know If Medical Cannabis Is Right For You? Many people, with and without a medical condition can benefit from cannabis use. CED champions a holistic approach to healthcare and wellness that includes medicinal cannabis. Meet with our team of marijuana doctors in Massachusetts to discuss your medical marijuana card needs – through a cannabis evaluation, we’ll review your medical history, answer all your questions, address your symptoms and discuss how cannabis could better your health. If you think getting a Massachusetts medical marijuana card could be right for you, request an appointment online at your preferred time or call us to schedule one at (617) 500-3595 and we will be more than happy to guide you through the process. [...] Read more...
March 7, 2023Medical cannabis use was approved in 2006 for Rhode Island residents with a qualifying condition. The Rhode Island Department of Health’s Medical Marijuana Program administers all aspects of the state Medical Marijuana Act and all regulations for patients and certifying practitioners. This includes who is eligible to receive a Rhode Island medical marijuana card, based on their qualifying health or medical condition. Medical Cannabis Use in the United States Over the past few decades, the benefits of medical cannabis have become increasingly accepted. One survey showed that 86 percent of respondents believe in the positive benefits of cannabis for medical conditions. There are nearly 20,000 medical marijuana cardholders in Rhode Island. Because marijuana is not federally-regulated, each state that has a legal medical marijuana program has its own set of laws. Medical marijuana is available in Rhode Island for a variety of conditions. First, a patient must obtain a formal diagnosis in a medical cannabis evaluation to apply for their Rhode Island medical marijuana card. Qualifying Conditions toApply for Medical Marijuana in Rhode Island In the state of Rhode Island, there are two categories of qualifying conditions required to get a medical marijuana card. The first category lists specific health diseases or illnesses. Cannabis is also authorized to help with symptoms derived from the treatment of these conditions. • Cancer • Glaucoma • Positive status for Human Immunodeficiency Virus (HIV) • Acquired immune deficiency syndrome (AIDS) • Hepatitis C The second category of qualifying conditions can relate to a chronic or debilitating disease,medical condition, or its treatment that produces one or more of the following: • Cachexia or wasting syndrome • Severe, debilitating, chronic pain • Severe nausea • Seizures, including but not limited to those characteristic of epilepsy • Severe and persistent muscle spasms, including but not limited to those characteristic of multiple sclerosis or Crohn’s disease • Agitation related to Alzheimer’s Disease Determining the Diagnosis of Your Qualifying Condition CED Clinic provides medical cannabis services for those seeking treatment for Rhode Island’s qualifying conditions. At CED Clinic, our cannabis doctors and physicians focus on individual patient care for specific needs. Our clinicians will review your health history in a medical cannabis evaluation to better assess the benefits for your medical concerns. During this cannabis clinic visit, it is important to talk to your doctor about all of the symptoms you are experiencing. Some chronic symptoms that do not respond to general medical treatment may qualify you for Rhode Island’s medical marijuana program – even if they are not in one of the two explicit categories. Mental health conditions like depression, anxiety, and post-traumatic stress disorder (PTSD) are not on the list of qualifying conditions but may be considered for a medical marijuana prescription. Applying for a Rhode Island Medical Marijuana Card The first step in the medical cannabis application process is to be formally diagnosed. CED Clinic offers telehealth options across multiple states, including Rhode Island. You can expedite the process by scheduling your appointment and filling out the intake form. Our cannabis clinicians will evaluate your health history and Rhode Island qualifying conditions for a cannabis medical card. We are here to walk you through the medical marijuana card application process and look forward to helping you feel empowered and educated about your cannabis choices. [...] Read more...
February 28, 2023The disappearance of Plant Medicine from mainstream American Medicine was a complex phenomenon that involved various factors, including the rise of modern medical care, the growth of a modern pharmaceutical industry, and changing attitudes towards natural remedies. One of the key events that contributed to the disappearance of plant medicine was the passage of the Pure Food and Drug Act of 1906. This legislation required manufacturers to accurately label their products and disclose any harmful or addictive ingredients. While this was a step forward for consumer protection, it also created an environment in which synthetic drugs could plant a foothold in the consumer market, as medicines/formulations could be patented and sold exclusively by their manufacturers, at great financial benefit. At the same time, the medical profession was undergoing a transformation, with doctors increasingly turning to scientific research and laboratory testing to guide their practice. This shift away from traditional remedies was fueled by the belief that science could provide more effective treatments for disease than natural remedies, which were more challenging to study. The Flexner Report, published in 1910, played a significant role in this transformation, as it called for medical schools to adopt a more scientific and rigorous approach to education and research. The rise of the pharmaceutical industry also played a crucial role in the disappearance of plant medicine. Pharmaceutical companies were able to invest heavily in research and development – and political lobbying efforts – and they could patent and market their products directly to doctors and patients. As a result, synthetic drugs began to replace natural remedies, which were often difficult to standardize and lacked the financial incentives of patented drugs. At the same time as the pharmaceutical industry blossomed and a more sterile system of ingredients and methods of study evolved, changing attitudes towards natural remedies also contributed to the disappearance of plant medicine. As modern medicine became more dominant, natural remedies were often seen as outdated and unscientific. This attitude was reinforced by the media, which often portrayed natural remedies as ineffective or even dangerous, relative to the more machined alternatives. The disappearance of plant medicine from mainstream American medicine was a complex phenomenon that involved a wide variety of interconnected factors, including the rise of the modern medical approach, birth and growth of the pharmaceutical industry, and evolving attitudes towards natural remedies by experts and professionals. While plant medicine is still used today by some healthcare providers, its disappearance from mainstream medical care was largely due to the emergence of synthetic drugs and the transformation of the medical profession towards a more scientific approach to treatment. [...] Read more...
February 8, 2023Once you have your medical marijuana card, it’s easy to feel like you’re on your own. Unfortunately, there is a trend among cannabis clinics of providing exceptional service until clients have their medical marijuana certifications, and then rushing them out the door. That’s not the case at CED Clinic. Current cannabis cardholders — not just those hoping to become patients — are welcome to make telemedicine appointments at any time with their medical cannabis doctor. Our Massachusetts cannabis doctors are here to provide holistic, cannabis-centered care throughout the duration of your treatment. These are just some of the reasons you might schedule a follow-up. 1. Your medical needs have changed. Life is dynamic. Whether you obtained your medical cannabis card last week or two years ago, your overall wellness may have changed since. The following are some examples of updates you may want to communicate to your cannabis doctor: New diagnosis Upcoming medical procedures Changing or worsening symptoms Dramatically improved symptoms Your cannabis doctor can answer questions, provide professional insight, and recommend any necessary adjustments to your medical marijuana prescription. 2. Your cannabis prescription isn’t working out the way you’d hoped. Perhaps you’re not seeing the results you wanted from cannabis use. This could mean you’re not feeling relief from your symptoms or the effect is minimal. Perhaps cannabis use is helping, but with other undesired effects. It’s important to remember that these issues occur with prescription medications, and you can consider a follow-up at our cannabis clinic the same way you would with your primary care provider. The truth is, there are myriad reasons why cannabis might not be delivering the desired benefits: it could be related to your dosage, the products you’re using, the method of consumption, or even other aspects of your routine or treatment regimen. By raising your concerns, you allow your canna-doctor to identify potential causes and make informed recommendations. 3. Your treatment used to work, and is now no longer effective. Sometimes cannabis loses its effectiveness — even when you’ve been using the same strain from the same company for an extended period of time. Trust us, you’re not crazy. There are several potential causes: Lack of consistency in medical cannabis products (which is a well-known problem in the industry) You’re building up a tolerance Changes in your medications, routine, or diet During your appointment, your cannabis doctor can shed some light on the issue, and offer suggestions on how to combat it. 4. There are updates to share with your cannabis doctor about your journey. When you have a traditional check-up, it helps your PCP stay informed of your wellbeing, monitor your progress with various treatments, and learn of any changes in your health. Our goal is for you to think of your care at CED Clinic the same way. Consider this: you want a medical professional to keep tabs on your overall well being, your prescriptions and whether they’re helping your symptoms; why wouldn’t you want the same as a medical marijuana patient? 5. You need a medical liaison to represent your cannabis treatment. Whether you have a regular doctor’s appointment approaching, are seeing a new specialist or have an upcoming medical procedure, your cannabis use may be relevant information. These are all opportunities for your cannabis doctor to offer support. Dr. Caplan can communicate directly with the providers involved, acting as a go-between or liaison for your medical needs. Further, receiving updated medical details allows him to make recommendations for your cannabis care routine if necessary — for example, increasing your dosage after a procedure, or altering usage to prevent adverse reactions with new medications. 6. You’re curious about new developments in the medical cannabis industry. Maybe you’ve heard about new cannabis products or formulations, or while conducting your own research, stumbled across new potential use cases, studies or data. As a result, you wonder, “How does this affect me, and what does it mean for my cannabis treatment? Should I alter my approach?” Luckily, you’re in the right place for this conversation. Dr. Caplan is not only the founder of other cannabis businesses (such as EO Care, Inc, a new digital therapeutics company that is changing the future of cannabis care), but shares access to the CED Clinic Library, (which is the world’s largest digital library of free medical cannabis research). By sharing free research with his medical cannabis patients, there are no barriers to learning cannabis health for all. You’re welcome to make an appointment to gain his professional insight and to discuss this research or other cannabis-related developments. 7. You want to learn how cannabis interacts with your medications, diet and more. If you’ve been experiencing altered effects in your cannabis use, have you noticed they correlated with changes in your health and wellness routine? If so, you could be onto something. The way that cannabis affects your body — specifically, how cannabinoids interact with your endocannabinoid system — is directly connected with things like food, exercise habits, sleep patterns and much more. If you’re seeking information about the potential interactions of cannabis and related effects (especially if you’re starting a new medication), Dr. Caplan would be happy to address this with you. Remember: cannabis knowledge is power over your own health. Ready to schedule your appointment Just visit our website and request an appointment online for a medical cannabis evaluation. If you have questions, please feel free to contact us. We look forward to hearing from you! [...] Read more...
January 31, 2023The endocannabinoid system (ECS) has long been associated with how we process emotions, including stress and fear. Anandamide, the very first discovered, and likely most well-understood endogenous cannabinoid, functions as a neurotransmitter that actively combats the feelings of stress and fear. In the body, Anandamide is degraded by the Fatty Acid Amide Hydrolase (FAAH), so blocking FAAH activity can effectively increase anandamide in our bodies, much like how preventing a faucet from closing will set up for a flood of extra water. Fear extinction is one of the core known functions of the anandamide molecule. When a stimulus is un-coupled from a fear response in the body, this is a process governed by anandamide. For example, mice can be trained to associate a certain noise with a shock (fear training) and then dissociate the noise from the shock when they are presented with the noise by itself (fear extinction training). Research about the endocannabinoid system and fear In astudy published in Molecular Psychiatry, administration of an FAAH inhibitor in mice decreased fear when it was paired with a fear extinction training. Interestingly, however, the FAAH inhibitor did not impact fear if no extinction training occurred. Of particular interest, anandamide levels in the amygdala, another memory organ in the body, were increased, after fear extinction training, an effect that was increased further in the presence of a FAAH inhibitor. Considering these findings, the researchers speculate that variations in the FAAH gene, and therefore one’s expected level of anandamide breakdown, may be a relevant chemistry dynamic that underlies differences in one person’s ability to detect fear or cope with stress, from another’s. Consider, for example, a young boy who is afraid of a spider. When he notices the spider, consciously or not, his body immediately responds with a flight or fight response. This process happens in a synchronized way across multiple organs, including the amygdala, the adrenal glands, and traversing blood vessels throughout the body and brain. What does this mean for me? Toward a goal of minimizing the impact of fear, the natural response can be subdued in the presence of anandamide, perhaps aided and amplified by the actions or inactions of FAAH. Should someone have a gene which builds for them a very weak FAAH system, it is likely that they will have a much easier time recovering from fearful stimuli, because there will be less breakdown of anandamide. On the other hand, someone who has a very strong FAAH system would degrade their natural levels of anandamide and may have more persistent fear responses. In a world flush with fear, anxiety, and aggression, it is easy to imagine the relevance of a body system that helps to quell these negative emotions. Or, the contrary, it becomes simple to see the opportunity presented by a system of introducing molecular copy-cat molecules to some of the substances. To learn more about the endocannabinoid system and existing research about cannabinoids, explore the CED blog for our insights.   [...] Read more...
January 30, 2023Why is industrial hemp growth coming from the Cannabis Sativa L. strain of cannabis is restricted in many countries? Because it’s often confused with marijuana. But this lower THC strain has very little psychoactive properties, and is more often used for textile purposes. Also, essential oils from this low THC cannabis strain may have hidden benefits: antimicrobial activity. Can Hemp Oil Fight Bacteria? This essential oils of industrial hemp study looked at the antimicrobial properties of hemp oils against different types of bacteria. They looked at three different hemp oils (Carmagnola, Fibranova, and Futura) and found the oils might be most effective at fighting off gram positive bacteria (i.e. strep or staph infections). Futura Oil Fought Best Out of three different varieties of industrial hemp, oils from the Futura plant were the best at fighting a broader range of bacteria including food-born pathogens. Futura oils were virtually identical in composition to the other two essential oils, with the exception of a twofold increase in terpinolene compared to Carmagnola and Fibranova. The Key is Terpinolene Concentration Therefore, the higher terpinolene concentration is likely the cause of the increased antimicrobial activity. This effect is particularly applicable in the context of rising antibiotic resistance, where diseases such as MRSA become resistant to our current antibiotics. Topical hemp oils with antimicrobial effects could provide an alternative method of fighting off bacteria. Curious About Hemp and Cannabis as an Alternative to Antibiotics? To learn how the essential oils of hemp and cannabis could be used to help fight against antibiotic-resistant bacteria, book an appointment with our medical cannabis doctors through our virtual booking link or by giving us a call (617-500-3595). Dr. Caplan and his team at The CED Clinic in Chestnut Hill, MA are available to guide and support you! Social Media Post This study finds yet another use for industrial Hemp – antimicrobial activity. The researchers here tested essential oils from three different types of industrial hemp plant (Carmagnola, Fibranova, and Futura) against bacteria. They found that Futura oils had the broadest and most pronounced antimicrobial activities compared to the other two hemp varieties. Futura oils had a higher concentration of the compound terpinolene compared to Carmagnola and Fibranova oils, which likely explains their higher antimicrobial activity. Hemp oils might be a beneficial alternative to fight bacteria, particularly in the context of increasing antibiotic resistance. Tweet Hemp oils have antimicrobial properties and could be used to help fight against antibiotic resistant bacteria. Infographic/Question Would you trust hemp oils over other antibiotic treatments such as neosporin? [...] Read more...
January 24, 2023Cannabis aversion in mice increases at higher doses of THC How much is too much when it comes to marijuana use? While marijuana in small doses can be rewarding, high doses could lead to anxiety and paranoia. Although anecdotally documented in humans, mice studies have found inconsistencies in the rewarding versus aversive (unpleasant) properties of cannabis. This review untangles the dose-dependent effects of THC in mice studies that use a place conditioning paradigm to determine the rewarding and aversive potential of marijuana. Do Mice Find Marijuana Rewarding? Using conditioned place preference and aversion tests determine whether mice find a certain stimulus – in this case marijuana – rewarding or aversive. Unsurprisingly, this review finds that mice given higher doses of THC found the THC aversive as opposed to rewarding. Priming mice with a low dose of THC a day or two before testing on the conditioned place paradigm seemed to increase the likelihood that mice would find THC rewarding. Interestingly, at smaller doses, mice were just as likely to have no preference for cannabis as they were to find it rewarding. Given the reported rewarding properties of cannabis among humans, perhaps these mice studies should be taken with a grain of salt. Worried About Anxiety or Paranoia from Cannabis? To learn if cannabis is right for you or how to avoid high doses, book an appointment with our medical cannabis doctors through our virtual booking link or by giving us a call (617-500-3595). Dr. Caplan and his team at The CED Clinic in Chestnut Hill, MA are available to guide and support you! Social Media Post Aversion to THC in mice increases at higher doses. A comprehensive review of THC’s rewarding or aversive effects in mice shows that mice given higher doses of THC found the THC aversive as opposed to rewarding. Priming mice with a low dose of THC a day or two before testing their preference for THC increases the likelihood that mice will find THC rewarding. Interestingly, even at smaller doses of THC, mice were just as likely to have no preference for cannabis as they were to find it rewarding. Given reported rewarding properties of cannabis among humans, perhaps these mice studies should be taken with a grain of salt. Tweet A review shows that mice do not always find THC rewarding – even at small doses, but do find it aversive at high doses. [...] Read more...
January 17, 2023Peripheral nervous system cannabinoids may increase neuromuscular communication   Many studies focus on how cannabinoids function in our brains. Of course, most of us have heard about the cannabinoids which can make us feel joyful and light. Some are familiar with cannabinoids that can make you feel creative, giggly, sleepy, or hungry. As time marches on, people are starting to hear of cannabinoids that can help with improving focus or reducing appetite.   In addition to the many areas of exploration about cannabis and its action within the brain, there is a whole sector of the endogenous cannabinoid system that resides outside of the brain. Almost every immune cell, for example, has a cannabinoid receptor on it, ready to receive the signal to change its behavior.   Let’s explore the therapeutic effects of cannabinoids that are outside of the brain in our peripheral nervous systems.   Cannabinoids and the Neuromuscular Junction The neuromuscular junction is the name of the region which links the motor nerves in the body, which control movement, to our skeletal muscles.   In the brain, endogenous cannabinoids such as 2-Arachidonoylglycerol (2-AG) have been shown to decrease neuromuscular junction transmission. They are also shown to promote reduced communication between motor neurons and skeletal muscles.   The opposite effect happens in the peripheral nervous system, where cannabinoids happen to actually increase neuromuscular transmission. The authors of this paper about neuromuscular transmission also found that cannabinoids may provide therapeutic potential for diseases such as myasthenia gravis. Here, there is a breakdown in communication between nerves and muscles, as well as many other models of disease where neuromuscular communication is vital to normal functioning.   In a mouse model of myasthenia gravis, administration of the cannabinoid WIN 55,212-2 increased neuromuscular communication, suggesting that peripheral nervous system cannabinoids are worth consideration for therapy for individuals with this, or related autoimmune diseases.   Enhancing Neuromuscular Communication with Cannabinoids If neuromuscular communication can be enhanced or suppressed by cannabinoids, it is logical that products will arise that can manipulate the neuromuscular junction toward desired aims, like:   Stronger grip More durable hold Muscle strength Endurance   These are interesting questions to consider as the medical cannabis industry matures.   Is the athletic community aware of these advances? Would this effect prohibit cannabis from the acceptable medicinal substances list? Is cannabis a performance enhancing drug?   The answers to these critical questions will present themselves in short time, as the industry matures and products become more specific. A clear understanding  of the relationship between products and illnesses needs to be honed.   Would You Like to Explore Cannabis for Performance? To learn how cannabis may be able to enhance or suppress your physical performance, book an appointment with our medical cannabis doctors through our virtual booking link or by giving us a call (617-500-3595).   Dr. Caplan and his team at CED Clinic in Chestnut Hill, MA are available to guide and support you!   Additional info provided- can probably be removed-   Social Media Post While most studies have looked at how cannabinoids act in the brain, this study finds a novel therapeutic potential of cannabinoids in the neuromuscular junctions of the peripheral nervous system. Here they find that cannabinoids can increase communication between the nerves and muscles in the peripheral nervous system. This had the ability to negate the neuromuscular communication breakdown in a mouse model of the autoimmune disease myasthenia gravis.   Tweet A preliminary mouse study suggests that cannabinoids in the peripheral nervous system may increase neuromuscular communication and are a therapeutic potential for autoimmune diseases such as myasthenia gravis.   Infographic/Question How much do you trust preliminary mouse studies in the context of therapeutic treatments for humans? [...] Read more...
Cannabis News
December 5, 2023Cannabis News​Lawmakers in the Ohio Senate want to eliminate growing marijuana at home, increase the tax rate and change who gets the money from the state’s new legal marijuana program Lawmakers… The post Ohio senators want to make major changes to marijuana law OK’d by voters, ax home grow appeared first on Cannabis Business Executive – Cannabis and Marijuana industry news. Read More Feedzy  [...] Read more...
December 5, 2023Cannabis News​ Bipartisan Wisconsin lawmakers will soon be introducing a bill to decriminalize low-level marijuana possession—an incremental reform that they hope will break the logjam on cannabis policy in the GOP-controlled legislature. As other legislators push for broader adult-use legalization, Reps. Shae Sortwell (R) and Sylvia Ortiz-Velez (D), along with Sen. Lena Taylor (D), are sponsoring the simple decriminalization legislation, which would also give employers more discretion in workplace cannabis testing policies. The bill would make possession of up to 14 grams of cannabis punishable by a $100 civil forfeiture, without the threat of jail time. It would also stop courts from “counting” possession convictions involving up to 28 grams, meaning people would not be charged as repeat offenders who could face more serious penalties. “For small, simple possessions of marijuana, Wisconsin should not be throwing people in prison,” the sponsors said in a cosponsorship memo, first reported by the Wisconsin State Journal, late last week. They pointed out that the state makes an average of 15,485 arrests per year over the minor offense, which is currently punishable by a maximum $1,000 fine and up to six months in jail. “North Dakota, New Hampshire, Hawaii, Louisiana, Mississippi, North Carolina, and Nebraska have passed legislation that removes jail time for possessing small amounts of marijuana (not including full legalization states),” they said. “It is time for Wisconsin to join the national discussion.” The penalty for possession or use of marijuana paraphernalia would be similarly reduced to a maximum $10 civil forfeiture without jail time. As it stands, current law allows local governments to enact their own ordinances banning cannabis possession and imposing additional fines. This legislation would preempt those localities by making it so they would need to set a forfeiture amount for possession of 14 grams or less that is at least $100 but no more than $250. “Under the bill, the court may impose, instead of the forfeiture amount, no less than 16 hours nor more than 40 hours of community service for violating an ordinance prohibiting the possession of 14 grams or less of marijuana,” a legislative analysis that was shared with Marijuana Moment says. “The bill does not change the current law that allows local governments discretion in the forfeiture amount imposed for possession of more than 14 grams of marijuana.” People who receive the fine for cannabis or paraphernalia possession would need to be given the opportunity to submit a deposit for payment in lieu of making a court appearance; the court would have to consider such a deposit a plea of no contest and enter a judgment accordingly. In addition to decriminalizing possession, the bill would also make it so law enforcement would have additional flexibility in how they choose to handle individual cannabis cases. Police would have the choice of whether or not to book and process a person for possession, though they would still be required to collect certain personal information about them. This meant to “save time, money, and resources,” the memo says. “The burden placed on local resources, from police focus, man-hours for arrests, paper work, and court appearances, to the court system dockets and public defender costs, would be much better spent on serious, violent crimes.” Additionally, the legislation would limit liability for employers who choose not to require THC drug testing for job applicants or workers. However, there are exemptions to the discretionary policy. People would still be required to submit to drug screenings for jobs involving a federal contract, U.S. Department of Transportation (DOT) compliance or collective bargaining agreements with specific mandates, for example. “Employers across the country have been discontinuing the long-standing practice of drug testing their employees and prospective employees because it is costly,” the lawmakers said. “Employers in Wisconsin should be given the tools to decide for themselves whether or not they wish to continue drug testing for employment purposes by limiting their liability.” The sponsors are requesting that lawmakers contact their offices to become cosponsors by Thursday before the bill is formally introduced. While advocates would generally welcome any measure to end marijuana-related arrests in the state, decriminalization falls short of the more ambitious goals of enacting comprehensive legalization that’s being championed by Democrats such as Senate Minority Leader Melissa Agard (D), who is calling on the public to pressure their representatives to hold a hearing on her reform legislation. —Marijuana Moment is tracking more than 1,000 cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.— Wisconsin has become an island of prohibition in the region, with neighboring Illinois, Michigan and Minnesota each having legalized the plant in recent years. Despite that, the conservative legislature has long resisted even incremental reform—stripping marijuana proposals from the governor’s budget requests, for example. GOP leaders have insisted that they’ve been working on medical cannabis legislation in the background, but that’s yet to be seen. Another GOP lawmaker in the state, Sen. Mary Felzkowski (R), said recently that Democrats like Agard who are advocating for comprehensive legalization are detracting from efforts to advance incremental reform. But as the minority leader has pointed out, Republicans wield control of both chambers and could theoretically move whatever version of the reform they’d like at any point. Meanwhile, the state Department of Revenue released a fiscal estimate of its economic impact earlier this month, projecting that the reform would generate nearly $170 million annually in tax revenue. As legalization stalls, Gov. Tony Evers (D) granted another round of pardons, including dozens issued for people with prior marijuana convictions, last month. Separately, bipartisan and bicameral Wisconsin lawmakers recently came together to introduce a bill that would create a psilocybin research pilot program in the state. Read the text of the Wisconsin lawmakers’ marijuana decriminalization bill memo below:  CO-SPONSORSHIP MEMORANDUM  TO: All Legislators  FROM: Representatives Shae Sortwell and Sylvia Ortiz-Velez Senator Lena Taylor DATE: Thursday, November 30th RE: Co-Sponsorship of LRB-0510 relating to: penalties for possession of marijuana, employer liability for not drug testing employees and prospective employees, and providing a penalty. Deadline: Thursday, December 7th at 5pm  From 2010-2019, 154,295 arrests were made for possession of marijuana. That is an average of 15,485 per year. Current law prohibits a person from possessing or attempting to possess marijuana. A person who is convicted of violating the prohibition may be fined not more than $1,000 or imprisoned for not more than six months, or both, for the first conviction and is guilty of a Class I felony for a second or subsequent conviction.  For small, simple possessions of marijuana, Wisconsin should not be throwing people in prison. Because marijuana is illegal at the federal level, LRB-0510 does not legalize marijuana. Instead, it reduces the penalties for possessing negligible amounts (from .1gs to 28gs/1oz) and marijuana paraphernalia at the state and local levels, while still maintaining a level of municipal discretion. Additionally, this bill streamlines law enforcement and the courts’ booking process to save time, money, and resources. The burden placed on local resources, from police focus, man-hours for arrests, paper work, and court appearances, to the court system dockets and public defender costs, would be much better spent on serious, violent crimes. Furthermore, this bill limits the liability of an employer that does not require an employee or prospective employee to submit to a test for the presence of any tetrahydrocannabinol (THC), synthetic cannabinoid, or a controlled substance analog to THC or a synthetic cannabinoid in his or her system (drug testing) as a condition of employment. Employers across the country have been discontinuing the long-standing practice of drug testing their employees and prospective employees because it is costly. Employers in Wisconsin should be given the tools to decide for themselves whether or not they wish to continue drug testing for employment purposes by limiting their liability. North Dakota, New Hampshire, Hawaii, Louisiana, Mississippi, North Carolina, and Nebraska have passed legislation that removes jail time for possessing small amounts of marijuana (not including full legalization states). It is time for Wisconsin to join the national discussion. Read the text of the cannabis decriminalization bill below:  States Where Marijuana Is Illegal Typically See Higher Rates Of Treatment Admissions, Federal Study Says Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.  Read More Feedzy  [...] Read more...
December 5, 2023Cannabis News​ An Ohio Senate committee has given initial approval to a newly unveiled proposal to fundamentally alter the state’s voter-approved marijuana legalization law that’s set to take effect later this week. The legislation being advanced in the GOP-controlled chamber would eliminate a home grow option for adults, criminalize the use and possession of marijuana obtained outside of a licensed retailer, reduce the possession limit, raise the sales tax on cannabis and steer funding away from social equity programs and toward law enforcement—along with other amendments concerning THC limits, public consumption and changes to hemp-related rules that stakeholders say would “devastate” the market. During a 30-minute hearing on Monday, the Senate General Government Committee voted 4-1 to attach the cannabis legislation to an unrelated House-passed bill on alcohol regulations. As revised, the legislation contains several provisions that Republican leaders have previewed in recent weeks since voters approved legalization at the ballot last month, but it also goes further, for example, by proposing to criminalize people who grow their own cannabis at home. Senate President Matt Huffman (R) said he’s aiming to pass it on the floor as early as Wednesday before it’s potentially sent over to the House for concurrence. The plan is to get the changes enacted on an emergency before the legalization of possession and home cultivation becomes legal on Thursday. Advocates and Democratic lawmakers have already expressed frustration with the leadership push to revise the voter-initiated statute. Republicans, including Gov. Mike DeWine (R), have insisted that voters were only supportive of the fundamental principle of legalizing marijuana without necessarily backing specific policies around issues such as tax revenue. But while they’ve made that argument in the context of more incremental changes, the idea of eliminating home grow is likely to generate sizable pushback given its centrality to Issue 2. That could complicate its path to being enacted. An emergency clause would mean the bill would require a two-thirds vote instead of a simple majority to pass. In repealing key sections of the initiated statute and replacing them with amended language, it appears the bill would also re-criminalize use and possession of marijuana if the product is obtained outside of a licensed retailer. And those retailers couldn’t open for at least one year after the effective date, so possession would effectively remain illegal under any circumstances until that point. There’s no mandate for regulators to license retailers by a certain date, so it’s unclear when it would become legal to possess cannabis under the legislation. “The silver lining in my opinion of some of this, if we want to look at it that way, is that marijuana has always been operating in a black market, the sale of marijuana for some time,” Sen. Rob McColley (R), who described the proposed changes, said at the committee hearing on Monday. “This is an opportunity for Ohio, if done correctly, to try and stamp out that black market to the extent possible, and then also put a program in place to make sure that Ohioans have accessible, reasonable and safe marijuana products for their purchase.” In addition to striking home cultivation, the legislation would increase the excise tax rate on marijuana sales from 10 percent to 15 percent at the point of sale, in addition to a 15 percent gross receipts tax on cultivators. As approved by voters, the law would have directed marijuana tax revenue to go to social equity and jobs programs (36 percent), localities that allow adult-use marijuana enterprises to operate in their area (36 percent), education and substance misuse programs (25 percent) and administrative costs of implementing the system (three percent). The legislation that’s been attached to the revised bill would instead put 30 percent of revenue toward law enforcement training, 15 percent to substance misuse treatment, 10 percent to a safe driving initiative and the remainder to the state general fund. It would cut the possession limit for adults from 2.5 ounces to one ounce. And it would reduce the THC limit from 35 percent for flower and 90 percent for extracts to 25 percent for flower and 50 percent for extracts. Hemp industry stakeholders are also sounding the alarm about provisions that they say would “devastate the hemp industry in Ohio, and set back years of efforts in the state to support hemp farmers.” The U.S. Hemp Roundtable sent out a call-to-action alert following Monday’s committee vote, imploring supporters to contact their representatives and urge them to oppose the amendment package because it would prohibit the sale of full-spectrum hemp products. Hemp items could not contain more than 0.5 milligrams of delta-9 THC per serving (and a maximum of two milligrams per product). That would apply to non-ingestible hemp products such as topical CBD lotions, too. The legislation would additionally bar the sale of hemp containing other THC types like delta-8 and delta-10. The bill as amended would also add criminal penalties for public consumption, restrict marijuana advertising, reduce the cap on cannabis dispensaries from 350 to 230 and allow localities to ban marijuana cultivators in their borders. “Let’s look at what we’ve seen so far before of what works. Let’s have the safe product,” Senate General Government Committee Chairman Michael Rulli (R) said at his panel’s hearing. “My only concern for this is I want a safe product. I want no fentanyl. I want no mold…I want the black market destroyed. The people have spoken; I want them to buy a quality product that is safe for consumption. That is the goal of this committee to provide the people’s wishes with the safe product.” Sen. William DeMora (D) criticized the proposal from his Republican colleagues, saying, “from my mind, the voters’ intent is nowhere to be found in this—what I call a shell of what the voters passed.” While he said was “willing” to have a conversation about potentially limiting the number of plants that adults could grow under the initiated statute, he said “more than half the people that voted for this voted because of home growth, and so taking that away from what the voters clearly wanted is something that I have huge problem with.” The chairman said the public only had until 2:30pm ET on Monday to submit comment on the cannabis legislation—just hours after it was unveiled and moved through committee during the brief hearing. No additional public testimony will be accepted on Tuesday or Wednesday before a potential vote to send it to the floor. “Almost two years after first receiving Issue 2’s language and after Ohio voters overwhelmingly passed it, some in the Ohio Senate propose to gut Issue 2’s most important provisions, including home grow and social equity, and to put in place higher taxes that will entrench the illicit market and force Ohioans to continue to buy their cannabis products in Michigan,” Tom Haren, spokesperson for the Issue 2 campaign, said on Monday. “This is not what voters wanted.” “What’s more, they will apparently attempt to declare an ‘emergency’ and to pass this bill (crafted behind closed doors) in a rushed process designed to prevent meaningful input—all to subvert the will of Ohio voters,” he said. “But let’s be clear: the democratic process is not an emergency. Members of the Ohio Senate should shelve this proposal and instead implement the results of a free and fair election in accordance with their duties as public servants.” “Voters deserve to have the core components of Issue 2 respected by their elected officials with any changes being made only after robust opportunity for debate and participation by the general public,” Haren said. Ohio Rep. Casey Weinstein (D), who has championed cannabis reform measures in the legislature, told Marijuana Moment on Monday that the amendment package that advanced in committee is “an unsurprising byproduct of Republicans at the statehouse who design their own districts to insulate themselves from the public will.” “Ohio voters were very clear with us in overwhelming numbers, and this sham from Senate Republicans effectively overturns legalization,” he said. Karen O’Keefe, director of state policies at the Marijuana Policy Project (MPP), told Marijuana Moment that the revised bill is a “slap in the face to voters” that would “gut and replace Ohio’s voter-enacted law with Prohibition 2.0.” “HB 86 eliminates home cultivation, more than doubles taxes, caps potency lower than any other state, and creates new penalties—including a three-day mandatory minimum for passengers vaping or smoking in a car or boat,” she said. “Outrageously, it appears to completely do away with legal possession for at least a year,” she added, noting the lack of a deadline to authorize sales that would mean “regulators could indefinitely delay legalization.” “If enacted, instead of December 7 being a day of cannabis freedom, consumers could find themselves facing harsher penalties than they did before Election Day,” O’Keefe said. Unlike the Senate leader and governor, House Speaker Jason Stephens (R) has maintained that legislators should more thoughtfully address amendments to the initiated statute, even if that takes more time. He’s pointed out that changes to provisions on taxes and advertising, for example, wouldn’t become relevant until later next year given that regulators still need months to develop licensing rules before retailers open shop. While some Democratic lawmakers have indicated that they may be amenable to certain revisions, such as putting certain cannabis tax revenue toward K-12 education, other supporters of the voter-passed legalization initiative are firmly against letting legislators undermine the will of the majority that approved it. Ohio Rep. Juanita Brent (D) recently emphasized that people who’ve been criminalized over marijuana, as well as those with industry experience, should be involved in any efforts to amend the state’s voter-approved legalization law, arguing that it shouldn’t be left up to “anti-cannabis” legislators alone to revise the statute. Meanwhile, Rep. Gary Click (R) filed legislation last week that would allow individual municipalities to locally ban the use and home cultivation of cannabis in their jurisdictions and also revise how state marijuana tax revenue would be distributed by, for example, reducing funds allocated to social equity and jobs programs and instead steering them toward law enforcement training. Rep. Cindy Abrams (R) also introduced a bill last month that would revise the marijuana law by putting $40 million in cannabis tax dollars toward law enforcement training annually. The Ohio Department of Commerce was quick to publish an FAQ guide for residents to learn about the new law and timeline for implementation, though regulators repeatedly noted that the policies may be subject to change depending on how the legislature acts. Prohibitionist organizations that campaigned against Issue 2, meanwhile, are set on a fundamental undermining of the newly approved law, with some describing plans to pressure the legislature to entirely repeal legalization before it’s even implemented. For what it’s worth, a number of Ohio lawmakers said in September that they doubted the legislature would seek to repeal a voter-passed legalization law. The Senate president affirmed repeal wasn’t part of the agenda, at least not in the next year. Voters were only able to decide on the issue after lawmakers declined to take the opportunity to pass their own reform as part of the ballot qualification process. They were given months to enact legalization that they could have molded to address their outstanding concerns, but the legislature ultimately deferred to voters by default. As early voting kicked off in late October, the GOP-controlled Senate passed a resolution urging residents to reject measure. Unlike the top state Republican lawmakers, one of the state’s GOP representatives in Congress—Rep. Dave Joyce, co-chair of the Congressional Cannabis Caucus, said in September that he would be voting in favor of the initiative in November. He encouraged “all Ohio voters to participate and make their voices heard on this important issue.” Senate Banking Committee Chairman Sherrod Brown (D-OH) said in late October he voted in favor of the legalization ballot initiative, calling it a “hard decision” but one that was based on his belief that the reform would promote “safety” for consumers. Meanwhile, Vivek Ramaswamy, a 2024 Republican presidential candidate, said he voted against a ballot initiative to legalize marijuana in Ohio because he’s concerned the federal government could “weaponize” criminalization against people who are engaged in state-legal cannabis activities under the “fake” pretense that they’re protected from federal prosecution. Senate Majority Leader Chuck Schumer (D-NY), for his part, said recently that Ohio’s vote to legalize marijuana at the ballot is one of the latest examples of how Americans are rejecting “MAGA extremism,” and he added that he’s committed to continuing to work on a bipartisan basis “to keep moving on bipartisan cannabis legislation as soon as we can.” Rep. Earl Blumenauer (D-OR), co-chair of the Congressional Cannabis Caucus, told Marijuana Moment that “the vote in Ohio was a great big exclamation point on the things we’ve been talking about.” “We’ve been saying for years how this issue has crested, how it’s got broad momentum, how it is inclusive. It’s sort of like the success with the issue—except this was more pronounced,” he said. “We got more votes than the abortion issue. We get more votes than anybody on the ballot.” The White House has separately said that “nothing has changed” with President Joe Biden’s stance on marijuana, declining to say if he supports Ohio’s vote to legalize or whether he backs further reform of federal cannabis laws. Meanwhile, as Ohio voters approved statewide legalization, activists also chalked up a series of little-noticed wins to decriminalize larger amounts of cannabis in three Ohio cities, according to preliminary county election results. Read the text of the marijuana legalization amendment below: New Bipartisan Wisconsin Bill Would Decriminalize Marijuana Possession Photo courtesy of Philip Steffan. Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.  Read More Feedzy  [...] Read more...
December 5, 2023Cannabis News​ Last week the Congressional Research Service issued a report on the 2023 Farm Bill which focused on hemp industry issues. The primer, written by Renee Johnson, a specialist in agricultural policy, was prepared as a document for congressional committees and members of Congress. In other words, a Cliff Notes version of the Farm Bill. On Nov. 15, Congress passed a continuing resolution for the budget, which averted a government shutdown. That included an extension of the 2018 Farm Bill through September 2024. According to Farm Aid, it’s expected that Congress will use this extension to present a draft of a new farm bill early next year. Current Hemp Market According to the report, the U.S. Department of Agriculture said that the farm-level value of total utilized hemp production was $238.4 million in 2022, down from $824 million in 2021. Floral hemp grown in the open was the dominant type grown in 2022, as measured by total value and acreage. Floral hemp tends to command higher market prices compared with other marketable uses for hemp, including hemp fiber, grain, and seed production. In 2022, U.S. hemp growers planted 28,300 acres of hemp and harvested about 18,300 acres, accounting for a small share of total U.S. harvested cropland acres. Hemp is grown in all U.S. states under a USDA-approved state plan or a USDA general license. The leading hemp-producing states, with more than 1,000 harvested acres grown in the open (2022), were: South Dakota (2,550 acres) Oregon (1,900) Montana (1,470) Missouri (1,400) Kentucky (1,300) Production by state tends to be highly variable year-to-year. Proposed Amendments While there are various hemp industry organizations with differing priorities, one area they agree upon is that the USDA’s regulatory requirements are overly restrictive and impractical. One such changes that stakeholders would like to see is reduction of the Drug Enforcement Administration’s oversight role in hemp. That includes removing the requirement that hemp be tested at DEA-registered labs or that eligible testing labs be DEA-accredited. There is also a desire to change the definition of hemp, raising the allowable THC level from 0.3% to 1%, to provide additional flexibility to growers and avoid crop destruction if that limit is exceeded. The testing itself is also on the proposed change list. Stakeholders want the USDA’s regulatory requirement for measuring THC content to be based on total THC, which includes the potential conversion of tetrahydrocannabinolic acid into THC, rather than the delta-9 THC concentration. However, any changes to the USDA’s testing methods would result in the agency following procedures for rulemaking and commenting periods which would delay the hemp industry even further. Other changes include: Repealing the existing exclusion that keeps people with a felony controlled substance-related conviction from obtaining a hemp license. Exempting hemp farmers who focus on fiber and grain end products from background checks and testing protocols. Addressing the requirement for government-certified or approved seed. Product Safety Since the 2018 Farm Bill, which focused primarily on hemp cultivation issues, the industry has expected that the FDA would review hemp products and issue guidance on uses in food, cosmetics, and other goods. But that hasn’t happened. Congress has introduced legislative proposals that would remove FDA restrictions on the marketing of food and dietary supplements containing added hemp-derived cannabinoids. Plus, some proposals would establish federal quality and safety standards and labeling requirements for such products. There is also a desire to get better information regarding marketing capabilities around hemp products. Conversely, some want to ban some hemp products due to concerns over public safety. While it wasn’t completely clear which products these were, it seems like they are referring to intoxicating hemp products. Building USDA Support Overall the report said that most hemp advocates seek to expand USDA farm program support for hemp and hemp products. These proposals included: Expanding research related to genetics and management practices and targeted support to develop the processing capacity of hemp fibers for use in insulation, construction materials, and plastics. Expanding support for hemp climate-smart and sustainability practices, promoting hemp’s soil carbon sequestration and phytoremediation properties. Adding hemp to the statutory definition of a specialty crop, which most fruit and vegetable groups oppose. Designating hemp as a specialty crop could qualify hemp for certain USDA programs. Expanding federal crop insurance and improving risk management tools, given the risks involved in growing hemp. Improving access to credit and banking services. IF12278  Read More Feedzy  [...] Read more...
December 5, 2023Cannabis News​ A coalition of military veterans organizations is pushing President Joe Biden to ensure that the ongoing administrative review into marijuana’s scheduling status is completed in a “timely manner” and also take steps to “counter” misinformation while pursuing broader reform. In a letter sent to the president last week, multiple veterans-focused groups expressed appreciation for his directive initiating the marijuana review last year, which led the U.S. Department of Health and Human Services (HHS) to recommend that cannabis be moved from Schedule I to Schedule III of the Controlled Substances Act (CSA). “This process represents a significant opportunity for our nation to lead with science over fear, and begin righting the wrongs of prohibition,” the groups, which include Iraq and Afghanistan Veterans of America, wrote. “The actions taken by your administration and HHS have been historic, and lay the groundwork for the significant work ahead, including the need to ensure that the Drug Enforcement Administration (DEA) expeditiously accepts the scientific and medically founded recommendation.” DEA is currently completing its part of the review before making a final determination. While the scientific findings of HHS are binding, the law enforcement agency is not required to abide by the Schedule III rescheduling recommendation. “As representatives of our nation’s Veterans communities, these issues of safe access and research could not be more important,” the letter says. “The individuals who work every day to protect our great nation deserve every ounce of support as they tackle the physical and psychological impacts of their service as they return from active duty.” The groups included anecdotes from members in the letter, detailing how cannabis has helped them transition away from certain pharmaceuticals and improved symptoms of conditions such as post-traumatic stress disorder (PTSD) and depression. “While we are seeing incredible success through access to cannabis, these positive outcomes are limited by the stigma associated with admitting use and the fear associated with lost opportunities as a result of federal restrictions on cannabis,” the coalition said. “We understand that misinformation, driven by fear and misunderstanding, is common when it comes to cannabis,” they continued. “And we ask that your administration work diligently to counter this misinformation, and to listen when your Veterans say that something is not only important, it’s potentially life saving.” The letter also talks about the benefits of going beyond simple rescheduling by moving to federally legalize marijuana. Doing so would improve military readiness by addressing cannabis-related recruitment issues and broadly resolve state and military policy conflicts, they said. “As a community, we see the reclassification of cannabis as a first step in evolving our national understanding of a plant that thousands of veterans rely upon for chronic pain and other serious service-related ailments,” they said. “There is more progress to be made post-rescheduling and we will look to you, Mr President, to continue supporting and prioritizing access to the benefits of plant-based medicine for all of our active duty and Veterans communities.” The letter contains two specific asks for the president: 1) to ensure that the scheduling review process “is concluded in a timely manner” and 2) to see to it that Congress “builds on this historic progress to ensure our Veterans communities are not left behind.” “While the significance of cannabis rescheduling is unique to each community, as Veterans, reclassifying cannabis means a better future for those who chose to serve our country,” they said. “To us, it means access to life-changing medicine, to economic opportunity, to healthy futures—free of opioids, and to wellness without the weight and stigma of unscientific restrictions.” “Thank you Mr President for initiating this process. We look to your leadership in ensuring this action is just the beginning—laying the groundwork for a better tomorrow,” the letter concludes. “The undersigned organizations are with you in the fight for safe access, scientific research, and a better future for our Veterans communities.” Signatories on the letter include Hemp for Victory, Balanced Veterans Network (BVN), Iraq and Afghanistan Veterans of America (IAVA), Realm of Caring, Hero Grown, Santa Cruz Veterans Alliance and Texas Veterans for Medical Cannabis. The veterans groups aren’t the only ones proactively pushing for administrative support amid the ongoing scheduling review. Sen. Kirsten Gillibrand (D-NY) recently called on DEA to act with “great urgency” to reschedule marijuana in line with a recommendation from HHS, for example. A coalition of 31 bipartisan House lawmakers sent a letter the DEA administrator in October, urging her to take into account congressional and state marijuana legalization efforts as the agency carries out its scheduling review. They also criticized the limitations of simple rescheduling as they push for complete a complete removal of marijuana from the CSA. Those letters serve as a counterbalances to other recent messages DEA has received from congressional opponents of reform and former DEA and White House drug czars who argue that even moving marijuana to Schedule III would go too far. Fourteen Republican congressional lawmakers recently urged DEA to “reject” the top federal health agency’s recommendation to reschedule marijuana and instead keep it in the most restrictive category under the CSA. Two GOP senators, including the lead Republican sponsor of a marijuana banking bill that cleared a key committee in September, have also recently filed legislation to prevent federal agencies from rescheduling cannabis without tacit approval from Congress. Rep. Pete Sessions (R-TX) separately submitted an amendment for a spending bill that would prevent the Justice Department from using federal funds to reschedule or deschedule marijuana. Advocates and lawmakers who support cannabis reform, meanwhile, marked the one-year anniversary of Biden’s mass marijuana pardon and scheduling directive by calling on him to do more—including by expanding the scope of relief that his pardon had and by expressly supporting federal legalization. What’s also unclear is the timeline for when DEA will complete its cannabis review. For what it’s worth, however, a former Food and Drug Administration (FDA) official says he’d be “shocked” if DEA doesn’t reschedule marijuana by next year’s presidential election. Read the veterans groups’ letter to Biden on the marijuana scheduling review below: Ohio Senate Committee Advances Bill To Eliminate Marijuana Home Grow, Reduce Possession Limits And Raise Taxes—Days Before Legalization Takes Effect Photo courtesy of Mike Latimer. Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.  Read More Feedzy  [...] Read more...
December 5, 2023Cannabis News​ A final vote on a bill to legalize marijuana in Germany that was initially planned for this week has been called off amid concerns from leaders of the country’s Social Democratic Party (SPD). The delay means that action on the landmark proposal will be postponed until next year. “It always has to be approved by the parliamentary groups in the end,” Dirk Heidenblut, an SPD member of Germany’s Bundestag who is responsible for the party’s cannabis policy, said in an Instagram post. “And if a faction leader, in this case the SPD, has concerns, then it cannot be set up yet.” Despite the delay, Heidenblut added that as long as the measure advances by the end of January, the delay shouldn’t meaningfully impact the schedule for implementing legalization. If lawmakers pass the bill, the early stages of reform—including home cultivation for personal use—would begin as soon as April. View this post on Instagram The development is the latest of several delays to have slowed the bill’s pace through parliament. Lawmakers initially delayed their first debate on the legislation, which was held in October, ostensibly due to the conflict in Israel and Palestine. They also pushed back a vote scheduled for last month as supporters worked on improvements to the bill. While Heidenblut’s recent comments didn’t elaborate on SPD’s concerns or provide further details on the delay, proponents of the legalization measure faced criticism in the Bundestag last week that suggested ongoing hesitancy about the policy change. At a meeting on Wednesday, Health Minister Karl Lauterbach took questions from members, some of whom oppose legalization. At several points, he pushed back against lawmakers who suggested that legalization would send the wrong message to youth and lead to increased underage consumption, saying their arguments “misrepresented” the legislation, according to a translation. “The fact remains that child and youth protection is carried out through education, and sales to children and young people remain prohibited,” Lauterbach said. “That is the only change we have made in this area: a tightening.” Lawmakers also recently made a raft of adjustments to the bill, mostly designed to loosen restrictions that faced opposition from advocates and supporters in the Bundestag. They included increasing home possession maximums and removing the possibility of jail time for possessing slightly more than the allowable limit. Lawmakers further agreed to stagger the implementation of the reform, making possession and home cultivation legal for adults beginning in April. Social clubs that could distribute marijuana to members would open in July. Officials are eventually planning to introduce a complementary second measure that would establish pilot programs for commercial sales in cities throughout the country. That legislation is expected to be unveiled after its submitted to the European Commission for review. As for the latest delay, the German news outlet LTO reported that it’s unclear “whether the SPD faction leadership has a problem with the content of the law” or simply whether focusing on marijuana issues “in times of the budget crisis shortly before Christmas seems inappropriate to them.” The Bundestag could now take up the measure as soon as January 18 or 19, LTO said, “or just in February.” The German news publication Der Spiegel, meanwhile, reported that the hangup is the result of criticism from domestic SPD politicians. “There was no agreement with the domestic politicians of the SPD faction at any time,” domestic politician Sebastian Fiedler told the outlet. “If the law on cannabis legalization were to be voted on now, there would be a significant proportion of no votes from the SPD faction. Including my own.” An SPD spokesperson in the Bundestag, meanwhile, told the publication: “We are confident that the law will be passed promptly in the new year in the Bundestag.” A member of parliament from the Green Party, Kirsten Kappert-Gonther, expressed disappointment about the delay. “It is extremely unfortunate that #Cannabis is not yet on #Tagesordnug . A set-up would have been possible,” Kappert-Gonther said. She noted that the April start date for certain elements of legalization, however, can still “be achieved if it is set up at the beginning of the year!” Ates Gürpinar, who represents The Left party in the Bundestag, didn’t mince words on social media following announcement of the delay. “It is politically so stupid that the SPD leadership is stopping the #Cannabis law,” Gürpinar wrote on social media. “It is once again bowing to the culture war of the right – and thereby making it bigger. The messing around at #Legalisierung keeps the issue on the boil from the right. Just get through it, damn it.” Members of the German public are also disappointed, as evidenced by a social media post from Carmen Wegge, a member of the SPD who has supported the legalization proposal. “Dear everyone,” she wrote, “if you are dissatisfied, please write me an email or contact me in another way. Finding out my employee’s home number and making phone calls on the weekend doesn’t result in a setup.” The German Hemp Association has launched a protest action in response to the delay in which it’s urging lawmakers to move forward with the legalization bill. The group is asking supporters to send letters to their representatives to call for the bill to be passed without further restrictions. The SPD faction that’s holding up the process, the hemp association said, not only threatens to derail the country’s timeline for legalization, but it also “contradicts the statement of all other parties involved that there is an agreement on the content” of the bill. Following the bill’s final reading in the Bundestag, it will go to the Bundesrat, a separate legislative body that represents German states. Members of the Bundesrat tried to block the proposed reform in September but ultimately failed. The legalization proposal is being spearheaded by Lauterbach, the health minister, who first shared details about the revised legalization plan last April. The following month, he distributed the legislative text to cabinet officials. Lawmakers in the Bundestag recently held a hearing in the Health Committee, at which opponents criticized some elements of the proposal. The body also heard a competing policy proposal from The Union, a political alliance of the Christian Democratic Union and Christian Social Union (CDU/CSU), that would not legalize marijuana but instead “improve health protection and strengthen education, prevention and research,” Kappert-Gonther said at the time. The health minister responded to early criticism of the bill from medical and law enforcement groups by emphasizing that the reform would be coupled with a “major campaign” to educate the public about the risks of using cannabis. Germany’s Federal Cabinet approved the initial framework for a legalization measure late last year, but the government wanted to get signoff from the EU to ensure that enacting the reform wouldn’t put them in violation of their international obligations. The framework was the product of months of review and negotiations within the German administration and the traffic light coalition government. Officials took a first step toward legalization last summer, kicking off a series of hearings meant to help inform legislation to end prohibition in the country. Government officials from multiple countries, including the U.S., also met in Germany last month to discuss international marijuana policy issues as the host nation works to enact legalization. A group of German lawmakers, as well as Narcotics Drugs Commissioner Burkhard Blienert, separately visited the U.S. and toured California cannabis businesses last year to inform their country’s approach to legalization. The visit came about two months after top officials from Germany, Luxembourg, Malta and the Netherlands held a first-of-its-kind meeting to discuss plans and challenges associated with recreational marijuana legalization. Leaders of the coalition government said in 2021 that they had reached an agreement to end cannabis prohibition and enact regulations for a legal industry, and they first previewed certain details of that plan last year. A novel international survey that was released last year found majority support for legalization in several key European countries, including Germany. New Guide On ‘How To Regulate Psychedelics’ Lays Out Four-Tiered Model Focused Specifically On Nonmedical Use Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.  Read More Feedzy  [...] Read more...
December 5, 2023Cannabis News​ Four grocery chains will add Planet Based Foods’ taquitos later this month. Hemp-based food company Planet Based Foods Global Inc. (CSE: PBF) (OTCQB: PBFFF) (FRA: AZ0) raised C$3 million in a private placement of subordinate voting shares for C$0.10 per share. The net proceeds will be used for general working capital and corporate purposes. The company has also entered into a C$200,000 loan agreement secured against the company’s assets with a 10% interest rate. The loan will mature on Feb. 28, 2024. Expansion Planet Based Food’s best news, however, was that two versions of its taquitos will be found various Lazy Acres Natural Markets, New Leaf Community Markets, and Lunardi’s Markets store locations this month. “We’re happy to be disrupters in the culinary landscape,” said Braelyn Davis, CEO and co-founder of Planet Based Foods. “I’m happy that Planet Based Foods can remain at the forefront of food technology with our hemp-formulated superfood products. Our goal was to get our products out to the masses, and with our strategic partnerships in place, we’re achieving just that. The best of all, the feedback for our products has been fantastic.” Lazy Acres is a subsidiary of Bristol Farms and is dedicated to promoting natural approaches to optimal health and wellness. Lazy Acres serves local communities as a marketplace for individuals who prioritize healthy living and eating. New Leaf Community Markets is a grocery store chain primarily located in Northern California. Lunardi’s Markets is a family-owned grocery store chain primarily located in Northern California, specifically in the San Francisco Bay Area. Board Addition Planet Based Foods also appointed Kevin Vines as an independent director. Vines is recognized as a prominent exporting specialist in the realm of produce from North America. His expertise extends to a diverse range of items, including avocados, berries, cherries, and asparagus, with a primary focus on facilitating exports to Southeast Asia and the Middle East. “We have full confidence that his wealth of experience will significantly contribute to the company’s product development, particularly from the fresh food perspective,” Davis said.  Read More Feedzy  [...] Read more...
December 5, 2023Cannabis News​ The Daily Hit is a recap of the top financial news stories for Dec. 1, 2023. On the Site 2023 Farm Bill Primer Addresses Proposed Amendments Last week the Congressional Research Service issued a report on the 2023 Farm Bill which focused on hemp industry issues. The primer, written by Renee Johnson, a specialist in agricultural policy, was prepared as a document for congressional committees and members of Congress. Read more here. Cansortium Sees Opportunity in Florida – Even Without Adult Use Florida-based multistate operator Cansortium (CSE: TIUM.U) (OTCQX: CNTMF) reaffirmed its plans to expand operations in its home state and other markets during its third quarter earnings call, despite multimillion-dollar losses this year and uncertainty over the Sunshine State’s proposed adult-use marijuana ballot measure next year. Read more here. Exclusive Interview: Behind New York’s Crackdown on Out-of-State Brands Until now, brands have been allowed to enter the New York market legally via simple licensing and white label deals with permitted processors, but soon they will have to obtain a formal license from the Office of Cannabis Management, according to John Kagia, the OCM’s policy director. Read more here. Hemp-based Food Company Raises C$3 Million, Expands Store Presence Hemp-based food company Planet Based Foods Global Inc. (CSE: PBF) (OTCQB: PBFFF) (FRA: AZ0) raised C$3 million in a private placement of subordinate voting shares for C$0.10 per share. The net proceeds will be used for general working capital and corporate purposes. Read more here. For Illinois’ Cannabis Industry, the Roller-Coaster Ride Continues Four years into Illinois’ experiment with legal recreational marijuana sales, the industry looks very different — in ways that are both good and bad. Big companies continue to face headwinds and are looking for a lifeline from Washington, while many new small companies are defying the odds and pushing ahead to open shops and cultivation facilities. Read more here. In Other News Avicanna Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) closed a non-brokered private placement offering of 2,537,508 ‎‎units at a price of $0.35 per unit for aggregate gross proceeds of $888,127.80. The company intends to use the proceeds for general working capital purposes, general and administrative expenses, expenditures related to production and manufacturing, and research and clinical development. Read more here. Minnesota Minnesota now must hire top regulators for both its medical and recreational marijuana industries after the state’s medical cannabis director resigned this week. Chris Tholkes, who’s led the Office of Medical Cannabis within the state Department of Health since 2019, said Monday that she has resigned to take a job as the City of Minneapolis’ director of health operations. Read more here.  Read More Feedzy  [...] Read more...
December 5, 2023Cannabis News​ “Employees were basically told, ‘If you talk to the union, if you take a card, if you take a sticker, you’re out.” By Rebecca Rivas, Missouri Independent The first day was a breeze. Sean Shannon and Danny Foster walked into several marijuana dispensaries around Missouri with their matching “Union For Cannabis Workers” shirts and talked to employees about the possibility of unionizing. “The first day, there were 57 stops amongst the teams,” said Shannon, lead organizer with UFCW Local 655, which actually stands for United Food and Commercial Workers International Union. “Reception was out-of-this-world positive. Workers were so excited.” Shannon had gathered together a dozen organizers to help Local 655 visit every one of the approximate 100 dispensaries on the eastern half of Missouri—twice. Stirring up the excitement was the union’s big win of the recent settlement, where 10 Shangri-La South dispensary workers in Columbia received a collective $145,000 after being fired following a March union organizing drive. “They were excited to hear that Shangri La actually won,” he said. “They couldn’t believe people were getting their jobs back. They couldn’t believe the amount of money.” But by the third day, the reception got much colder, he said. Managers had warned their counterparts at other locations that union reps might be visiting. “Employees were basically told, ‘If you talk to the union, if you take a card, if you take a sticker, you’re out,’” he said. Still, since the tour, union activity has “blown up,” Shannon said. An active campaign means the employees have signed agreements, or authorization cards, with the union authorizing Local 655 to represent them. It also means union leaders believe workers have a good shot at succeeding. Shannon said Local 655 now has authorization to represent more than 20 locations in eastern Missouri. The next step is filing a representation petition with the National Labor Relations Board, seeking to have the board conduct an election among employees on whether or not to unionize. Last week, employees at Hi-Pointe Cannabis in St. Louis filed a petition—following the lead of workers at High Profile Dispensary in Columbia and Bloom Medicinal Dispensary in St. Louis in early November. In October, Homestate Dispensary employees in Kansas City voted 6–1 to have Teamsters Local 955 represent them, becoming the second unionized dispensary in Missouri. The first was Root 66 Dispensary in St. Louis, where employees voted to join UFCW Local 655 in April 2022. A big reason why employees are moving towards unions, Shannon said, is because Missouri is at the point where the “canna-bliss” of working with marijuana professionally is starting to wear off. Now the reality that workers aren’t getting paid enough, are sometimes working in poor conditions and have no job stability is starting to set in, said Danny Foster, a former cannabis worker who was helping with the union’s tour. “We really weren’t given the industry that we were promised,” Foster said. “We all came in super excited. We love cannabis. We wanted to be able to make it a career. But as it is right now, cannabis isn’t a career.” ‘Vision of fully restorative relief’ The motivation to unionize for Andrew Nussbaum, the most veteran worker at Shangri-La South dispensary in Columbia, was to ensure job security. Because he loves his job as a patient consultant supervisor. “A lot of us just want to help people and help them find something that works for them,” he said. “I’ve talked to people for 45 minutes to an hour to kind of get them squared away.” When he and other dispensary workers filed a representation petition in April, they encountered strong resistance. After he and nine other employees were fired, the board swiftly and firmly sided with the workers and approved a settlement that awards backpay to all the “unlawfully terminated employees.” It also cleared a path for them to unionize. Announcing the agreement, the board made a pointed statement about the case reflecting the “general counsel’s vision of fully restorative relief.” Nussbaum is among five of the 10 terminated employees who will be returning to work in the near future. And despite it being a tumultuous year, he said he’s committed to his role. He has a degree in plant biology, and he enjoys learning about how cannabis can help people. “That’s what this is all about,” he said. “That’s why it’s so important to all of us, because this was not an easy ordeal for any of us.” An attorney representing the company in the case did not return The Independent’s request for comment. One of the things that draws people to the industry is the camaraderie among employees who are passionate about cannabis, Shannon said. And that’s also what makes it the perfect breeding ground for organizing. “Cannabis workers are the right community,” he said. “This is a tight knit community that takes care of each other. They’re already learning that … having a union backing you up, it’s the only way to truly make a difference. I’ve been telling people, ‘Wait till you feel that contract high.’” Are they ag workers? Will Braddum, a post-harvest technician, is facing a different kind of battle at BeLeaf Medical’s Sinse Cannabis site in St. Louis. Not long after he and 17 other employees filed their petition in September, the company argued before the board that the employees aren’t manufacturer workers—they’re agricultural workers. Agricultural laborers aren’t protected under the 1935 National Labor Relations Act, which ensures employees have the “fundamental right to seek better working conditions and designation of representation without fear of retaliation.” It’s a frustrating “gray area” for manufacturing cannabis employees looking to unionize, Shannon said. On October 27, company representatives described the employees’ job descriptions to the board, which included “a whole bunch of the cultivation side’s job description,” Braddum said. It was eye-opening for the employees who testified and had to refute that description, he said. “I’ve never watered anything and never touched any soil,” he said. “I’ve never touched a living plant at work. So I guess if they’re gonna tell the National Labor Relations Board that we’re doing agricultural work, maybe they’re not necessarily on our side at all.” An attorney for BeLeaf Medical said the company was not able to comment. It’s unclear how long it will take to get a decision from the board, but the decision will likely be reviewed closely nationwide. Braddum has been at BeLeaf for the last year and a half, but he’s been part of the legacy market since 2009. “I just kind of segued,” he said. “I went from an illegal career to a legal career without a hiccup basically.” For him, this is his career. He’s seen how “cutthroat” the corporate side can be and how a human relations officer has the power to make someone lose their agent ID, or state-issued license to work in cannabis. He doesn’t want that to happen to him or any of his team. “The only way to pad myself from Human Resources is to cultivate a union movement,” he said, “and talk to my co-workers about job security.” This story was first published by Missouri Independent. Missouri Lawmaker Urges Investigation Into ‘Egregious Exploitation’ In Marijuana Social Equity Licensing Process Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.  Read More Feedzy  [...] Read more...
December 5, 2023Cannabis News​ 10% – Percentage of cannabis consumers who prefer strains with 6%-10% THC content A common theme resonating through many recreational cannabis markets is: How high can we get the THC level? But low-THC strains may be gaining in popularity. This year, more consumers have said they prefer this range of THC percentage than ever before. But these products can be hard to come by. With 1-in-10 flower users preferring this range, there’s a solid opportunity for sales. Source: Brightfield Group, U.S. Cannabis Consumer Insights, Q3 2023  Read More Feedzy  [...] Read more...
December 5, 2023Cannabis News​ Hawthorne, the hydroponic subsidiary of fertilizer company The Scotts Miracle-Gro Co. (NYSE: SMG), is looking to strike out on its own – a move that Scotts CEO Jim Hagedorn hinted at on the company’s earnings call in November. “We’ve made progress on a range of potential solutions that should benefit shareholders and create opportunities for that business to grow,” Hagedorn said about Hawthorne at the time. “We’re in active discussions to create a leading vertically integrated cannabis company. I can’t share more at this time, but we will provide an update as soon as we can.” Just a few years ago, Hawthorne was riding high as the cannabis industry’s mantra was bigger is better. Multistate operators were competing with each other over who could build the biggest grow facilities – and that meant lots and lots of lights. However, the cannabis bubble burst and the business wilted. Hawthorne President Chris Hagedorn made difficult decisions to adjust to the new reality and eliminated almost a thousand jobs. He restructured debt and cut expenses. Now the company is positioning itself to become profitable again. Options Green Market Report spoke with Jim and Chris Hagedorn at the MJBiz Conference last week, where the two opened up about the options being considered. Essentially, there appear to be two roads out of Scotts: Spinning out into a separate public company Joining forces with Riv Capital (TSX: RIV) (OTC: CNPOF), which has an investment connection with Hawthorne “We’ve said as much publicly, but I think the interesting part of the conversation is why?” Jim Hagedorn said. “(Scotts will) keep the debt. You move it without any debt at all. So completely clean. Hundreds of millions of inventory and upward capital.” New PubCo Scotts could spin Hawthorne out into its own public company where it would compete with the likes of Ubi-grow, Agrify, and Grow Generation. However, these companies receive little analyst coverage, and there is concern that Hawthorne’s assets wouldn’t be recognized. Hawthorne has engaged in considerable research, and Chris Hagedorn doesn’t want that to get lost by being lumped in with other hydroponic companies. Riv Capital Option Riv Capital and Hawthorne are already associated with each other. In 2021, RIV Capital Inc. signed a deal with The Hawthorne Collective, a  cannabis-focused subsidiary of Scotts for the purchase of a $150 million unsecured convertible note from RIV Capital. However, Riv Capital is best known for paying top dollar to buy New York medical operator Etain. The Hagedorns acknowledged the criticism that the deal received but maintain that the New York market still holds great promise. Jim Hagedorn pointed out that Riv Capital is currently sitting on almost $90 million in cash, but it only has a market cap of roughly $10 million. In Talks “So the audience of people who we’re talking to, we haven’t had anybody yet say no. The question is how do we do this so that we create a company that you would look at and say, holy f*ck,” Jim Hagedorn said. “I sat with those guys and they were giving me big time hints that there is going to be a consolidation here that’s sort of across the board that creates the best pot company in the United States. “There are different permutations on how to get there. And these are conversations that are live right now,” he added. Chris Hagedorn noted that in those conversations, they’ve been told, “We see the R&D you guys do. They look at it as there’s the tax-yielding, which is exciting because everyone’s looking for tax mitigation. Hawthorne has the highest possible quality produced at the lowest possible cost.” The pair believe that cannabis will be rescheduled next year, which will release a lot of capital into the market. And with that there’s a lot of opportunity ahead for Hawthorne.  Read More Feedzy  [...] Read more...
December 4, 2023Cannabis News​ A man in Minnesota is providing free growing and cannabis basics workshops—free to the public—to help people get a foot in the door of the industry. Minnesota allows home cultivation under its recently approved adult-use cannabis law, and residents are eager to see if they have a green thumb. Minnesota adults are allowed to grow up to eight plants, four mature. Growing cannabis takes years of experience to master, but you gotta start somewhere.  Inforum reports that Steve Rosenfeldt, who is the owner of Ediblez OTC in Moorhead, Minnesota, wants to share his expertise with the plant to others. Rosenfeldt is hosting monthly Cannabis 101 and Growing 101 Workshops, held on the last Tuesday of each month at the Midtown Tavern in Moorhead. Locals say the skills they’re picking up will be valuable. “Really nice to be able to learn how to grow your own and not have to go to the store,” Jamie Carrillo, who was one of 40 people to attend the most recent workshop held on Nov. 28, told Inforum. Inforum reports that it’s the third class Rosenfeldt has taught so far. Each class attracted dozens of curious would-be growers of all ages, and some are reluctant to grow due to the lingering stigma surrounding pot. “There’s still a lot of stigma, people are skittish of even being seen in here, so it was kind of a surprise to have as many people turn out,” he said. Rosenfeldt is legally allowed to sell seeds that can grow cannabis at his store, but he cannot yet sell marijuana products. The store instead sells hemp-derived CBD and THC products. The seeds cost around $30 or $40, and it takes about four months for the seedlings to become mature plants. Last May, Minnesota Gov. Tim Walz signed the state’s cannabis legalization bill into law, officially making Minnesota the 23rd state in the nation to legalize recreational cannabis. The 300-page bill allows adults in the state over the age of 21 to use recreational cannabis and looks to transform the current illicit market into regulated, state-licensed businesses around the state. It specifically creates a new regulatory framework to license cannabis businesses to cultivate, manufacture and sell cannabis at retail dispensaries. There are a total of 12 different business licenses a person can apply for in the recreational market, along with additional licenses for medical cannabis. The legislation also expunges low-level cannabis convictions. The new law will automatically expunge non-felony cannabis offenses, and it will establish a board to review more serious cannabis crimes. The bill was designed with social equity in mind, granting social equity status to military veterans or active service members denied honorable status because of a cannabis offense, farmers from underrepresented communities and residents of areas which have “experienced a disproportionately large amount of cannabis enforcement.” The industry is overseen by the Office of Cannabis Management, which controls the regulation and sale of cannabis products in Minnesota. When Minnesota legalized cannabis for adult use, it set the home limit at 32 ounces or 2 pounds. But out in public, Minnesota adults are allowed up to 2 ounces. The legislation allows adults to grow up to eight cannabis plants at home, including four mature, flowering plants. Out of the states that have legalized cannabis for adult use, the limit for personal amounts at home in some states ranges from 1-10 ounces. Most states with home cultivation don’t have any limits set. “The vast majority of adult use states that allow home cultivation don’t have any explicit limit,” NORML Political Director Morgan Fox told High Times at the time. “And most of them explicitly say that you can keep whatever you grow in your own home. There are four states aside from Minnesota that actually have set limits. Massachusetts has 10 ounces, Michigan has 10 ounces, Oregon is eight ounces and New York is 5 pounds.” “If you’re gonna put a limit on it, I think it’s a good idea to have it towards the higher end of the spectrum and possible so that you can avoid potentially criminalizing people that are growing their own medicine or growing cannabis for their own purposes, but who are trying not to transfer to anybody else, you know, they’re not trying to gift it out, and certainly don’t want to be selling it. Local business owners in the area, however, said that they predict 99% of consumers in the state aren’t going to have a need for 2 pounds of cannabis at home, and if they do, they will probably sell it illegally.  Despite having the higher limit, industry insiders say it’s not enough for the state’s four-plant home grow limit.  Read More Feedzy  [...] Read more...
December 4, 2023Cannabis News​The first day was a breeze. Sean Shannon and Danny Foster walked into several marijuana dispensaries around Missouri with their matching “Union For Cannabis Workers” shirts and talked to employees… The post Cannabis workers across Missouri push to unionize dispensaries appeared first on Cannabis Business Executive – Cannabis and Marijuana industry news. Read More Feedzy  [...] Read more...
December 4, 2023Cannabis News​Possession of up to 14 grams of marijuana would be decriminalized under a bipartisan Wisconsin bill announced Friday. The proposal, which was announced in a memo seeking legislative support and… The post Small amounts of marijuana decriminalized under bipartisan Wisconsin bill appeared first on Cannabis Business Executive – Cannabis and Marijuana industry news. Read More Feedzy  [...] Read more...
December 4, 2023Cannabis News​ Oregon cannabis producers grew too much weed again this year, according to a new report, continuing the glut of marijuana that has plagued the state’s regulated pot industry for years.  For much of this year, analysis of Oregon’s production of cannabis showed that the state was on a downward trend compared to last year, leading to a modest increase in prices. But a new report from state economists Mark McMullen and Josh Lehner that was released on November 20 shows that this year’s fall harvest of outdoor weed pushed this year’s total crop beyond production levels posted in 2022. “Through the first nine months of the year, the marijuana harvest was nine percent lower than a year ago, and 15 percent lower than the record crop back in 2021,” the economists wrote. “As the market appeared to be adjusting, prices were stabilizing. That changed with the large October outdoor harvest which is 15 percent larger than last October.” Oregon’s cannabis cultivators have been growing more weed than the state’s consumers can smoke for at least five years. Mark Pettinger, a spokesman for the Oregon Liquor and Cannabis Commission (OLCC), said last year that the problem is caused in part by the difficulty operators and regulators have in predicting weed production. Because much of the state’s weed is harvested at the same time, the industry can be slow to adjust to changing market conditions at the wholesale and retail level. “It’s because about 85% of the crop is grown outdoors, comes down in October during harvest time, but planting planning is made the following April — which there really hasn’t been enough time to really gauge how the harvest from the previous fall is impacting the market,” Pettinger told a local television news outlet in 2022. The glut of weed in Oregon’s regulated market has wreaked havoc on the industry for years. Because of the oversupply, prices on wholesale cannabis and retail products have plummeted. While the decline in prices is welcomed by most consumers, cannabis companies have been left with dwindling margins and falling, or nonexistent, profits. As a result, producers, wholesalers and retailers throughout the state are having a difficult time making ends meet. Beau Whitney, a Portland-based economist who monitors cannabis prices in Oregon and throughout the United States, said that more than one-third of respondents to a cannabis industry survey said that they are having difficulty paying their taxes. Even more said that managing debt is a problem.  Whitney said that the latest report of Oregon’s abundant fall harvest “couldn’t have come at a worse time.” “People are walking away from cannabis licenses or selling them for pennies on the dollar,” Whitney told Willamette Week. The slump in cannabis prices has also been reflected in the collection of Oregon’s weed taxes. Throughout the state, tax delinquencies are up and cannabis tax revenue has fallen short of estimates for four of the past five quarters. Whitney noted that Oregon regulators could spur an increase in cannabis prices with a curb in production, which could be accomplished by limiting the number of licenses or their capacity. But Pettinger of the OLCC said that the current oversupply conditions are the result of intentional policy decisions coupled with the federal government’s continued refusal to legalize cannabis, which would open up markets across the country for Oregon’s weed growers. “The state and the industry and elected officials envisioned Oregon becoming a net exporter under federal legalization,” Pettinger says. “The oversupply we’re seeing underscores the dilemma in all states where marijuana is legal—it’s the equivalent of an Iowa corn farmer only being able to sell his crop within Iowa.” Falling weed prices and the resulting instability of Oregon’s cannabis industry led two industry groups to join forces in a recent merger. The two groups, the Oregon Cannabis Association and the Cannabis Industry Alliance of Oregon, announced the merger last month following unanimous votes by the boards of directors of each organization.  “There’s a lot of knowledge, there’s a lot of passion, there’s a lot of really educated folks within the cannabis industry in Oregon,” said Hunter Neubauer, board member of the combined trade group. “Those folks need one place to go to, where they can take a little bit of money that they have, and hopefully become members, and show up with us in Salem and advocate for reasonable regulations and future opportunities for the industry.” The newly merged group is named the Cannabis Industry Alliance of Oregon and represents more than 500 member businesses in the state’s licensed cannabis market, which generates about $1 billion in sales annually. “It’s a community that we all really value and we want to see survive and thrive,” Mike Getlin, the board chair of the Cannabis Industry Alliance of Oregon, told local media. “We want something more than a bunch of minimum wage jobs owned by out-of-state and potentially even overseas financial interests. So that’s what this fight is really about for us.”  Read More Feedzy  [...] Read more...
December 4, 2023Cannabis News​ The New Jersey Economic Development Authority (NJEDA), an agency responsible for providing financial assistance to New Jersey-based businesses, recently announced that it will now be accepting applications for Phase II of its cannabis equity seed grant program. This phase includes a total of $8 million that will be split up between 48 applicants ($150,000 each). The entirety of the Cannabis Seed Equity Grant Program offers a total of $20 million to applicants with either a conditional or annual cannabis license, with the goal of providing funds for start up and operation expenses during a business’s first three years. The first phase of the program allocated only 40% of funds for social equity applicants, whereas Phase II is utilizing 100% of reserved funding for social equity purposes. The application window for Phase II opened on Nov. 30 at 10am, and approved applicants will receive $150,000 and “no-cost technical assistance,” which includes an eight-week program for grant recipients to benefit from in the form of webinars. “The technical assistance program will provide training on converting a conditional license to an annual license, building a cannabis business team, financial management, securing investors, supply chain management, and more,” NJEDA stated. According to NJEDA Chief Executive Officer Tim Sullivan, building out this program will bolster the state’s cannabis industry. “Under Governor Murphy’s leadership, New Jersey is on the forefront of creating a stronger and fairer cannabis market, especially for communities historically harmed by the unjust War on Drugs,” said Sullivan. “The Seed Equity Grant, which is specifically designed for social equity applicants, will help create an equitable, inclusive marketplace that will create jobs and strengthen communities, all while ensuring our entrepreneurs are able to reap the industry’s economic benefits and have access to the resources needed to succeed.” The Cannabis Regulatory Commission (CRC) also signed off on the effort to prioritize social equity. “We are excited to see grant funding being used to help social equity applicants realize their entrepreneurship dreams. Beyond the skills and business acumen it takes to be an entrepreneur in any industry, starting a cannabis business faces additional challenges—including limited access to traditional means of business funding,” said CRC chair Diana Houenou.  Phase I applicants were not required to have secured real estate or municipal approval for their cannabis business. For Phase II grant applications, applicants must meet all CRC criteria as well as have already obtained a conditional license. According to the NJEDA website, the most recent application window was so popular that by Dec. 1, new applicants were placed on a waitlist. “Based on significant interest in the Cannabis Equity—Seed Equity Grant, the NJEDA has already received applications up to or exceeding the amount of funding available under this program,” the agency posted on its website. “All submitted applications that are received at this time will be placed on a waitlist and will be reviewed if the NJEDA can determine there is funding available to support the application.” Recently in October, NJEDA announced $12 million in funds for 48 cannabis business applicants ($250,000 each), describing the round as one of the largest social equity grants of its kind in the U.S. Gov. Phil Murphy spoke about how essential it is to invest in social equity applicants. “As the cannabis industry continues to reach new heights in New Jersey, it is important that we build on our efforts to support the businesses seeking to enter and grow within this emerging market. The Cannabis Equity Grant Program allows us to simultaneously expand the pool of cannabis businesses in our state while also focusing on those communities most impacted by the unethical War on Drugs,” said Murphy. “As we work to create a stronger, fairer, and more equitable cannabis market, our Administration will continue to increase access and opportunity to the small businesses entering the industry.” Also in October, Murphy and Attorney General Matthew J. Platkin announced that $5.5 million in cannabis tax funds would be put toward the New Jersey Hospital-Based Intervention Program. The money comes from the Cannabis Regulatory, Enforcement Assistance, and Marketplace Modernization Fund, with a goal of support victims of crime through crisis intervention and victim compensation. The $5.5 million will be granted to eligible applicants starting in 2024. A poll conducted earlier this year in May by Stockton University showed the changing attitudes of cannabis in New Jersey. Out of more than 660 participants, one-third of them said that they’ve used cannabis since it was legalized. Forty-four percent said that they used cannabis for recreational purposes, while 39% said it was for both medical and recreational purposes, and only 13% said they tried cannabis for medical consumption only. The poll showed that 69% of consumers purchased their cannabis products through a legal dispensary, and 86% of them said that they were “satisfied” or “very satisfied” with the experience. However, with the state having some of the highest cannabis prices in the country, only 7% of participants said that they approve of current cannabis prices.  Read More Feedzy  [...] Read more...
December 4, 2023Cannabis News​ A California man has been extradited to the U.K. to face manslaughter  charges over the death of a woman at his 2016 slapping therapy workshop.  An investigation was opened in October, 2016 when 71-year-old Danielle Carr-Gomm was found dead in her hotel room at Cleeve House in Seend, Wiltshire. Carr-Gomm had recently attended a paida lajin retreat, which is a form of therapy from China wherein a person vigorously slaps certain parts of the body in order to expel certain toxins from the blood.  60-year-old Hongchi Xiao, a man from California who was in Australia at the time of his extradition, was held and questioned in the U.K. in 2016 along with two other men in relation to Carr-Gomm’s death. “Hongchi Xiao, 60, of Cloudbreak, California, returned to the United Kingdom from Australia on an extradition warrant and has been taken to Gablecross custody in Swindon where he was charged. This relates to the death of Danielle Carr-Gomm, 71, at Cleeve House in Seend in October 2016,” said local police to the Guardian.  According to a BBC article on the subject of paida lajin, the head and joint areas of the patient are repeatedly slapped until they turn red or bruised. This is based around the ancient Chinese belief in “sha,” meaning that “toxins” from the blood vessels which appear during the course of paida lajin therapy in the form of redness or bruising at the slapping site are a sign of latent disease. Critics of this practice have pointed out, somewhat redundantly, that this is just the result of blood vessels breaking and skin bruising.  According to ABC Australia, Xiao was previously investigated over the 2015 death of a seven-year-old diabetic boy in Sydney, Australia who had previously attended one of his workshops. Xiao received a 10-year sentence for his involvement in the boy’s death in 2019. An investigation revealed he told the boy’s parents that the boy would not need insulin or medical treatment for his diabetes if he attended the slapping therapy. An Australian news outlet reported in 2022 that Xiao’s charges had been overturned after he appealed his case on the grounds that the evidence presented was inconsistent. He had served six years of his 10-year sentence at the time, and was out of jail a little over a year-and-a-half before his extradition  Matthew Carr-Gomm, Danielle’s son, told the Guardian that his mother was diabetic but had difficulty injecting her insulin due to a fear of needles, thus leading her to seek holistic methods to treat her ailments.  “She was always keen to try and find alternative methods of treating and dealing with her diabetes and was very interested in alternative and holistic medicine and therapies. I know she was desperate to try and cure herself of this disease. She always maintained a healthy lifestyle and was adamant that nothing would stop her from living a full life,” Matthew said. “In recent years, mum was in a great place with a partner, a lovely home, and was traveling the world. She had a lot of life left in her.” A BBC reporter with a knee injury actually reported on her firsthand experience attending a paida lajin workshop in 2015, though she was actually beaten with bamboo sticks instead of slapped.  “He felt around my knee for where he thought the “little clots” were and without warning, forcefully whacked my knee. He aimed for exactly the same spot each time. It was excruciating. I yelled in surprise. The bruises turned purple quickly and minutes later, I had to halt the blows,” said BBC reporter Pamela Koh. “The beating needed to continue for at least 20 minutes to be effective, I was told. I gritted my teeth between the sharp, swift blows but I had to tell him to stop. He resumed until it became unbearable again and I tried to sit through the full 20 minutes of pain.” Incidentally, Koh reported that her knee eventually did get better but that the bruises took weeks to heal properly and she was unsure if her knee got better because of the therapy or because of the body’s natural ability to heal. A video of Xiao demonstrating paida lajin therapy can be found at this handy dandy little hyperlink. He was charged with manslaughter by gross negligence upon his return to the U.K. It was not immediately clear how much prison time he faced if convicted.   Read More Feedzy  [...] Read more...
December 4, 2023Cannabis News​ All eyes again are focused on Washington for help, but this time from bureaucrats, not legislators. President Joe Biden has directed regulators to reschedule marijuana as a less-dangerous controlled substance, which many in the industry expect to happen in the next several months. If marijuana is reduced from a Schedule 1 to a Schedule 3 drug, it would lower taxes for cannabis companies, which currently can’t deduct the same day-to-day expenses as traditional businesses. The impact would be far greater than the banking reform legislation that the industry has been pursuing for several years. The future of the SAFER Banking law, which looked promising a few months ago, seems doubtful, given the political turmoil in the U.S. House, tempering some of the enthusiasm for industry fortunes. Stock prices got a lift in September when the Department of Health & Human Services recommended rescheduling, but they have retreated a bit since then. Verano Holdings’ stock price is up 38% so far this year; Green Thumb Industries’ shares are up 21%; and Cresco Labs’ stock is down 6%. All three stocks are still down by at least half from where they were trading two years ago. Illinois joined several other states in offering some relief, allowing cannabis companies to deduct business expenses from state taxes — a move that could save them millions a year. The roller-coaster ride for publicly traded companies flows through to private companies. As stocks slid, valuations of private firms slumped, too. Deals such as Dispensary 33’s planned sale of two Chicago pot shops to Miami-based Ayr Wellness fell through. Just five Illinois dispensary licenses were transferred in the fiscal year ended June 30, down from 17 and 15 licenses sold in each of the previous two years, respectively, according to state records. “Rescheduling has the biggest immediate impact,” Paxhia says. “We would start to see exits again. Without it, a lot of small companies won’t make it.” Meanwhile, in Springfield, the cannabis industry is pushing for regulations to restrict the sale of competing hemp-based products, such as Delta 8. Fourteen states, including Colorado and New York, have banned Delta 8. “We have to move forward to regulating intoxicating hemp, which is a direct competitor to our social-equity licensees,” Johnson says. “I do think the Legislature has the appetite to regulate intoxicating hemp.”  Read More Feedzy  [...] Read more...
December 4, 2023Cannabis News​ NY marijuana license injunction lifted; OH legalization revision plans; R’s one-year sales anniversary; NJ cannabis equity grants; AL licenses awarded Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Email address: Your support makes Marijuana Moment possible… Before you dig into today’s cannabis news, I wanted you to know you can keep this resource free and published daily by subscribing to Marijuana Moment on Patreon. We’re a small independent publication diving deep into the cannabis world and rely on readers like you to keep going. Join us at https://www.patreon.com/marijuanamoment / TOP THINGS TO KNOW The Department of Health and Human Services had a Saturday deadline to send Congress a report on marijuana’s “potential therapeutic effects” and recommendations to overcome “barriers” to researching it. HHS and other agencies were already late with a separate cannabis report that was due to lawmakers last month. An official with the National Center for Complementary and Integrative Health said the government is working to launch a new cannabis research center to help overcome “barriers that have hampered” studies on marijuana—including “complex” federal rules such as Schedule I registration requirements. The New York Supreme Court officially lifted an injunction that has blocked regulators from processing hundreds of new marijuana retailer licenses—clearing the path to significantly expand the state’s cannabis market. Ohio Senate President Matt Huffman (R) discussed his plan to change provisions of the voter-approved marijuana legalization law, which involves amending a House-passed bill in committee on Monday and getting it enacted before cannabis possession becomes legal on Thursday. Rhode Island Gov. Dan McKee (D) and the Cannabis Control Commission celebrated the one-year anniversary of legal adult-use marijuana sales launching in the state. Germany’s health minister defended the government’s marijuana legalization plan from criticism ahead of a vote that had been planned for this week. Meanwhile, the state of Bavaria is exploring legal options to stop or slow down cannabis reform from taking effect locally. In a letter ahead of Monday’s oral arguments in federal court, lawyers for a proposed safe consumption site for illegal drugs slammed the Department of Justice’s “irreconcilable” position that giving out food is a protected “religious exercise” but providing harm reduction services is not. The New Jersey Economic Development Authority is accepting applications for “Seed Equity” grants that will provide up to $8 million in funding for 48 marijuana equity businesses. The Alabama Medical Cannabis Commission awarded cultivator, processor, dispensary, secure transport and testing lab business licenses—for the third time, in a round that regulators hope will avoid further litigation. / FEDERAL The Department of Veterans Affairs highlighted a study that indicates the “risk of cannabis use disorder varies by race.” The House marijuana banking bill got one new cosponsor for a total of 96. The House bill to federally legalize marijuana got four new cosponsors for a total of 73. / STATES Massachusetts’s treasurer accused the suspended chair of the Cannabis Control Commission of making “racially, ethnically, culturally insensitive statements.” A Virginia senator discussed the prospects for passing legislation to legalize marijuana sales. Utah regulators filed rules on cannabis testing quality assurance. A Minnesota regulator said her office lacks legal authority to inspect raw hemp flower to determine whether they exceed the 0.3 percent THC limit. The California Legislative Analyst’s Office projected cannabis tax revenues of $702 million in 2023-24. Colorado regulators are developing guidelines for law enforcement and medical professionals responding to psychedelic-related incidents. Illinois officials discussed a new state-level workaround to the 280E tax penalty on marijuana businesses. Ohio regulators published updated medical cannabis patient and caregiver numbers. California’s Cannabis Advisory Committee will meet on Thursday. —Marijuana Moment is tracking more than 1,000 cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.— / LOCAL Detroit, Michigan officials are being sued by companies that say the city improperly rescinded approval for a marijuana cultivation and processing facility. / INTERNATIONAL The Victoria, Australia Legislative Council Economy and Infrastructure Committee filed a hemp report. / SCIENCE & HEALTH A study of mice found that “cannabidiol protects the liver from α-Amanitin-induced apoptosis and oxidative stress.” / ADVOCACY, OPINION & ANALYSIS The Star Tribune editorial board said officials are right to be careful in selecting the state’s top marijuana regulator. / BUSINESS StateHouse Holdings Inc. reported quarterly net revenue of $25.5 million. POSaBIT Systems Corporation reported quarterly revenue of $13.6 million and a loss of $7.5 million. Canopy Growth Corporation completed the sale of its BioSteel business. MedMen Enterprises Inc. sent an update on its ability to timely file required financial statements. Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox. Email address: Photo courtesy of Chris Wallis // Side Pocket Images. Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.  Read More Feedzy  [...] Read more...
December 4, 2023Cannabis News​ At last week’s MJBiz Conference in Las Vegas, Farechild Events and MJBizCon announced the winners of the 2023 EMJAYS International Cannabis Awards. The event, held at the iconic Pearl Theater in the iconic Palms Hotel, Las Vegas, recognized businesses and individuals who have made significant contributions across various sectors of the cannabis industry. Celebrity presenters included Xzibit, Hope Wiseman, Jim McMahon, Kyle Turley, and more. 2023 EMJAYS Award Winners: Accounting Firm of the Year: Citrin Cooperman Advocacy Group of the Year: Last Prisoner Project Apparel / Lifestyle Brand of the Year: Jeeter Branding / Marketing Agency of the Year: PufCreativBusiness Software of the Year: Jane Technologies Cannabis Business Insurance of the Year: HUB International Cannabis Consulting Firm of the Year: Sapphire Risk Advisory Group Cannabis Friendly Bank of the Year: Dama Financial Cannabis Law Firm of the Year: Clark Hill Law Firm Cannabis Podcast of the Year: MITA Unshackled Cannabis Training / Education Services of the Year: Green Flower Consumer Gear / Tech Product of the Year: Flower Mill Grinder Investment Firm of the Year: Merida Capital Holdings Lighting Company of the Year: Fluence Market Research / Data Firm of the Year: Cannabiz Media Packaging Company of the Year: Grove Bags Public Relations Agency of the Year: Grasslands Retail POS System of the Year: Dutchie Seed Bank of the Year: Royal Queen SeedsSocial Content Creator of the Year: Roger Volodarsky @jollyroger Staffing & Recruiting Agency of the Year: Vangst Testing Lab of the Year: SC Labs Trade Association of the Year: Minority Cannabis Business Association Vaporizer Hardware Brand of the Year: Puffco  Read More Feedzy  [...] Read more...
December 4, 2023Cannabis News​ Two new bills regarding medical marijuana have been prefiled for New Hampshire’s legislative session that begins in January, with at least seven others already requested by lawmakers. One of the two proposals prefiled on Friday, HB 1231, would allow patients and caregivers to cultivate marijuana for therapeutic use. It’s sponsored by Rep. Wendy Thomas (D), as well as fellow Democratic Reps. Maria Perez, Jodi Newell, Alissandra Murray and Jonah Wheeler. Thomas sponsored similar medical marijuana homegrow legislation last session. Under the new legislation, home cultivation would be limited to three mature cannabis plants, three immature plants and 12 seedlings, and it could not take place within public view. Patients or caregivers would be allowed to purchase seedlings from dispensaries, and they would have to report their cultivation operations to state regulators. The other prefiled bill, HB 1240, would add eating disorders as qualifying conditions for the state’s medical marijuana program. It’s sponsored by Rep. Heath Howard (D) along with Thomas and Reps. Suzanne Vail, Christine Seibert, Newell, Murray and Hope Damon, all Democrats. The qualifying condition legislation would specifically allow doctors to recommend medical cannabis to patients with anorexia nervosa, bulimia nervosa, binge eating disorder, avoidant restrictive food intake disorder and other specified feeding and eating disorder. The two measures were prefiled Friday and are set to be taken up by the House Health, Human Services and Elderly Affairs Committee next year. According to a list of state legislative service requests, which indicate that a lawmaker has asked for a bill to be prepared, at least seven other marijuana-specific measures are still pending. Among them are proposals around qualifying conditions, criminal penalties and possession limits under the state’s medical marijuana program. Another, from Wheeler, relates to annulling, resentencing or discontinuing prosecution of certain cannabis offenses. —Marijuana Moment is tracking more than 1,000 cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.— Another requested bill, sponsored by Rep. Erica Layon (R) and eight lawmakers others, would legalize and regulate cannabis for adults. Meanwhile another Republican-requested bill, from Rep. Kevin Verville (R), relates to “the use of psychedelics for therapeutic purposes.” New Hampshire legalized medical marijuana in 2013, with patients able to obtain cannabis from licensed dispensaries—known in the state as alternative treatment centers (ATCs)—beginning in 2016. Lawmakers have also attempted to pass adult-use legalization in past sessions, but so far those efforts have fallen short. A special state commission that was convened to study legalization and recommend a novel system of state-run stores, last month voted against recommending a legalization bill at all—the culmination of a meandering, sometimes standoffish series of meetings over the past few months among a 19-member panel that included multiple opponents of the reform. Contributing to the commission’s inability to reach a consensus on the proposal was a last-minute message from Gov. Chris Sununu (R), who said he’d support no more than 15 retail outlets statewide. He also demanded that the industry be banned from lobbying and other political advocacy. Top Federal Agency Promotes New Marijuana Research Center Amid Scientists’ Complaints About ‘Complex’ Study ‘Barriers’ Under Prohibition Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.  Read More Feedzy  [...] Read more...
December 4, 2023Cannabis News​ Despite fears by critics that marijuana legalization would lead to sharp increases in problematic use, newly published data from the federal Substance Abuse and Mental Health Services Administration (SAMHSA) shows that states where cannabis sales remained illegal typically had the highest rates of treatment admissions for the drug. The data, which was published last week and covers 2021, show admissions to substance use treatment services among people aged 12 and older who go to state-licensed facilities. All told, the SAMHSA report presents findings from nearly 1.5 million admissions nationwide over the course of the year. Of all the tallied admissions nationwide in the new Treatment Episode Data Set (TEDS), 10.2 percent were for marijuana or hashish as the primary substance, according to the SAMHSA data. That’s the fourth most common substance after alcohol (34.8 percent of all admissions), heroin (20.2 percent) and methamphetamine (13.5 percent). It’s just above “other opiates/synthetics” such as pain medications or fentanyl (9.1 percent) and cocaine (5.6 percent). In terms of states with the highest admissions rates where marijuana was the primary substance, on a per capita basis, the top 10 states were South Dakota (151 per 100,000 residents), Iowa (144), Connecticut (141), South Carolina (119), Minnesota (110), New York (95), Wyoming (85), Georgia (84), North Dakota (81) and New Jersey (80). Substance Abuse and Mental Health Services Administration While all those states except South Carolina and Wyoming permitted medical marijuana use, none of the top 10 states had legal recreational sales at the start of 2021. New York, New Jersey and Connecticut all legalized adult-use cannabis at some point in 2021, but retail sales didn’t begin until subsequent years. The states with the lowest rates of admissions primarily for marijuana, meanwhile, were New Hampshire (2 per 100,000 residents), New Mexico (3), West Virginia (3), Montana (4), Puerto Rico (5), Hawaii (10), Arizona (15), Illinois (16), Maine (15), Massachusetts (21) and Pennsylvania (21). Notably, two states where recreational marijuana sales were legal in 2021—Washington State and Oregon—did not report figures for the SAMHSA report. Treatment admissions overall were down nationally between 2020 and 2021, during the height of the coronavirus pandemic. As noted by the prohibitionist group Smart Approaches to Marijuana (SAM), admissions for cannabis treatment in 2021 fell by more than 10,000 since the year before, dropping from 141,091 to 129,343—even as more states enacted legalization. Proportionally, treatment admissions for heroin fell by a larger degree over the same period. While the admissions numbers provide some indication of substance use disorders, they’re a messy measurement. Other factors affecting treatment admissions—such as sufficient space and resources, as well as how people are referred to treatment—also impact who receives services and for what substances. Substance Abuse and Mental Health Services Administration (SAMHSA) For example, the most common way for people to be referred to treatment in 2021 was “self or individual.” But the second-most common was through the criminal justice system, and procedures for referring defendants to drug treatment vary significantly by state. A study published in September that was based on SAMHSA data, for example, found that referrals for marijuana-related treatment declined more rapidly after states legalized cannabis, a trend authors said was “likely due to falling cannabis-related arrests” among people 18 to 24 years old. That study, which looked at data from 2008 to 2019, found that criminal justice referrals to treatment for cannabis use disorder are already falling nationally—both proportionally and in terms of raw numbers—even in states where marijuana isn’t legal. But in states that legalized marijuana for adults, the proportion of referral rates from the criminal justice system fell faster after legalization. While that trend indicates fewer admissions fueled by the drug war, it also worried the researchers, who said admissions rates were falling even as risk factors for problem marijuana use were rising. Rather than seek to increase criminal justice referrals, however, the report recommended that primary care physicians and other healthcare professionals play a greater role in recognizing cannabis use disorder and referring people to treatment. In a separate study published in August, researchers found that referrals to foster care also fell after marijuana legalization—but only following the adoption of medical cannabis laws. States that legalized adult-use marijuana, that study found, saw “no corresponding change in the number of foster care entries related to parental or teenage drug abuse relative to control states.” Drug misuse is the second most common reason that a child is placed into foster care. While that study didn’t identify a meaningful link between adult-use legalization and foster care drug misuse cases, a report published last year did. Researchers at the University of Mississippi found that recreational legalization was associated with at least a 10 percent decrease in foster care admissions on average, including reductions in placements due to physical abuse, neglect, parental incarceration and misuse of alcohol and other drugs. Another study published earlier this year found that marijuana is “significantly” associated with reduced opioid cravings for people using them without a prescription, suggesting that expanding access to legal cannabis could provide more people with a safer substitute. Ohio GOP Senate President Outlines Plan To Amend Voter-Approved Marijuana Law Next Week, Days Before Legalization Takes Effect Photo courtesy of Martin Alonso. Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.  Read More Feedzy  [...] Read more...
December 4, 2023Cannabis News​ The proliferation of marijuana brands from out of state has become a bone of contention among some in the New York cannabis industry. Until now, brands have been allowed to enter the New York market legally via simple licensing and white label deals with permitted processors, but soon they will have to obtain a formal license from the Office of Cannabis Management, according to John Kagia, the OCM’s policy director. John Kagia There are multiple types of licenses for this purpose, but the easiest option is the third level of processor permit, which Kagia said is basically designed for out-of-state companies that want to have a New York presence. The application window for such licenses is currently open until Dec. 18. Kagia recently sat down with Green Market Report to explain how the brand creation and distribution process will work going forward. This interview has been edited for length and clarity. What will cannabis brands have to do to stay in compliance with the legal New York market moving forward? Kagia: One of the licenses that we do want to call special attention to is what we’re calling our brand license. It’s a license that enables companies who may not necessarily want to either do the processing or the manufacturing, but want to create brands for the New York marketplace to be able to operate in our market. So if you are a an out-of-state brand, or you’ve identified the partner that you want to work with in New York, you set up the agreements and send them the specs for the product that you want them to manufacture. All of that remains the same. The one distinction is that in addition to setting up those agreements, the brand that wishes to operate in New York, whether it’s an in-state brand or one from out of state, would need to also register with the state so that we’re ensuring that that all of the brands operating in New York are under the purview of Office of Cannabis Management. Part of the value of having this brand license has is that it enables us to more effectively ensure that the stakeholders in this market are complying with our two-tier market rules, so that you don’t have stakeholders who are playing both on the supply side and on the retail side. This gives us visibility into the businesses, who their stakeholders are, and gives us more robust ability to protect the two-tier market. How many different processor licenses are available? Kagia: Our type one processor license allows the licensee to engage in all of the processing activities, so you can buy biomass from our growers, you can do the processing, or you can do the extraction. And we’re agnostic about what extraction technologies or approaches you use. The type two license does not include the authorization to engage in extraction activities. So you can’t run the biomass through the CO2 processor, but you can buy the extracted oils from other processors. So in the scenario where, for example, somebody has deep experience manufacturing chocolates and that’s all they want to do. You can get a type two processing license, it will allow you to buy extracted cannabinoids and extracts, make your infused chocolates, package, market, and sell them on the market. The type three license is the white labeling license. It doesn’t allow you to process or to manufacture, but it does allow you to essentially put your label on a product that has been produced and sell it onto the market. It provides a very easy path into the market for somebody who may not necessarily want to engage in some of these more resource-intensive or technical expertise intensive activities. This we think is a particularly attractive license, for example, to the legacy operators in New York, people who may have had experience building highly popular, highly visible, successful brands in the market, but may not necessarily yet be ready to or want to go through the kind of cultivation and manufacturing process. Then out-of-state companies and brands that just want to have a brand presence in New York, would they have to go and then get a type three processor license? Exactly right. Every brand that is sold in New York, regardless of who is the manufacturer, will need to be licensed. So in the case Cookies or STIIIZY or any other large out of state brand, those brands would also need to get a type three license even if somebody was doing the manufacturing for them in the state. Is that a change in the regulations?  The requirement for type three white label license was included in our regulations package. And it had always been there, we had always had this as something that the market was going to lead into. However, when we initially launched the market with our conditional cultivators and processors, just for market efficiency’s sake, we allowed for this alternative approach, which is the way the market has worked to this point, where the out-of-state brands were just able to enter these agreements directly with a licensee, but not have to apply for license directly to the office. The reason for that was because we’re building the broader regulatory structure. So we wanted the market to be moving, but we fully expected that we’re going to have a much more robust regulatory structure included in the regulatory package that was passed in September. We’ve been telegraphing that this was coming for a while. And yes, it is a departure from the way brands have operated to this point. But that is because we are sunsetting this conditional program under which our cultivators and processors have been have been operating. Is it a lighter load for businesses to get a type three processor license (compared to type one or two)? It really is. This is arguably the easiest license for which to apply, in part, because this is one which we have tried to kind of really make accessible to the market. So it’s a $1,000 application fee, but $1,000 is what we charge for all of our applications. So that’s standard. The license fee itself is $2,000 for a two-year license. And if you are a social equity brand, under any one of our five social and economic equity categories, you can get that reduced by 50% to $1,000 for a two-year license. In terms of having a business location, you really just need to submit the location where your business is registered. You don’t need a manufacturing location, like you would need for type-one or type-two license. New York Cannabis Insider reported recently that there’s a number of out-of-state brands already operating in New York, and that many of them are apparently breaking various rules, trying to bribe retailers for shelf space and that sort of thing. Has there been serious confusion to date over how  brands are allowed to operate in New York? Adherence to our rules is critically important. And we take any allegations, any charges of folks being out of compliance or violating the letter and spirit of our rules very, very seriously. While we hope that there is no confusion in the market about what our expectations are – we have very clear regulations and a lot of guidance out there – we will continue to work very intentionally to make sure that the market is fully clear on the expectations of the OCM and how to be good actors and remain in good standing in this market. Finally, this brand license is one of the critical tools we have that enables us to ensure we have both oversight and insight into the activities in which our businesses who are operating in New York’s legal cannabis industry are engaged in. Do you have any estimate on how many brands are available or doing business so far in New York? We don’t have a good estimate of that. We’ve certainly very rapid growth in the number of brands that are in New York’s market. When I last looked, we had over 200 brands now already in our stores, kind of distributed across our 200 stores. And we expect that number is going to be going into overdrive as we open more stores and issue more production and retail licenses. The fact that we will have this as a license will ensure that we know exactly how many out-of-state brands we have operational in New York and what those brands are. We very much welcome brands to come into New York, and we welcome local operators to build brands that reflect the richness and diversity of New York. We would just encourage those who intend to have a light footprint to at a minimum get this type-three processor license to ensure that the operating in compliance with our rules.  Read More Feedzy  [...] Read more...
December 3, 2023Cannabis News​ With oral arguments set for Monday in a federal court case over a proposed Philadelphia safe drug consumption site, counsel for the would-be facility sent a letter to the judge in the case on Thursday calling out the Department of Justice (DOJ) for taking apparently contradictory legal positions. In the Philadelphia safe consumption site case itself, the letter says, DOJ has argued that the harm reduction aims of Safehouse, the nonprofit attempting to open facility where people can use illicit substances in a medically supervised environment, are “socio-political” rather than religious. In a separate case involving an Episcopal church in Oregon, however, DOJ recently filed a statement of interest arguing that “distribution of free meals to persons in need is ‘religious exercise’” that would be infringed by a local zoning ordinance. Writing to Judge Gerald McHugh of the Eastern District of Pennsylvania, DLA Piper attorney Ilana Eisenstein said the government can’t have it both ways. DOJ’s arguments in the Oregon case, Eisenstein wrote, “demonstrate that Safehouse has adequately pled a substantial burden on its religious exercise.” In other words, the letter asserts that if the government views handing out free meals to people in need as protected on religious grounds, it can’t simultaneously deny that harm reduction services could deserve similar protections. “DOJ’s positions in that case are irreconcilable with its arguments here,” the letter says, “and confirm that this Court should deny the DOJ’s pending motion to dismiss.” In its lawsuit attempting to allow the facility to open, Safehouse has argued that its harm reduction activities are protected under the Religious Freedom Restoration Act (RFRA) and other federal laws protecting worship because the group’s mission aligns with sincerely held religious beliefs. But the federal government has asked the court to throw out Safehouse’s lawsuit, arguing that the matter isn’t a religious one at all. In September, DOJ lawyers argued that “Safehouse is not a religious organization and thus cannot plausibly assert a RFRA or Free Exercise claim on behalf of the corporation itself.” DOJ also maintains that the nonprofit’s “professed ‘belief’ in facilitating illegal drug use is not a ‘religious’ one, but rather a socio-political belief informed by harm reduction principles.” Safehouse is not a religious organization itself, but in August, a group of 35 Christian and Jewish faith leaders from 19 states submitted an amicus brief in which they supported the nonprofit’s establishment of overdose prevention site. They said that while the organization may be secular, board members are nevertheless motivated by a faith-based understanding of their obligation to prevent unnecessary drug overdose deaths. Ahead of DOJ’s initial response to the suit, several local lawmakers, including Democrats championing marijuana legalization, asked the federal court to block Safehouse from opening and requested permission to file a brief in the case. A coalition of 20 Pennsylvania community groups also requested that the court allow it to intervene, but in recognition of the fact that the government is defending the existing statute and opposing overdose prevention sites, the court denied that group’s request. The Justice Department previously declined to file a brief to offer its position on the harm reduction issue, and it asked for more time to respond in the “complex” case. Last year, the department said it was in the process of evaluating possible “guardrails” for safe consumption sites. In January, Safehouse and the department agreed to transfer the case to mediation before a magistrate judge to settle the issue. The talks had been described as “productive,” leaving some advocates hopeful that DOJ might drop the dispute altogether. The Justice Department first blocked Safehouse from opening the overdose prevention center under the Trump administration. Supporters hoped the department would cede the issue under President Joe Biden, who has promoted harm reduction policies as an alternative to criminalization, but so far they’ve been disappointed. The Supreme Court rejected a request to hear a case on the legality of the Safehouse facilities in October 2021. While the Philadelphia facility was being held up in the litigation, New York City opened the first locally sanctioned harm reduction centers in the U.S. in November 2021, and officials reported positive results saving lives. A study published by the American Medical Association (AMA) last year found that the recently opened New York City facilities had decreased the risk of overdose, steered people away from using drugs in public and provided other ancillary health services to people who use illicit substances. Separate research published last month by the American Medical Association found that New York City’s first drug overdose prevention centers (OPCs) have not led to increased crime despite a significant decrease in arrests. But a federal prosecutor who has jurisdiction over Manhattan recently emphasized in a statement to The New York Times that the sites are illegal and that he is “prepared to exercise all options—including enforcement—if this situation does not change in short order.” Congressional researchers have highlighted the “uncertainty” of the federal government’s position on such facilities, pointing out last November that lawmakers could temporarily resolve the issue by advancing an amendment modeled after the one that has allowed medical marijuana laws to be implemented without Justice Department interference. Meanwhile, National Institute on Drug Abuse (NIDA) Director Nora Volkow has tacitly endorsed the idea of authorizing safe consumption sites, arguing that evidence has effectively demonstrated that the facilities can prevent overdose deaths. Volkow declined to say specifically what she believes should happen with the ongoing lawsuit, but she said safe consumption sites that have been the subject of research “have shown that it has saved a significant patients from overdosing.” Rahul Gupta, the White House drug czar, has said the Biden administration is reviewing broader drug policy harm reduction proposals, including the authorization of supervised consumption sites, and he went so far as to suggest possible decriminalization. The National Institutes of Health (NIH) put out a pair of requests for applications in December 2021 to investigate how safe consumption sites and other harm reduction policies could help address the drug crisis. Gupta, the director of the White House Office of National Drug Control Policy (ONDCP), has said it’s critical to explore “any and every option” to reduce overdose deaths, which could include allowing safe consumption sites for illegal substances if the evidence supports their efficacy. New York Supreme Court Lifts Marijuana Licensing Blockade, Allowing Regulators To Process Hundreds Of New Retailers Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.  Read More Feedzy  [...] Read more...
December 3, 2023Cannabis News​That penetrating sound emanating from New York Friday evening was the collective sigh of relief from hundreds of provisional CAURD licensees upon hearing the news that Supreme Court Judge Kevin… The post Judge Approves ‘Fiore’ Settlement, Ending Injunction appeared first on Cannabis Business Executive – Cannabis and Marijuana industry news. Read More Feedzy  [...] Read more...
December 2, 2023Cannabis News​ “The week we had had a good process—it’s worked well. The presenters brought things to the forefront that maybe we didn’t see otherwise, that you can’t really see in a paper application.” By Alander Rocha, Alabama Reflector The Alabama Medical Cannabis Commission Friday awarded 20 licenses for the production and distribution of medical cannabis in its third attempt to get the new industry started in the state. The awards followed three days of presentations from applicants and months of litigation over the AMCC’s prior methods of evaluating applications. “The week we had had a good process—it’s worked well,” said Rex Vaughn, the chair of the AMCC. “The presenters brought things to the forefront that maybe we didn’t see otherwise, that you can’t really see in a paper application.” The commission awarded licenses for every category—cultivator, processor, dispensary, secure transport and testing lab—except for integrated facilities, which can produce medical cannabis products from seed to shelf. These companies are expected to present their application to the commission next week. Awards are expected on December 12. The commission can award up to 12 licenses to cultivate cannabis, four licenses for those who want to process it and four licenses to dispense the product. There are no caps on licenses for secure transporters and testing labs. Antoine Mordican, CEO of Native Black Cultivation, one of the companies denied a license in the first two awards, received a cultivator license on Friday. Mordican said he is “happy to be where felt deserved to be.” “I’m happy that the commission was able to hear me give my presentation and able to recognize the individual that operates the company,” he said. The AMCC first awarded licenses in June, but scoring inconsistencies led the commission to void the awards and reevaluate the applications. A lawsuit alleging the commission violated the Open Meetings Act halted the process again in August. That prompted the commission to rescind the awards a second time, negotiating with claimants on a possible process to move forward with the awards. The AMCC adopted new licensing and application rules in October after months of legal dispute and stalled settlement negotiations, which set the latest round of applications in motion. The Alabama Legislature approved a medical cannabis program for the state in 2021, but the bill authorizing the program did not allow licenses to be issued until September 1, 2022. The AMCC began accepting applications late last year. When the product is available, patients certified by participating physicians will be able to use medical cannabis for 15 conditions, including cancer, chronic pain, depression and Parkinson’s Disease. Patients will have to apply for a card to obtain medical cannabis from licensed dispensers. The law forbids smoking medical cannabis or consuming it in food. It will be available as tablets, capsules, gelatins, oils, gels, creams, suppositories, transdermal patches, or inhalable oils or liquids. Cannabis gummies will only be allowed to be peach-flavored. 12 applicants vied for the 12 cultivator licenses. Another 12 applied for four available processor licenses, while 18 have applied for the four dispensary licenses.  The commission also received 11 applications for the transport license and three applications for testing licenses. Mordican said that as a Black man, working twice as hard comes as second nature to him. He said that from the beginning, he used every tool at his disposal to provide the commission with information about his company. He garnered over 100 comments on his application, showed up to nearly every commission meeting, and vocalized his concern that his application was not properly evaluated. “Just as an individual, I’m relentless,” he said. “We’re going to continue to press forward and continue to help people along the way.”   Cultivators Location CRC of Alabama A registered office in Troy Greenway Botanicals A registered office in Anniston Gulf Shore Remedies Fairhope in Baldwin County Native Black Cultivation Bessemer Creek Leaf Wellness Birmingham Twisted Herb Cultivation Greenville I AM FARMS Knoxville Processors Location Organic Harvest Lab Bessemer Coosa Medical Manufacturing Centreville 1819 Labs Dothan Jasper Development Group Inc. Jasper in Walker County Dispensary Location CCS of Alabama Address on business records is listed at the Birmingham law firm of Maynard GP6 Wellness Birmingham Capitol Medical Auburn RJK Holdings AL Listed on business records as located in an office building near the State House in Montgomery Secure Transport Location Alabama Secure Transport Montgomery Tyler Van Lines Troy PICK UP MY THINGS Dothan International Communication Birmingham Testing Lab Location Certus Laboratories Grand Bay in Mobile County This story was first published by Alabama Reflector. New York Supreme Court Lifts Marijuana Licensing Blockade, Allowing Regulators To Process Hundreds Of New Retailers Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.  Read More Feedzy  [...] Read more...
December 2, 2023Cannabis News​ As German lawmaker prepare to vote on a revised marijuana legalization bill next week, the country’s health minister defended the reform against critics in the legislature, while briefly outlining next steps for a commercial sales pilot program. Meanwhile, one German state is signaling that it will pursue legal action to block the reform from taking effect within its borders. At a meeting before the Bundestag on Wednesday, Health Minister Karl Lauterbach took a series of questions from members, some of whom oppose legalization and others who expressed interest in expeditiously enacting the reform. At several points, he pushed back against lawmakers who suggested that legalization would send the wrong message to youth and lead to increased underage consumption, saying their arguments “misrepresented” the legislation, according to a translation. “The fact remains that child and youth protection is carried out through education, and sales to children and young people remain prohibited,” Lauterbach said. “That is the only change we have made in this area: a tightening.” “As part of this legalization, we are pushing back the black market,” he said. “The less of the black market there is, the lower the risk that our children will be brought into consumption through the black market.” Another member asked the health official about the second part of the government’s legalization plan. While the bill that’s heading for a vote next week would legalize adult use and cultivation, while establishing social clubs that could distribute cannabis to members, less is known about the path forward for the “second pillar” of creating a commercial sales pilot program. Asked about the timeline for that component, Lauterbach said “we are currently examining” the details of the forthcoming plan. He said that federal agencies that would be involved in the commercial sales pilot program have been sent questions to inform the next steps and they are “currently preparing them.” “The schedule set for next year appears to be achievable at this point,” he said. When it comes to the more immediate legalization and social club legislation, the expectation is that the Bundestag will pass it, about two weeks after an initial vote was postponed to the disappointment of advocates. The Bundesrat, a separate legislative body that represents German states, hasn’t approached the proposal with as much favor, however. Members of the Bundesrat tried to block the proposed reform in September but ultimately failed. Now the state of Bavaria says that it intends to mount a legal challenge to block the reform in its jurisdiction, Bayerischer Rundfunk reported. Bavarian Health Minister Judith Gerlach said “we will definitely examine legally…whether we can still legally defend ourselves against it.” If legalization takes effect, Bavarian officials will interpret its provisions “as restrictively as possible,” she said. The legalization bill that’s advancing was recently revised by the so-called traffic light coalition, with most of the amendments designed to loosen restrictions that faced opposition from advocates and pro-legalization legislators. For example, possessing slightly more cannabis than the allowable amount will not be automatically treated as a criminal offense punishable by jail time. Instead, possession of between 25 and 30 grams will be considered an administrative violation. Similarly, the possession limit for home grown marijuana will be increased from 25 to 50 grams, with the same administrative violation stipulation applied to possession of between 50 and 60 grams. —Marijuana Moment is tracking more than 1,000 cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.— Lawmakers in the Bundestag recently held a hearing in the Health Committee, at which opponents criticized some elements of the proposal. The body also heard a competing policy proposal from The Union, a political alliance of the Christian Democratic Union and Christian Social Union (CDU/CSU), that would not legalize marijuana but instead “improve health protection and strengthen education, prevention and research,” Kirsten Kappert-Gonther, a Green Party lawmaker who supports cannabis reform, said at the time. Germany’s Federal Cabinet approved the initial framework for a legalization measure late last year, but the government wanted to get sign-off from the EU to ensure that enacting the reform wouldn’t put them in violation of their international obligations. The framework was the product of months of review and negotiations within the German administration and the traffic light coalition government. Officials took a first step toward legalization last summer, kicking off a series of hearings meant to help inform legislation to end prohibition in the country. Government officials from multiple countries, including the U.S., also met in Germany last week to discuss international marijuana policy issues as the host nation works to enact legalization. A group of German lawmakers, as well as Narcotics Drugs Commissioner Burkhard Blienert, separately visited the U.S. and toured California cannabis businesses last year to inform their country’s approach to legalization. The visit came about two months after top officials from Germany, Luxembourg, Malta and the Netherlands held a first-of-its-kind meeting to discuss plans and challenges associated with recreational marijuana legalization. Leaders of the coalition government said in 2021 that they had reached an agreement to end cannabis prohibition and enact regulations for a legal industry, and they first previewed certain details of that plan last year. A novel international survey that was released last year found majority support for legalization in several key European countries, including Germany. Marijuana Regulators, Stakeholders, Advocates And Opponents Discuss Legalization Landscape At National Academies Meeting Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.  Read More Feedzy  [...] Read more...
December 2, 2023Cannabis News​ A top federal health agency says it recognizes that there are ample concerns among scientists about how they’ve “encountered barriers that have hampered their research” into marijuana under federal prohibition, including “complex” federal regulations and inadequate supplies of cannabis. That’s why the National Institutes of Health (NIH) is now seeking to resolve some of those challenges by standing up a Resource Center for Cannabis and Cannabinoid Research, an official said in a blog post on Tuesday. NIH posted a notice of funding opportunity late last month, explaining how it’s seeking an entity to operate the center through a cooperative agreement in order to “address challenges and barriers to conducting research on cannabis and its constituents.” To help facilitate that process, the National Center for Complementary and Integrative Health’s (NCCIH) Patrick Still announced that the health agency will be holding a webinar on January 25 to provide potential applicants with technical assistance. “There’s growing interest in potential therapeutic uses of cannabis and its constituents among both health care providers and the public,” Still, who is a program director for NCCIH’s Basic and Mechanistic Research branch, wrote. “Substances in cannabis have a variety of pharmacologic effects, and rigorous research is needed to understand their mechanisms of action and investigate their possible value in helping to manage health conditions.” “However, investigators working in this field have encountered barriers that have hampered their research,” he said, pointing to feedback NCCIH received as part of a request for information last year. “The barriers that many of them have mentioned include difficulty meeting complex federal and state regulatory requirements, problems obtaining cannabis products suitable for research, a lack of validated measures of cannabis use and exposure, and inadequate scientific infrastructure to support research studies,” Still wrote. To help account for those issues, he said that the forthcoming center is “expected to be a focal point for investigators who are studying cannabis or cannabinoids or who are interested in entering this research space.” Institutions that are invited to submit applications to operate the center include universities, non-profit organizations, local and federal government agencies and more. Letters of intent are due by March 16, which is also when applications will begin to be accepted. In the interim, NCCIH said it will be holding a webinar in January to “discuss the funding opportunity and answer questions.” “Participating in the webinar is not a requirement for submitting an application, but it’s a great way to get details about this unique project from NIH program and review staff,” Still said. Addressing marijuana research barriers has been a key priority for multiple federal health agencies as scientists continue to face an onerous and costly registration process in order to access cannabis due to its current status as a Schedule I drug under the Controlled Substances Act (CSA). The center won’t be able to independently change that policy, which is actively under review by the Drug Enforcement Administration (DEA) following a U.S. Department of Health and Human Services (HHS) recommendation to move cannabis to Schedule III. But NIH offered some examples of how it plans to have the center lessen the burdens. For instance, it could assist with DEA Schedule I research registration costs and “other relevant federal regulatory requirements.” It could also address equipment and material needs for storage and monitoring purposes. NIH outlined three “core components” of the center’s objectives: regulatory guidance, research standards and research support. Regulatory Guidance Core Establish a policy clearinghouse to consolidate and link to existing DEA/FDA guidance. Organize regular meetings with DEA/FDA to receive updates regarding regulatory information relevant to researchers. Provide summaries and updates on policy changes to a centralized Center webpage on policy changes related to the regulatory environment surrounding cannabis research for the extramural community. Research Standards Core Identify and disseminate information on high-quality cannabis research products and provide guidance on matching specific cannabis product vendors to the research objectives of investigators utilizing the Center. Develop research standards and metrics to enhance the rigor of chemical analysis of complex cannabis products to improve the reproducibility of research. Build a repository of best practices (e.g., reagents, standards, survey measures, data elements, and analytical methods), including the 5 mg tetrahydrocannabinol (THC) standard unit for measuring and reporting research results (NOT-DA-21-049). Research Support Core Organize annual meetings (e.g., annual investigator meetings). Use social media to transmit scientific information. Organize and convene webinar series on topics that reflect Center core activities in regulatory guidance, research standards, and research support. Organize and convene both virtual and hands-on events such as workshops at meetings, summer institutes, and grant writing assistance and workshops. Identify and disseminate early career NIH reviewer opportunities. Administer seed funding for registration support and proposal development (see seed funding description below and Section IV. Application and Submission Information, R&R Budget and R&R Subaward Budget sections, for more information). Regardless of how many awards are granted, seed funding will be capped at $50,000 per year for each project. Several agencies under NIH will play supportive roles in the center’s work. They are NCCIH, National Institute on Drug Abuse (NIDA), National Institute on Aging (NIA) and National Cancer Institute (NCI). NCCIH will provide $1 million in total costs in fiscal year 2025 to fund the center. NIDA and NIA will each contribute $100,000 in co-funding, while NCI will provide $200,000 in co-funding. Separately, NCI recently awarded researchers $3.2 million to study the effects of using cannabis while receiving immunotherapy for cancer treatment. The announcement about the center came months after a National Advisory Council for Complementary and Integrative Health (NACCIH) meeting, where members approved the concept for the institute, which is “expected to be a focal point for researchers entering the cannabis research space and to support the development and establishment of research tools and studies that will improve upon and eventually change the landscape of cannabis research.” Germany’s Top Health Official Defends Marijuana Legalization Bill Against Critics Ahead Of Next Week’s Vote Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.  Read More Feedzy  [...] Read more...
December 2, 2023Cannabis News​ Ohio’s Republican Senate president says his chamber will take the first step toward amending a voter-approved marijuana legalization law at the beginning of next week, with just days left before key provisions of the initiated statute take effect. But the House speaker, for his part, still says he doesn’t necessarily see the urgency. GOP legislative leaders and Gov. Mike DeWine (R) have been discussing revisions to the cannabis statute ever since voters passed the reform at the ballot last month, with the main focus being on possible changes to provisions concerning tax revenue,  youth prevention and impaired driving. Two Republican-led bills to amend the legalization law have been introduced so far, but Senate President Matt Huffman (R) said the plan is to take up separate, unrelated House-passed legislation in the Senate General Government Committee on Monday, attach yet-to-be-seen cannabis amendments as an emergency clause and advance the proposal on the floor on Wednesday. The House would then need to concur with the changes. An emergency clause would mean the bill would require a two-thirds vote instead of a simple majority to pass, but it’d mean the legislation would take effect immediately rather than after a standard 90-day period following signature by the governor. That seems to be the only option if lawmakers want to revise the marijuana law before possession and cultivation become legal on Thursday. “It would be better for people going forward to know what the law is than people begin spending money or taking actions and then the law changes six months from now or 90 days, you know, a year from now,” Huffman told WCMH. The expedited timeline might be favorable to the Senate leader and governor, but House Speaker Jason Stephens (R) has maintained that legislators should more thoughtfully address amendments to the initiated statute, even if that takes more time. He’s pointed out that changes to provisions on taxes and advertising, for example, wouldn’t become relevant until later next year given that regulators still need months to develop licensing rules before retailers open shop. “We are being very thoughtful about the legislation that was passed by the voters,” he said. “We want to be respectful of that. We also want to have the guardrails in place.” “It doesn’t matter whether it’s marijuana or soybeans or oil, there are certain rules for alcohol, tobacco that these industries have established over decades,” Stephens told WCMH. “And trying to start from scratch is not the easiest thing to do.” Still, the House speaker said it would be “great” if the revisions to the cannabis law were accomplished through an emergency clause as his Senate counterpart is proposing. “We are coalescing around some ideas that can gain the support of the majority of the House,” he said, referencing zoning rules for where cannabis businesses could be located as an example. “One of the things I want to avoid, and a lot of people want to avoid is having marijuana stores everywhere,” Huffman, the Senate president, said. “You can’t open a liquor store anywhere you want. You have to have a permit and the size of your population of your local community determines the number of local liquor permits you have, so I think it has to be somewhat limited.” The governor, for his part, said he expects to see action in the legislature “shortly.” “We’ve been having conversations with about what we’re interested in,” DeWine said. “They’ve told us some of the things they’re interested in, and I think you’ll have some information shortly.” While some Democratic lawmakers have indicated that they may be amenable to certain revisions, such as putting certain cannabis tax revenue toward K-12 education, other supporters of the voter-passed legalization initiative are firmly against letting legislators undermine the will of the majority that approved it. NORML recently launched a letter writing campaign, urging Ohio residents to tell their state representatives to “keep your hands off Issue 2.” “Even before the ink on the new law is dry, some lawmakers are calling on the legislature to amend or even repeal parts of the law. Prohibitionist groups are similarly encouraging lawmakers to take legislative action to thwart the will of the people,” NORML wrote. “We must not let these groups accomplish through backroom deals what they couldn’t accomplish at the ballot box. The will of the majority of Ohio’s voters must be respected.” Ohio Rep. Juanita Brent (D) recently emphasized that people who’ve been criminalized over marijuana, as well as those with industry experience, should be involved in any efforts to amend the state’s voter-approved legalization law, arguing that it shouldn’t be left up to “anti-cannabis” legislators alone to revise the statute. Meanwhile, Rep. Gary Click (R) filed legislation this week that would allow individual municipalities to locally ban the use and home cultivation of cannabis in their jurisdictions and also revise how state marijuana tax revenue would be distributed by, for example, reducing funds allocated to social equity and jobs programs and instead steering them toward law enforcement training. Rep. Cindy Abrams (R) also introduced a bill last month that would revise the marijuana law by putting $40 million in cannabis tax dollars toward law enforcement training annually. The Senate president said last month that he didn’t think most voters considered the nuances of the cannabis reform proposal when they went to the ballot and instead simply passed it based on the broad belief that marijuana should be legal for adults. He argued, for example, that the majority probably doesn’t support prioritizing cannabis business licensing for people who’ve been disproportionately targeted by criminalization. —Marijuana Moment is tracking more than 1,000 cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.— The Ohio Department of Commerce was quick to publish an FAQ guide for residents to learn about the new law and timeline for implementation, though regulators repeatedly noted that the policies may be subject to change depending on how the legislature acts. Prohibitionist organizations that campaigned against Issue 2, meanwhile, are set on a fundamental undermining of the newly approved law, with some describing plans to pressure the legislature to entirely repeal legalization before it’s even implemented. For what it’s worth, a number of Ohio lawmakers said in September that they doubted the legislature would seek to repeal a voter-passed legalization law. The Senate president affirmed repeal wasn’t part of the agenda, at least not in the next year. Voters were only able to decide on the issue after lawmakers declined to take the opportunity to pass their own reform as part of the ballot qualification process. They were given months to enact legalization that they could have molded to address their outstanding concerns, but the legislature ultimately deferred to voters by default. As early voting kicked off in late October, the GOP-controlled Senate passed a resolution urging residents to reject measure. Unlike the top state Republican lawmakers, one of the state’s GOP representatives in Congress—Rep. Dave Joyce, co-chair of the Congressional Cannabis Caucus, said in September that he would be voting in favor of the initiative in November. He encouraged “all Ohio voters to participate and make their voices heard on this important issue.” Senate Banking Committee Chairman Sherrod Brown (D-OH) said in late October he voted in favor of the legalization ballot initiative, calling it a “hard decision” but one that was based on his belief that the reform would promote “safety” for consumers. Meanwhile, Vivek Ramaswamy, a 2024 Republican presidential candidate, said he voted against a ballot initiative to legalize marijuana in Ohio because he’s concerned the federal government could “weaponize” criminalization against people who are engaged in state-legal cannabis activities under the “fake” pretense that they’re protected from federal prosecution. Senate Majority Leader Chuck Schumer (D-NY), for his part, said recently that Ohio’s vote to legalize marijuana at the ballot is one of the latest examples of how Americans are rejecting “MAGA extremism,” and he added that he’s committed to continuing to work on a bipartisan basis “to keep moving on bipartisan cannabis legislation as soon as we can.” Rep. Earl Blumenauer (D-OR), co-chair of the Congressional Cannabis Caucus, told Marijuana Moment that “the vote in Ohio was a great big exclamation point on the things we’ve been talking about.” “We’ve been saying for years how this issue has crested, how it’s got broad momentum, how it is inclusive. It’s sort of like the success with the issue—except this was more pronounced,” he said. “We got more votes than the abortion issue. We get more votes than anybody on the ballot.” The White House has separately said that “nothing has changed” with President Joe Biden’s stance on marijuana, declining to say if he supports Ohio’s vote to legalize or whether he backs further reform of federal cannabis laws. Meanwhile, as Ohio voters approved statewide legalization, activists also chalked up a series of little-noticed wins to decriminalize larger amounts of cannabis in three Ohio cities, according to preliminary county election results. Top Federal Agency Promotes New Marijuana Research Center Amid Scientists’ Complaints About ‘Complex’ Study ‘Barriers’ Under Prohibition Photo courtesy of Philip Steffan. Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.  Read More Feedzy  [...] Read more...
December 2, 2023Cannabis News​ This story was republished with permission from Crain’s Cleveland Business and written by Jeremy Nobile. Among two dozen states that have legalized recreational marijuana, the current effective tax rates for adult-use cannabis in Ohio—which will be between approximately 16% and 18%, depending on the county—are right in the middle of the pack, according to a new analysis by The Ohio State University’s Drug Enforcement and Policy Center. DEPC’s report comes as Ohio lawmakers consider adjusting proposed tax rates for recreational marijuana following the passage of Issue 2 earlier this month. While the state’s adult-use law is slated to go into effect Dec. 7, the soonest rec sales are expected to commence is September 2024. This is due to several procedural steps that must be addressed first. Regulators must still draft some rules for the rec program, for example, and adult-use licenses must be awarded to cannabis businesses. In the meantime, Ohio Gov. Mike DeWine has called on the state legislature to review various aspects of the adult-use law. This includes finding a “sweet spot” for tax rates, which the governor doesn’t want to be too high as to dissuade people from buying legal marijuana here but also not too low. But according to DEPC’s research, Ohio’s taxes for legal marijuana seemingly are already in a sweet spot when compared with other markets. Issue 2 levies a 10% excise tax on adult-use sales. Coupled with state sales tax of 5.75% plus local sales tax, which varies by jurisdiction, the effective tax rate at the point of sale on rec products in Ohio should be between about 16% to 18%. DEPC notes that comparing tax rates among all legal marijuana markets is complex due to so many variations. Depending on the state, those taxes could include a special marijuana sales tax as a percentage of price; general state sales tax; applicable local sales tax; weight-based sales tax; and a tax based on THC potency. Nonetheless, when looking at 19 states with a percentage-of-price retail tax at the point of sale, the median and average tax rate among those states are 17% and 18%, respectively. Among those 19 states, just two charge less than 10%. Eleven states charge between 10% to 19%. And six charge 20% or more. Meanwhile, Michigan—where many Ohioans go to purchase legal marijuana—has an effective tax rate of 16% (there are no local sales taxes there). A concern among industry stakeholders is that some Ohioans may still go to Michigan for recreational marijuana if taxes and overall prices are lower. An even higher tax rate, it is feared, could have the effect of pushing consumers away from legal shops here, whether those people are crossing state lines or buying from the illicit market. “In respect to the tax rate, the Ohio General Assembly will need to balance their desire to maximize tax revenue and maximize deterrence of problematic use with their desire to curtail the illicit cannabis market as much as possible,” according to the DEPC report. “A higher tax rate might theoretically bring in additional tax revenue, but it can also incentivize adult customers to purchase their cannabis product from unsanctioned sellers if the higher tax results in uncompetitive prices for legal cannabis product.” As of this March, taxes and fees related to the medical marijuana program have generated an estimated $183.33 million for Ohio’s state and local government entities since sales began in 2019, according to DEPC. With an adult-use program in place, Ohio could see approximately $276 million to $404 million in additional annual tax revenues in the fifth year of rec sales. Those projections could be more or less on target contingent on a host of factors that may shape consumer demand, of course, including pricing and taxes. DEPC’s latest analysis also takes a look at how tax proceeds are expected to be disseminated here and how that compares with other markets. How proceeds are presently set to be allocated is another aspect of the adult-use law under consideration by Ohio lawmakers. Industry stakeholders are waiting anxiously for clarity on rules and regulations that will shape the market as they attempt to prepare for adult-use sales.  Read More Feedzy  [...] Read more...
Cannabis Recipes
August 3, 2023This recipe may be used with heavy cream or whole milk. Materials -Medium Sauce-Pan -​Thermometer -Mesh-sieve or cheesecloth Ingredients ​6 grams cannabis flower 2 cups whole milk or heavy cream ​ Directions ​ ​1. Decarboxylate the cannabis Heat the oven to 225°F. Spread cannabis buds out into an even layer on a baking sheet and place in the oven. ​Take care not to let the temperature go over 225°F and burn (if this happens, you can lose potency). Bake for about 35–40 minutes, then remove from the oven and cool before grinding into a coarse powder. ​ The decarboxylated cannabis will keep in an airtight container in a cool, dark place for up to 2 months 2. Heat the milk or heavy cream, in a saucepan over medium-low heat. Add the decarboxylated cannabis and cook, taking care not to let the temperature go over 200°F for about 45 minutes. 3. Remove from heat and let sit, undisturbed, for 10 minutes 4. Strain through a fine mesh-sieve set over a bowl. Press carefully with a spoon to extract as much oil as possible ​The milk will keep for up to 6 weeks if covered and refrigerated. This recipe is available for download HERE Original recipe from Vice.com [...] Read more...
August 3, 2023Ingredients 1 cup breadcrumbs 1/2 cup canna-milk 1 lb ground beef 1/2 lb ground pork 1/2 lb Italian sausage, casing removed 1 small onion, finely diced 3 cloves garlic, minced 1 cup grated parmesean cheese 1/4 cup chopped parsley 2 large eggs, beaten 2 Tbsp canna-oil 1 (32oz) jar marinara sauce Instructions 1. In a small bowl, stir bread crumbs with canna-milk until evenly combined. Let sit 15 minutes, or while you prep other ingredients. 2. In a large bowl, use your hands to combine beef, pork, sausage, onion, and garlic. Season with salt and pepper, then gently stir in breadcrumb mixture, eggs, Parmesan, and parsley until just combined. Form mixture into 1” balls. 3. In a large high-sided skillet over medium heat, heat oil. Working in batches, sear meatballs on all sides to develop a crust. Set meatballs aside, reduce heat to medium-low, and add sauce to skillet. Bring sauce to a simmer then immediately add meatballs back to skillet. Cover and simmer until cooked through, about 8 minutes more original recipe from eatyourcannabis.com [...] Read more...
August 3, 2023Materials -Medium Sauce-Pan -​Thermometer -Mesh-sieve or cheesecloth Ingredients -​6 grams cannabis flower -2 cups oil (olive, coconut, canola or vegetable oil) Directions ​ ​1. Decarboxylate the cannabis Heat the oven to 225°F. Spread cannabis buds out into an even layer on a baking sheet and place in the oven. ​Take care not to let the temperature go over 225°F and burn (if this happens, you can lose potency). Bake for about 35–40 minutes, then remove from the oven and cool before grinding into a coarse powder. ​ The decarboxylated cannabis will keep in an airtight container in a cool, dark place for up to 2 months 2. Heat the oil in a saucepan over medium-low heat. Add the decarboxylated cannabis and cook, taking care not to let the temperature go over 200°F for about 45 minutes. 3. Remove from heat and let sit, undisturbed, for 10 minutes 4. Strain through a fine mesh-sieve set over a bowl. Press carefully with a spoon to extract as much oil as possible ​The oil will keep for up to 6 weeks if covered and refrigerated. This recipe is available for download HERE Original recipe from Vice.com [...] Read more...
August 3, 2023This recipe can be used with your favorite vegetables and breakfast meats Ingredients Base: 4 large eggs salt and pepper (to tasste) 1 tbsp butter (canna-butter may be used to increase potency) 1/2 cup canna-milk Filling: 2 tbsp diced green pepper 2 tbsp diced green onion 2 tbsp ham or meat of your choice 1/4 cup shredded cheese ​ Instructions 1. Beat eggs in a bowl with a whisk. 2. Add canna-milk and season with salt and pepper 3. Add any vegetables and/or meat fillings to the eggs and whisk for a few minutes until egg mixture if foamy — beating in air makes the omelette fluffy​ 4. Melt butter in a small, nonstick skillet over medium-low heat. Pour in egg mixture and twirl skillet so the bottom is evenly covered in egg. 5. Cook until egg starts to set. Lift the edges with a spatula and tilt the skillet so uncooked egg mixture can run towards the bottom of the skillet to set Repeat until no visible liquid egg remains 6. Carefully flip omelette and cook another 30 seconds to 1 minute 7. Sprinkle cheese in one line in the middle of the omelette and fold it in half, cook another 20 seconds them slide the omelette on to the plate This recipe is available for download HERE Original recipe from the Canna School [...] Read more...
August 3, 2023Ingredients 4 quarts popped popcorn 1 cup brown sugar 1/2 cup corn syrup light 1/2 cup cannabis butter 1/2 tsp salt 1/2 tsp pepper 1 tsp vanilla extract 1/2 tsp baking soda Instructions Preheat your oven to 250 degrees Fahrenheit. Spray a large shallow roasting pan with cooking spray and add popcorn. In a separate bowl mix brown sugar, corn syrup, cannabis butter, and salt in a heavy saucepan. Stirring constantly, bring to a boil over medium heat. Boil 5 minutes without stirring. Remove from heat. Stir in baking soda and vanilla; mix well. Pour syrup over warm popcorn, stirring to coat evenly. Bake for 45 minutes, stirring occasionally. ​ Enjoy! Keep refrigerated for extended shelf life. This recipe is available for download HERE Original recipe from thecannaschool.com [...] Read more...
August 3, 2023Ingredients 3 Tbsp mayonnaise 2 Tsp Dijon mustard 1/2 Tsp salt 1/2 Tsp pepper 2 Eggs, lightly beaten 1lb Lump crab meat 2 Tbps finely chopped parsley 3 Tbsp canna-butter Instructions 1. Whisk together mayonnaise, mustard, salt, pepper and eggs. Then gently stir in crab meat, panko and parsley. 2. Shape mixture in to 12 (3-inch) patties, pressing gently to flatten. Cover with plastic wrap and refrigerate for 1hr. 3. Melt half the canna-butter in large, nonstick skillet over medium heat. Add 6 patties to the pan and cook for 2 minutes on each side, or until golden brown. Repeat with the remaining half of canna-butter and remaining 6 patties. The recipe is available for download HERE original recipe from eat your cannabis.com [...] Read more...
August 3, 2023Ingredients 2/3 cup Cannabis oil (coconut or olive oil will work) 4 large potatoes peeled 3 tbsp salt Instructions Preheat your oven to 400 degrees Fahrenheit and line a large baking sheet with parchment paper. Cut your peeled potatoes into strips (cut them into fries!) and spread them evenly on the baking sheet. Drizzle the cannabis-infused oil over them and season with salt. Try to coat each fry relatively evenly with the oil so that there is a consistent potency. Cook the fries until they are golden brown. Around 15–20 minutes. Allow the fires to cool down, around 5 minutes. Divide the fries into equal proportions and serve. This recipe is available for download HERE Original recipe from thecannaschool.com [...] Read more...
August 3, 2023Ingredients ¼ cup cannabuter, room temperature ½ cup regular butter, room temperature 1 cup brown sugar ½ cup white sugar 2 eggs, room temperature 1 tsp vanilla extract 2 ½ cups all-purpose flour 1 tsp cinnamon ½ tsp baking soda ½ tsp sea salt 1 cup mini chocolate chips 1 cup mini marshmallows 18 graham crackers Coating chocolate, melted Directions Preheat oven to 350°F/175°C. Line a cookie sheet with parchment paper. Cream the regular butter, cannabutter, brown sugar & white sugar together until fluffy. Beat in eggs one at a time. Beat in the vanilla. In a small bowl, mix together the flour, cinnamon, baking soda & salt. Add to the creamed mixture. Mix well. Add the mini chocolate chips & mini marshmallows. Mix until evenly distributed. Evenly space the graham crackers on the prepared liner. Use a 2 oz scoop to portion the cookies & place in the center of the graham cracker. Bake for 12–15 minutes. Allow the cookies to cool. Push all of the baked cookies together & drizzle with coating chocolate. Allow the chocolate to set & enjoy! This recipe is available for download HERE Original recipe from myedibleschef.com [...] Read more...
August 3, 2023Ingredients 2 slices of bread Cheese Canna-Butter Optional fillings: tomato, green onion, chicken, tuna Directions 1. Use a knife to coat both pieces of bread with canna-butter Be sure to coat both sides of the bread 2. Bring skillet to medium heat and add a small scoop of canna-butter ​ 3. One the butter has melted, place one slice of bread on the skillet 4. Add as much cheese and fillings as you like, then place the second slice of bread on top 5. Flip the sandwich when the bottom is golden brown, add more butter if needed for the new side 6. When the sandwich looks adequately fried and the cheese is melted to your liking, take it off of the skillet, slice in half, and enjoy! Original recipe from Satori MJ [...] Read more...
August 3, 2023Ingredients 6 cups fresh or frozen blueberries (you may substitute some pitted cherries too!) 1 Tbsp lemon juice 1/4 cup all-purpose flour 1/2 cup white sugar (you may add canna-sugar for increased potency) 1/4 tsp cinnamon 2 Tbsp canna-butter, cut into small pieces (you may substitute canna-coconut oil) 2x pie crust recipe or store bought Directions Preheat oven to 350°F/175°C. Line a cookie sheet with parchment paper. Cream the regular butter, cannabutter, brown sugar & white sugar together until fluffy. Beat in eggs one at a time. Beat in the vanilla. In a small bowl, mix together the flour, cinnamon, baking soda & salt. Add to the creamed mixture. Mix well. Add the mini chocolate chips & mini marshmallows. Mix until evenly distributed. Evenly space the graham crackers on the prepared liner. Use a 2 oz scoop to portion the cookies & place in the center of the graham cracker. Bake for 12–15 minutes. Allow the cookies to cool. Push all of the baked cookies together & drizzle with coating chocolate. Allow the chocolate to set & enjoy! This recipe is available for download HERE Original recipe from myedibleschef.com [...] Read more...
August 3, 2023Servings: 12 Ingredients 1 cup soybean oil ½ ounce ganja shake 2 large egg yolks 1 teaspoon fresh lemon juice Pinch of salt 1 teaspoon white vinegar ½ teaspoon Dijon mustard ​Directions In a double boiler, combine the oil and ganja. Heat over low until the ganja smell is pronounced but not nutty or burnt. (The oil should have an earthy green tint to it.) Let cool. Remove and strain the herb, squeezing the weed in a metal strainer against the mesh with the back of a spoon to wring out every drop of oil. Make sure that all your ingredients have been brought to room temperature — this is crucial! ​In a small metal bowl, use an immersion blender or whisk to thoroughly blend the egg yolks, lemon juice, salt, vinegar, and mustard. This can also be done in a food processor or blender. ​Using a ½ teaspoon measure, very slowly add the infused oil to the small metal bowl, a few drops at a time, while constantly blending on low or whisking until the mayo is thick and starting to form ribbons. (If it’s too thick, you can add room-temperature water in tiny increments.) If your mixture “breaks,” it can be repaired by whisking some more room-temperature egg yolks in a separate bowl, then slowly whisking those yolks into the “broken” mayo mixture. If that doesn’t do it, add a few drops of hot water. ​Cover and chill; it’ll keep in the refrigerator for 4 to 5 days. Original recipe from: Boudreaux, Ashley. The Official High Times Cannabis Cookbook. Red Eyed Deviled Eggs. https://saltonverde.com/wp-content/uploads/2017/09/10-High_Times_Cannabis_Cookbook.pdf [...] Read more...
August 3, 2023This soup can be enhanced with any of your favorite vegetables. Materials Soup Pot Frying Pan Hand-Blender or Regular blender (optional) Ingredients ​3 cups vegetable stock 1 cup chopped broccoli 1/2 red onion, chopped 2 stalks of celery, chopped 1 and 1/2 cup heavy cream (canna-cream may be substituted or blended with regular cream for increased potency) 2 TBSP olive oil Fresh cilantro (optional) Salt and Pepper to taste ​Canna-Oil (dose-dependent) Directions 1. Heat vegetable stock and broccoli in a large pot Boil for around 6 minutes 2. On another burner, saute garlic, onion and celery in olive oil until soft — about 4 minutes ​​ 3. Take the pan off the heat and add desired dose of canna-oil to vegetables Stir thoroughly and then pour mixture in to the big soup pot Be sure to scrape all material to get the maximum amount of canna-oil 4. Heat for another 6–8 minutes then reduce heat to low and add heavy cream, add salt and pepper to taste ​ 5. Let simmer for 5 minutes, serve hot  ​Garnish with cilantro if desired This recipe is available for download HERE The original recipe is from Royal Queen Seeds [...] Read more...
August 3, 2023Ingredients Cupcakes: 2 cups flour 1 cup sugar 1 Tbsp baking powder 1/4 Tsp salt 1 cup milk 2 eggs 1/4 cup canna-oil (vegetable is best) 1/4 vegetable oil 2 Tsp vanilla extract 1/3 cup rainbow sprinkles Frosting: 1 cup sugar 1 cup egg whites 1lb butter, salted, room temperature 1 Tsp vanilla extract ​ Directions ​Cupcakes: Preheat oven to 350°F. Line a cupcake pan with cupcake liners. Mix all of the dry ingredients together in a medium bowl. Whisk all of the liquid ingredients together until blended. Add the liquid ingredients to the dry ingredients & mix until there are no large lumps. Do not overmix. Gently stir in the rainbow sprinkles until just blended. ​ Use a 2-ounce portion scoop & fill each cupcake liner with one scoop. Bake for 15–18 minutes or until a toothpick inserted in the middle comes out clean. Remove from the oven & allow to cool a bit before removing them from the pan. Frosting: Put 2 inches of water into a medium-size pot, & bring to a boil. Place the sugar & egg whites into a small stainless bowl that will sit on top of the pot of boiling water, or use a double boiler system. DO NOT allow the bowl with the egg white mixture to directly touch the boiling water or the egg whites will cook very quickly. Whisk constantly until temperature reaches 140°F/60°C or until the sugar has completely dissolved & the egg whites are hot to the touch. DO NOT leave unattended or you will have a sweet egg white scramble! Use a hand mixer or pour the egg white mixture into a bowl that is fitted for a stand mixer. Using the whisk attachment, begin to whip until the meringue is thick & glossy, about 10 minutes on medium-high. Place the mixer on low speed, add the cubes of butter, a couple at a time, until incorporated. Continue beating until it has reached a silky smooth texture. If the buttercream curdles simply keep mixing & it will become smooth. If the buttercream is too runny, refrigerate for about 15 minutes before continuing mixing. Add the vanilla & continue to beat on low speed until well combined. Once the cupcakes have completely cooled, place a large star tip into a piping bag & fill with the buttercream. Pipe a rosette onto each cupcake & add the sprinkles on top. Serve immediately, the same day or keep in an airtight container in the fridge for up to 4 days. They can also be frozen for up to 3 months. This recipe is available for download HERE Original recipe from myedibleschef.com [...] Read more...
August 3, 2023Ingredients blender ¼ cup tahini ¼ cup lemon juice, freshly squeezed w/o seeds 15 ounce can of chickpeas, drained and rinsed 2 garlic cloves ¼ cup CannaOil ½ cup ground cumin 2 tablespoons water salt and pepper to taste Instructions Combine lemon juice and tahini in a blender. Blend for 30 seconds. Add chickpeas, garlic, Canna Oil, cumin and water. Blend for 1 minute until smooth. Add more water if needed to reach desired consistency. Pour hummus in a serving bowl, or store in the refrigerator for later. This recipe is available for download HERE Original recipe from eatyourcannabis.com [...] Read more...
August 3, 2023Ingredients 1 can whole peeled tomatoes 28 oz. 1 jar roasted red peppers 12 oz. 4 large eggs ½ cup plain Greek yogurt ¼ cup CannaOil plus more for drizzling 1 teaspoon coriander seeds 1 teaspoon cumin seeds 6 garlic cloves divided 2 medium shallots divided Kosher salt Freshly ground black pepper Mint leaves and crusty bread for serving Crush coriander and cumin seeds, pressing down firmly with even pressure. Transfer seeds to a small heatproof bowl. Slice 2 garlic cloves as thinly and evenly as you can; add to bowl with seeds. Finely chop the remaining 4 garlic cloves. Cut half of 1 shallot into thin rounds and then add to the same bowl with seeds and garlic. Chop remaining shallots. Open a jar of red peppers and pour off any liquid. Remove peppers and coarsely chop. Combine ¼ cup oil and seed/garlic/shallot mix in the skillet you used for crushing seeds. Heat over medium and cook, stirring constantly with a wooden spoon, until seeds are sizzling and fragrant and garlic and shallots are crisp and golden, about 3 minutes. Place a strainer over the same heatproof bowl and pour in the contents of the skillet, making sure to scrape in seeds and other solids. Do this quickly before garlic or shallots start to burn. Reserve oil. Spread out seed mixture across paper towels to cool. Season with salt and pepper. Return strained CannaOil to skillet and heat over medium. Add remaining chopped garlic and shallot and cook, stirring often, until shallot is translucent and starting to turn brown around the edges, about 5 minutes. Season with salt and lots of pepper. Add chopped peppers to the skillet and stir to incorporate. Using your hands, lift whole peeled tomatoes out of the can, leaving behind tomato liquid, and crush up with your hands as you add to the skillet. Discard leftover liquid. Season with more salt and pepper. Cook shakshuka, stirring often, until thickened and no longer runs together when a spoon is dragged through, 10–12 minutes. Reduce heat to low. Using the back of a wooden spoon, create four 2″-wide nests in tomato sauce. Working one at a time, carefully crack an egg into each nest. Cover skillet and cook, simmering very gently and reducing heat if necessary, until whites of eggs are set while yolks are still jammy, 7–10 minutes. Uncover skillet and remove from heat. Season tops of eggs with salt and pepper. Top shakshuka with dollops of yogurt, sprinkle with seed mixture, then drizzle with more olive oil. Finish by scattering mint leaves over top. ​ Serve pita or crusty bread alongside. This recipe is available for download HERE Original recipe from eat your cannabis.com [...] Read more...
August 3, 2023Ingredients 2 cups shredded green cabbage 1 Tbsp lime juice 1/2 Tsp salt 3 Tbsp cilantro 1/4 cup canna-oil 1 tomato, diced 1/2 cup salsa 1/2 onion, diced 1 jalapeno, diced 1 avocado, sliced Meat of choice (fish or a ground meat like beef or turkey) 4 corn tortillas Directions 1. Cook choice of meat with fajita seasoning in frying pan, set aside 2. In a large bowl, mix shredded cabbage, line juice, salt and cilantro 3. In a separate bowl, mix canna-oil with tomato, onion, jalapeno and salsa 4. Wrap the tortillas in paper towels and heat in the microwave for 30 seconds, or until warm 5. Fill each tortilla with meat, cabbage mixture, cannabis salsa mixture and diced avocado ​Serve with lime wedge The recipe is available for download HERE Original recipe from Eat Your Cannabis [...] Read more...
August 3, 2023Ingredients 4 Pork chops Salt and pepper 1 Tbsp minced rosemary 2 Cloves minced garlic 1/2 Cup canna-butter 1 Tbps canna-oil Instructions 1. Preheat oven to 375°F. Season pork chops with salt and pepper 2. In a small bowl, combine canna-butter with rosemary and garlic. Set aside 3. In an oven-safe skillet over medium heat, heat canna-oil and add pork chops. Sear until golden, about 4 minutes, flip and cook for another 4 minutes. 4. Brush pork-chops generously with the garlic canna-butter mixture and place skillet in the oven to bake for 10–12 minutes. Serve with more garlic butter. ​If you do not have an oven-safe skillet, you may use a regular one and transfer to a baking dish. Be sure to collect all the oil from the pan when transferring. This recipe is available for download HERE Original recipe from Eat Your Cannabis.com [...] Read more...
August 3, 2023This recipe can be used with your favorite vegetables and breakfast meats Ingredients Base: 1 ½ cups of mozzarella cheese, shredded 1/2 cup cheddar cheese, shredded 6 eggs 1 cup of milk (canna-milk may be used for a more potent dish) 1 pie-crust, unbaked Filling: 1/2 cup of canna-butter 1 onion, diced 1 cup broccoli, chopped 1 head of garlic ​ Instructions 1. Melt canna-butter in a pan over medium heat ​ 2. Add vegetables to butter and cook on medium heat for about 5–8 minutes (or until veggies are cooked) Do not let the butter or vegetables burn, to maintain potency of the butter 3. Scoop cooked vegetables into empty pie crust and cover with shredded cheeses 4. Beat eggs and milk together and pour into the pie crust 5. Bake for 35–40 minutes at 360°F Allow quiche to cool 10 minutes before serving This recipe is available for download HERE Original recipe from cannabis.wiki [...] Read more...
August 3, 2023Ingredients 2 lbs of potatoes 4 tablespoons cannabutter 4 tablespoons sour cream or plain cream cheese Salt and pepper ¼ to ½ cup of milk or cannamilk for increased potency 2 cloves of garlic minced or 1 tsp of garlic powder Instructions Cut the potatoes in half or quarters to make medium-sized pieces. Place the potatoes in a saucepan filled with water and bring to a boil. Cook until fork-tender, between 20–30 minutes. Drain the potatoes and remove their skins. Add the cannabutter, garlic and sour cream to the bowl along with a splash of milk (don’t add it all at once.) Mash the contents, adding just a splash of milk each time until you’ve reached the desired consistency. ​ Stir in salt and pepper to taste. This recipe is available for download HERE original recipe from satorimj.com [...] Read more...
August 3, 2023Materials -Medium Sauce-Pan -​Thermometer -Mesh-sieve or cheesecloth Ingredients -​6 grams cannabis flower -1 pound unsalted butter Directions ​ ​1. Decarboxylate the cannabis Heat the oven to 225°F. Spread cannabis buds out into an even layer on a baking sheet and place in the oven. ​Take care not to let the temperature go over 225°F and burn (if this happens, you can lose potency). Bake for about 35–40 minutes, then remove from the oven and cool before grinding into a coarse powder. ​ The decarboxylated cannabis will keep in an airtight container in a cool, dark place for up to 2 months 2. Heat the butter in a saucepan over medium-low heat. Add the decarboxylated cannabis and cook, taking care not to let the temperature go over 200°F for about 45 minutes. 3. Remove from heat and let sit, undisturbed, for 10 minutes 4. Strain through a fine mesh-sieve set over a bowl. Press carefully with a spoon to extract as much oil as possible ​The milk will keep for up to 6 weeks if covered and refrigerated. This recipe is available for download HERE Original recipe from Vice.com [...] Read more...
August 3, 2023Ingredients 1 package of Instant Ramen Vegetable or Beef broth (use the amount listed on the package for water) Frozen vegetable medley One egg or tofu Dried seaweed (to garnish) Sesame Seeds (to garnish) Cannabis Tincture Directions 1. Follow the instructions on the ramen package, but swap the water out for broth 2. Add the frozen veggies when broth gets hot 3. Crack an egg in the hot broth and stir for a few minutes You can also use a hard-boiled egg or chopped tofu ​ 4. Add as much cannabis tincture that you want. If you are unsure, start with 1–2 drops 5. Top soup with dried seaweed and sesame seeds Original recipe from Satori MJ [...] Read more...
August 3, 2023Ingredients 2 cups all-purpose flour 4 Tbsp sugar (canna-sugar may be substituted to increase potency) 1 Tbsp baking powder ½ Tsp salt 2 large eggs 1 ½ cups whole milk (canna-milk may be substituted to increase potency) ¾ cup canna-butter, melted ​1 teaspoon vanilla extract Instructions 1. In a bowl, combine dry ingredients: flour, sugar, salt, baking powder 2. In another bowl, combine wet ingredients: beat the eggs with the milk, then add the vanilla extract 3. Stir the wet ingredients into the dry ingredients until just combined ​Do not over-mix, batter will be thick and slightly lumpy 4. Bake in a preheated waffle-iron according to manufacturer’s directions until golden brown This recipe is available for download HERE! Original recipe from allrecipes.com [...] Read more...
August 3, 2023Cannabis infused sugar offers a simple way to enhance your baked goods or beverages. Materials Mason Jar ​Cheesecloth Baking Sheet 9in x 13in Baking Pan Ingredients -3 grams of cannabis flower -1/2 cup of high-proof alcohol, such as Everclear -1/2 cup granulated sugar Directions 1. Decarboxylate the cannabis Heat the oven to 225°F. Spread cannabis buds out into an even layer on a baking sheet and place in the oven. ​Take care not to let the temperature go over 225°F and burn (if this happens, you can lose potency). Bake for about 35–40 minutes, then remove from the oven and cool before grinding into a coarse powder. ​ The decarboxylated cannabis will keep in an airtight container in a cool, dark place for up to 2 months 2. Transfer the cannabis to a jar and cover with the alcohol. Screw the lid on tight and shake every 5 minutes for 20 minutes. 3. Strain through a cheesecloth set over a bowl, discarding solids. Mix the strained alcohol with the sugar and spread into an even layer in a glass 9-by-13-inch baking dish. ​ 4. Bake at 200°F, stirring occasionally, until the alcohol has evaporated and the sugar is lightly golden. This recipe is available for download HERE The original recipe is from Vice.com [...] Read more...
August 3, 2023Ingredients -1.5 cups all-purpose flour -1 Tbsp sugar (canna-sugar may be substituted to increase potency) -1 Tbsp baking powder -1 Tsp salt -1 large egg -1.25 cups whole milk (canna-milk may be substituted to increase potency) -3 Tbsp of melted canna-butter or oil -​1 teaspoon vanilla extract (optional) Instructions 1. In a bowl, combine dry ingredients 2. In another bowl, combine wet ingredients 3. Stir the wet ingredients into the dry ingredients until just combined ​Do not over-mix, batter will be thick and slightly lumpy 4. Heat a large frying pan with with a small amount of butter or oil 5. Pour 1 cup of batter in the center of the pan. Fry 2–3 minutes before flipping 6. Fry an additional 3–5 minutes or until pancake reaches your preferred doneness and remove from pan 7. Garnish with your favorite toppings; powdered sugar, syrup, butter, chocolate chips or whatever you might enjoy! Original recipe from cannabis wiki [...] Read more...
August 3, 2023Ingredients 4 eggs 1 cup white sugar ½ cup brown sugar, packed 1 ¼ cups grapeseed oil ¼ cup canna-oil 2 tsp vanilla extract 1 ¾ cups pure pumpkin puree 3 cups all-purpose flour 1 tbsp ground cinnamon 1 tbsp pumpkin spice 2 tsp baking powder 2 tsp baking soda 1 tbsp orange zest, optional Directions Preheat the oven to 350°F/175°C. Line a jumbo muffin tin with liners. Place the eggs, white sugar, brown sugar, grapeseed oil & canna-oil into a bowl fitted for a stand mixer or use a whisk to thoroughly beat ingredients together. Blend in the pumpkin & vanilla extract. In a small bowl mix the dry ingredients together. Add to the wet ingredients & mix until just blended. Stir in the orange zest (optional). Divide the batter evenly between 12 muffin cups using a muffin scoop, about 3 ounces each. Sprinkle with pumpkin seeds. Bake for 22–25 minutes or until a toothpick inserted into the middle comes out clean. ​ Allow to cool, remove from the tins & sprinkle with cinnamon. This recipe is available for download HERE Original recipe from myedibleschef.com [...] Read more...